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Intraorally fast-dissolving drug 
formulations offer both good patient 
acceptability and pharmacokinetic 
advantages over conventional tablets 
and capsules. However, the poor sol-
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intraoral administration. In this the-
sis, cyclodextrins were demonstrated 
to be potential excipients to overcome 
these limitations in the development 
of intraorally fast-dissolving drug 
formulations.
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ABSTRACT 
 
Increasing interest is being paid to intraoral drug delivery, since it offers both good patient 
acceptability and pharmacokinetic advantages over peroral administration. Drug 
absorption into systemic circulation through the highly vascularized sublingual and buccal 
mucosae of the mouth often achieves a rapid onset of drug action and improved 
bioavailability for drugs that are susceptible to a first-pass effect or degradation in the 
gastrointestinal tract. Intraorally dissolving dosage forms are easy and convenient to use, 
and they are also suitable for use in individuals who are not able to swallow conventional 
solid dosage forms. However, drug absorption through the oral mucosal membranes 
requires that the drug dissolves sufficiently rapidly in a very small volume of saliva, which 
may represent an obstacle for poorly soluble drugs. Furthermore, many drugs have a very 
bitter and irritating taste that complicates their intraoral administration. These challenges 
could possibly be solved by complexing the drug with cyclodextrins (CDs). 
The general objective of the study was to investigate the use of CDs in fast-dissolving 
intraoral drug formulations. The model drugs used in the study were perphenazine and 
midazolam, which both are poorly soluble drugs that display high first-pass metabolism 
and have low bioavailability with peroral administration. 
In the present study, a sensitive gas chromatographicmass spectrometric method was 
developed and validated for the determination of perphenazine in rabbit plasma samples. 
Complexation with beta-cyclodextrin (β-CD) was found to increase the apparent aqueous 
solubility and dissolution rate of perphenazine. The sublingually administered 
perphenazine/β-CD complex improved the absorption of perphenazine in rabbits in 
comparison to peroral perphenazine solution. Amorphous perphenazine/β-CD complexes 
prepared by spray-drying or freeze-drying retained their rapid in vitro dissolution 
properties during storage at elevated temperature and humidity, even though changes in 
their crystal structure were observed.  
Hydroxypropyl-beta-cyclodextrin (HP-β-CD) and sucrose were found to increase the 
apparent aqueous solubility of midazolam in a synergistic manner. Both liquid and solid 
formulations containing midazolam, HP-β-CD and sucrose were rapidly and well absorbed 
in rabbits after sublingual administration. 
In conclusion, the results of the present study demonstrated that CDs are potential 
excipients for the development of intraorally fast-dissolving drug formulations, which 
show improved systemic absorption when compared to peroral formulations. 
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TIIVISTELMÄ 
 
Suunsisäisesti eli intraoraalisesti annettavat, nopeasti liukenevat lääkevalmisteet tarjoavat 
monia etuja suun kautta antoon verrattuna. Suun sublinguaalisten ja bukkaalisten 
limakalvojen läpi systeemiseen verenkiertoon imeytyvien lääkeaineiden vaikutus alkaa 
yleensä nopeasti. Antotapa sopii hyvin myös sellaisille lääkeaineille, joiden biologinen 
hyötyosuus suun kautta annettaessa on huono maksan ensikierron metabolian tai 
ruoansulatuskanavassa tapahtuvan hajoamisen vuoksi. Suussa liukenevat lääkevalmisteet 
ovat helppokäyttöisiä ja soveltuvat myös potilaille, joille perinteisten tablettien tai 
kapselien nieleminen on vaikeaa. Tällaisten valmisteiden kehitykselle haasteita kuitenkin 
asettavat muun muassa useiden lääkeaineiden huono vesiliukoisuus, hidas liukeneminen ja 
paha maku. Näitä ongelmia voidaan mahdollisesti ratkaista syklodekstriinien (CD) avulla. 
Tämän tutkimuksen tavoitteena oli selvittää syklodekstriinien käyttömahdollisuuksia 
nopeasti suussa liukenevien lääkevalmisteiden kehittämisessä. Mallilääkeaineina 
tutkimuksessa käytettiin perfenatsiinia ja midatsolaamia. Molemmat lääkeaineet liukenevat 
huonosti veteen, ja niiden hyötyosuus suun kautta annettaessa on alhainen runsaan 
ensikierron metabolian vuoksi. 
Tutkimuksessa kehitettiin ja validoitiin kaasukromatografimassaspektrometriaan 
perustuva herkkä analyysimenetelmä perfenatsiinin pitoisuuksien määrittämiseen kaniinin 
plasmanäytteistä. Lisäksi havaittiin, että kompleksoituminen beta-syklodekstriinin (β-CD) 
kanssa paransi perfenatsiinin näennäistä vesiliukoisuutta ja liukenemisnopeutta. 
Sublinguaalisesti kaniineille annettu perfenatsiini/β-CD-kompleksi imeytyi systeemisesti 
paremmin kuin peroraalisesti annettu perfenatsiiniliuos. Säilyvyystutkimuksissa havaittiin, 
että sumukuivaamalla tai kylmäkuivaamalla valmistettujen amorfisten perfenatsiini/β-CD-
jauheiden in vitro -liukenemisnopeus pysyi käytännössä muuttumattomana, vaikka säilytys 
kohotetussa lämpötilassa ja kosteudessa aiheutti muutoksia kompleksien kiderakenteessa.  
Midatsolaamin näennäinen vesiliukoisuus parani merkittävästi hydroksipropyyli-β-
CD:n (HP-β-CD) läsnä ollessa. Sakkaroosin havaittiin tehostavan HP-β-CD:n liukoisuutta 
parantavaa vaikutusta. Midatsolaami imeytyi nopeasti ja hyvin kaniineille sublinguaalisesti 
annetusta liuoksesta ja jauheesta, jotka sisälsivät HP-β-CD:ä ja sakkaroosia.  
Tutkimuksen tulokset osoittavat, että syklodekstriinit ovat lupaavia apuaineita 
kehitettäessä suunsisäisesti annettavia, nopeasti liukenevia lääkevalmisteita, joista 
lääkeaine imeytyy systeemiseen verenkiertoon paremmin kuin suun kautta annettavista 
valmisteista. 
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 1 Introduction  
Peroral administration of tablets or capsules is the most popular and widely used way to 
achieve the systemic delivery of small-molecule drugs. The advantages of conventional 
tablets and capsules include their ease of use in self-medication, accurate dosage, low 
production costs as well as their suitability for various types of drugs and drug release 
profiles (Patel et al. 2011). However, the peroral absorption of many drugs is limited by 
presystemic metabolism in the liver or the gut wall, or by degradation when they encounter 
the low gastric pH or digestive enzymes (Mathias and Hussain 2010). In addition, the 
peroral administration route is not optimal for individuals suffering from dysphagia, i.e. 
difficulty in swallowing. A recent study revealed that in a group of 1051 primary care 
patients, almost 40% had experienced difficulties in swallowing tablets and capsules 
(Schiele et al. 2013). In general, dysphagia is most common in the elderly and individuals 
suffering from certain health conditions, such as Parkinson´s disease, Alzheimer’s disease 
or stroke (Chen et al. 2009, Holland et al. 2011, Stegemann et al. 2012). Swallowing 
conventional tablets and capsules may also be difficult, even physically impossible, for 
pediatric patients, especially for children below the age of six years (EMA 2006a). 
Intraoral drug delivery involves the administration of drugs into the oral cavity for 
either local or systemic medication. The drugs can reach the systemic circulation by being 
absorbed from the sublingual mucosa under the tongue, or from the buccal mucosa in the 
cheek (Patel et al. 2011). There are some very well-known examples of intraoral drug 
delivery e.g. the use of sublingual glyceryl trinitrate for the treatment of angina pectoris, or 
the use of nicotine-containing chewing gums or sublingual tablets for smoking cessation. 
The intraoral administration route has some important pharmacokinetic advantages over 
the peroral route, such as the possibility to avoid first-pass metabolism, and a rapid onset of 
drug action. The intraoral route is also associated with high patient compliance in 
comparison to injections or some other transmucosal administration routes (Goswami et al. 
2008, Madhav et al. 2009, Mathias and Hussain 2010). Intraorally dissolving formulations 
may also be suitable for individuals with swallowing difficulties or with no ready access to 
potable water (Habib et al. 2000, Sastry et al. 2000, Fu et al. 2004). 
However, there are some challenges that complicate the intraoral administration of 
drugs. When systemic drug absorption through the oral mucosal membranes is desired, the 
drug has to dissolve rapidly in a very small volume of saliva before it is removed from the 
site of absorption by swallowing (Goswami et al. 2008, Mathias and Hussain 2010). This 
clearly represents an obstacle for poorly soluble or slowly dissolving drugs, or drugs which 
require high therapeutic doses. The taste of the active drug also needs to be taken into 
consideration. Since many drugs have a very bitter or irritating taste, this means that 
flavours, sweeteners or other taste-masking approaches usually need to be incorporated 
into intraorally dissolving formulations to make them acceptable to the patient (Seager 
1998, Habib et al. 2000).  
Cyclodextrins (CDs) are a group of cyclic oligosaccharides that are able to form 
reversible inclusion complexes with drugs or parts of drug molecules, resulting in 
improved physicochemical or biopharmaceutical properties of drugs (Davis and Brewster 
2004, Challa et al. 2005, Loftsson and Brewster 2010). CDs have several intraoral 
applications, e.g. to increase the poor solubility and dissolution rate of drugs in saliva, or to 
mask the unpleasant taste of drugs. However, the use of CDs in intraoral applications also 
involves some limitations, such as the effect of CDs on the bulk mass and volume of the 
formulation, and the possibility for insufficient drug release from the inclusion complex 
due to the small volume of saliva and short residence time in the oral cavity before 
swallowing (Stella et al. 1999, Loftsson 2002).  
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The present study focuses on the use of CDs in intraorally fast-dissolving drug 
formulations. A sensitive and selective gas chromatographicmass spectrometric method 
was developed and validated to permit the quantification of perphenazine in plasma 
samples. The effect of beta-cyclodextrin (β-CD) on the apparent aqueous solubility and 
dissolution rate of perphenazine was studied, and the sublingual absorption of fast-
dissolving perphenazine powders was investigated in rabbits. The chemical and physical 
stability of fast-dissolving, amorphous perphenazine/β-CD complex powders as well as the 
effect of storage on their dissolution properties were evaluated under accelerated storage 
conditions. In addition, hydroxypropyl-β-CD was used to prepare taste-masked midazolam 
formulations for intraoral administration, and the sublingual absorption of these 
formulations was investigated in rabbits. 
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2  Review of the Literature 
2.1 INTRAORAL DRUG DELIVERY 
2.1.1 Anatomy and histology of the oral cavity 
The oral cavity is the first part of the gastrointestinal tract and it plays an important role in 
eating, drinking, speaking and breathing. The main anatomical parts of the oral cavity are 
the lips, cheeks, tongue, teeth, gums, hard and soft palate and the floor of the mouth. The 
oral cavity is internally lined by a moist mucous membrane that provides mechanical 
protection to the underlying tissues, prevents the entry of harmful substances or 
microorganisms and which contains receptors for touch, pain and taste (Berkovitz et al. 
2009).  
The oral mucosa consists of a stratified squamous epithelium, a basement membrane and 
connective tissue that contains the supportive collagen fibres, blood vessels and nerves 
(Figure 2.1). The oral mucosa can be functionally classified into three types: masticatory 
mucosa, lining mucosa and specialized mucosa (Squier and Kremer 2001). Masticatory 
mucosa covers the hard palate and gums that are susceptible to the mechanical stress and 
abrasion caused by food mastication. In these areas, the epithelium is keratinized and 
tightly bound to the underlying bone. The majority of the oral mucosa is nonkeratinized 
lining mucosa that is elastic and flexible. The upper side of the tongue is regarded as 
specialized mucosa that contains both keratinized and nonkeratinized areas and carries out 
important sensory functions. The lining mucosa represents approximately 60%, the 
masticatory mucosa 25% and specialized mucosa 15% of the total surface area of the oral 
mucosa (Collins and Dawes 1987).  
 
 
Figure 2.1. General structure of keratinized (left) and non-keratinized (right) oral mucosa: 
connective tissue (a), basement membrane (b) and stratified squamous epithelium (c). In the 
upper cell layers of keratinized epithelium, the cells contain keratin and the extracellular spaces 
are filled with lipid sheets (d). The epithelium is covered by a salivary layer (e). 
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The oral mucosae can also be classified according to their location in the sublingual, 
buccal, gingival, palatal and labial mucosae, of which the sublingual (the floor of the 
mouth) and buccal (the inner lining of the cheek) mucosae are the most important areas for 
systemic drug delivery (Patel et al. 2011). The thickness of the oral epithelium varies 
depending on its location within the oral cavity. The buccal epithelium consists of 4050 
cell layers with a thickness proposed to be between 300 and 800 μm (Harris and Robinson 
1992, Prestin et al. 2012). The thinnest epithelium, approximately 100 μm thick, is found at 
the floor of the mouth, where the number of cell layers is also somewhat lower than in the 
buccal area. 
The oral epithelium undergoes a continuous process of renewal, where cells are shed 
from the epithelial surface and replaced from below (Berkovitz et al. 2009). The fastest 
turnover occurs in the buccal region, a site where the epithelium will be completely 
renewed in 57 days. In the sublingual and palatal areas, the turnover rate is substantially 
slower, approximately 20 days (Harris and Robinson 1992, Sohi et al. 2010). New cells are 
formed in the deepest cell layer of the oral epithelium, the basal layer, which contains 
frequently dividing stem cells. The cells formed in the basal layer are the least well 
differentiated within the oral epithelium and have a full set of intracellular organelles 
(Squier and Kremer 2001, Berkovitz et al. 2009). As the cells begin to differentiate, they 
migrate from the basal layer towards the epithelial surface. During maturation, the cells 
become progressively flattened, lose their intracellular organelles and begin to accumulate 
cytoplasmic proteins, cytokeratins (Harris and Robinson 1992). In the intermediate stages of 
maturation, small membrane-coating granules filled with lipids begin to appear in the 
intracellular space (Squier and Kremer 2001). When the migrating cells reach the upper 
third to one quarter of the epithelium, the membrane-coating granules fuse with the cell 
membrane and discharge their lipid contents in the extracellular space, forming the 
permeability barrier in the oral epithelium (Berkovitz et al. 2009). The differentiation 
process is especially evident in keratinized epithelium, where the released lipids are 
organized in broad, lamellar stacks that fill most of the extracellular space (Squier and 
Wertz 1996). In addition, the intracellular cytokeratin filaments aggregate in tight bundles, 
filling the cells entirely with keratin (Berkovitz et al. 2009). In nonkeratinized epithelium, 
the changes are less marked: the extracellular lipids do not form organized lamellae and the 
intracellular cytokeratin filaments do not aggregate together (Squier and Kremer 2001). The 
cells also retain their nuclei and some other cytoplasmic organelles. These differences lead 
to a greater permeability in the nonkeratinized epithelium as compared to keratinized 
epithelium.  
2.1.2 Physiological environment of the oral cavity 
The most important factor controlling the oral environment is the continuous secretion of 
saliva (Patel et al. 2011). Saliva is an aqueous fluid secreted by the three major salivary 
glands and several minor salivary glands located beneath the oral mucosa. Its main 
functions are to protect and lubricate the oral tissues and to maintain an appropriate oral 
pH and enzymatic activity. Saliva is mainly composed of water but it does contain 
approximately 1% of inorganic and organic substances, such as electrolytes, proteins and 
mucins (Rathbone et al. 1994, Patel et al. 2011). Mucins are glycoproteins that can form 
disulfide-connected networks and are thus responsible for the viscoelastic properties of 
saliva (Schenkels et al. 1996). They have an important role in the oral mucosal barrier 
function as the viscous mucin network slows the diffusion rate of exogenous compounds 
and restricts the passage of large molecules.  
Saliva is a weak buffer and its pH can range from 5.8 to 7.4 (Weatherell et al. 1996). The 
average volume of saliva present in the mouth is estimated to be 0.9 ml for men, 0.8 ml for 
women and 0.4 ml for five-year-old children (Lagerlöf and Dawes 1984, Watanabe and 
Dawes 1990). Saliva is distributed in the oral cavity as a thin mobile film, the average 
thickness of which is approximately 0.1 mm in both adults and children (Collins and Dawes 
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1987). In intraoral drug delivery, the continuous production of saliva provides a solvent for 
drug dissolution but, on the other hand, it may result in the rapid removal of drugs and 
drug delivery systems from the oral cavity due to involuntary swallowing (Rathbone et al. 
1996, Hao and Heng 2003). The salivary layer also contributes to the oral permeability 
barrier as it forms an unstirred water layer through which drugs have to diffuse before they 
can be absorbed across the epithelium. The interactions of drugs with the salivary mucin 
network may also influence the efficiency of intraoral drug delivery. 
Another physiological characteristic affecting the intraoral delivery of drugs is the 
vasculature of the oral cavity. Drugs absorbed through the oral mucosa enter directly into 
the systemic circulation via the three main veins that drain in the internal jugular vein 
(Rathbone et al. 1996). The blood flow varies in the different areas of the mouth, being the 
highest in the upper side of the tongue and lowest in the palatal areas and the floor of the 
mouth (Squier and Wertz 1996, Kurosaki and Kimura 2000). In spite of these variations, it is 
generally considered that the blood flow is sufficiently fast in all areas of the oral cavity that 
it would not be a limiting factor determining the rate of drug absorption (Kellaway et al. 
2002).  
2.1.3 Absorption of drugs through the oral mucosa  
The main permeability barrier of the oral mucosa is located in the outermost third or 
quarter of the epithelium in both keratinized and nonkeratinized epithelia (Squier 1991, 
Harris and Robinson 1992). The barrier coincides with the level where membrane-coating 
granules can be found and therefore, it has been concluded that the extracellular lipids 
between the flattened cells are mostly responsible for the barrier properties and that 
keratinization itself plays a less significant role in the barrier function. The lower, less 
flattened cell layers as well as the basement membrane and the connective tissue do not 
generally limit the passage of drugs. However, the basement membrane has been reported 
to act as a barrier for some large permeants such as immunocomplexes or endotoxins 
(Rathbone and Tucker 1993). The permeability of the oral mucosa varies between different 
regions of the oral cavity due to the local variation in the structure and thickness of the 
epithelium. The permeability has been found to decrease in the order sublingual > buccal > 
palatal, which is in accordance with the thickness and degree of keratinization of these 
epithelia (Harris and Robinson 1992). For example, in the study of Lesch and coworkers 
(1989), the permeability coefficients of tritiated water through human palatal, buccal and 
sublingual mucosae were determined to be 4.7×10-5, 5.8×10-5 and 9.7×10-5 cm/min, 
respectively. As another example, Squier and Hall (1985) studied the permeation of tritiated 
water and horseradish peroxidase through different areas of porcine oral mucosa. The 
permeability coefficients (cm/min) for tritiated water were 2.8×10-5 (palatal), 4.5×10-5 (buccal) 
and 7.5×10-5 (sublingual). For horseradish peroxidase, the corresponding values were 
2.2×10-5, 1.1×10-5 and 4.3×10-5, respectively. 
The absorption of a drug through the oral mucosa involves several steps (Figure 2.2), 
and any of these steps can be rate-controlling, depending on the physicochemical 
properties of the drug. Before absorption through the oral epithelium can take place, the 
drug needs to be released from the formulation and to dissolve in saliva (Mathias and 
Hussain 2010). The dissolved drug then has to diffuse through the unstirred salivary layer 
and the underlying epithelium. Most drugs move through the oral epithelium by passive 
diffusion via either the transcellular or the paracellular pathways (Harris and Robinson 
1992). In transcellular diffusion, the drug must pass through the cell membranes and across 
the cytoplasm from one cell to the next. In paracellular transport, the drug diffuses between 
the cells in the extracellular space. Both hydrophilic and lipophilic drugs can use either of 
the two routes or both routes simultaneously, but the route with the least penetration 
resistance is preferred. The paracellular diffusion of lipophilic drugs occurs in the lipidic 
areas of the extracellular matrix, whereas hydrophilic drugs use the aqueous channels 
between the lipidic areas (Rathbone and Tucker 1993). In transcellular permeation, 
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lipophilic drugs cross the cell membranes by diffusing through the lipid bilayers, and 
hydrophilic drugs enter the cell via the aqueous pores in the cell membranes.  
In addition to passive diffusion, there have been reported to be active transport 
mechanisms for some substances to help them cross the oral epithelium. For example, there 
is evidence of a saturable carrier-mediated transport mechanism for D-glucose on the 
surface of the tongue and across a cultured oral mucosal cell layer (Kurosaki et al. 1998, 
Kimura et al. 2002). Other substances reported to be absorbed through the oral epithelium 
by specialized transport mechanisms include nicotinic acid, amino acids, thiamine, 
glutathione and cefadroxil (Kurosaki and Kimura 2000). 
 
 
Figure 2.2. Sequence of drug dissolution and absorption through the oral mucosa, and the 
factors affecting each phase 
 
2.1.4 Methods to study drug permeation and absorption through the oral mucosa 
Several models have been applied to study the in vitro permeation and in vivo absorption of 
drugs through the oral mucosa. In vitro permeability experiments are usually done using 
either cell culture models or excised animal tissues mounted in diffusion cells (Goswami et 
al. 2008, Patel et al. 2012). TR146 cells are an example of a cell line used to model the oral 
mucosa. This cell line is derived from human buccal carcinoma (Jacobsen et al. 1995, 
Nielsen and Rassing 2000). Another example is the HO-1-u-1 cell line that originates from 
human sublingual squamous cell carcinoma (Wang et al. 2007, 2009). In both models, the 
cells grow to form a stratified nonkeratinized epithelium that both histologically and 
morphologically resembles the human oral mucosal epithelium. The benefits of cell culture 
models include the precise control of the experimental conditions, good reproducibility, 
possibility to study permeation mechanisms and pathways, and consistent supply of tissue 
without having to sacrifice animals (Audus 1996, Wang et al. 2007). On the other hand, the 
growth and differentiation of cultured cells may be different from the in vivo situation. In 
addition, the TR146 model shows greater permeability than excised buccal mucosa, 
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possibly due to its cancerous origin (Patel et al. 2012). For example, the apparent 
permeability coefficient (Papp) for nicotine (Mw 162.2 g/mol, log P 1.2) was 1675 times higher 
in the TR146 model as compared to the corresponding value obtained using excised porcine 
buccal mucosa (Nielsen and Rassing 2002). In another study, the Papp values obtained for 
mannitol (Mw 182.2 g/mol, log P -3.1) and testosterone (Mw 288.4 g/mol, log P 3.3) using the 
TR146 model were 1020 times higher than those observed when human or porcine buccal 
mucosa were used (Nielsen and Rassing 2000). 
Excised animal tissues represent a widely used method to study the permeability of oral 
mucosa, with the most common source being porcine buccal mucosa (Kulkarni et al. 2010). 
In these methods, the tissue is surgically harvested immediately after sacrificing the animal, 
and the isolated membranes are then placed in diffusion cells before undertaking the 
permeation experiments (Shojaei 1998). These models allow straigthforward modification 
of the study setup and conditions, but also have many drawbacks, such as extensive 
variability between experiments, decreasing viability and integrity of the tissue after 
dissection, and the absence of the salivary layer (Audus 1996, Goswami et al. 2008, Kulkarni 
et al. 2010, Patel et al. 2012). 
The choice of the appropriate animal species is essential both in studies applying excised 
tissues and in in vivo absorption studies. Most small laboratory animals, such as mice, rats 
and hamsters, have a fully keratinized oral mucosa that does not resemble human mucosa, 
and these models will therefore be of limited value in predicting the drug permeation and 
absorption in humans (Squier and Wertz 1996, Shojaei 1998, Goswami et al. 2008). The 
rabbit is the only laboratory rodent with a nonkeratinized lining mucosa, and it is therefore 
widely used for in vivo absorption studies (Dali et al. 2006). The limitations of the rabbit 
model include the small area of the nonkeratinized mucosa and the difficult access to the 
oral cavity. Larger animals, such as dogs, pigs and monkeys, have a nonkeratinized oral 
mucosa that resembles human oral tissues in terms of structure, composition and 
permeability (Squier and Wertz 1996). The porcine oral mucosa best resembles the human 
mucosa and therefore it has been extensively used in in vitro permeation experiments 
(Kulkarni et al. 2010, Patel et al. 2012). The oral mucosa of monkeys and dogs, on the other 
hand, is somewhat thinner and more permeable (Lesch et al. 1989, Squier and Wertz 1996).  
The most realistic evaluation of the in vivo intraoral absorption of drugs can be achieved 
with human volunteers. In humans, the intraoral absorption has been studied using the so-
called buccal absorption test, in situ perfusion cells, or various drug delivery systems, such 
as tablets, patches or gels (Harris and Robinson 1992, Patel et al. 2012). The buccal 
absorption test is a simple method, where a drug solution is swirled in the mouth for a 
given time and then expelled. In situ perfusion cells attached to the oral mucosa can be used 
to assess the absorption from a limited area of the oral mucosa and to study regional 
variations in drug absorption (Rathbone 1991, Kurosaki et al. 1997). The use of drug 
delivery systems is most similar to the real-life situation and it provides a way to evaluate 
the in vivo performance of drug formulations. In all these experimental setups, the drug 
absorption may be determined by following the appearance of the drug in the bloodstream 
or by analyzing the pharmacological response caused by the drug (Harris and Robinson 
1992). In some cases, the extent of drug absorption has been estimated by measuring the 
amount of drug that has disappeared from the vehicle or delivery system. However, it must 
be noted that the disappearance of the drug from the vehicle does not necessarily mean that 
the drug is absorbed through the oral mucosa into the systemic circulation, e.g. the drug 
may be stored in the oral mucosal membrane or it may have been unintentionally 
swallowed. Therefore, measuring the plasma concentration or the pharmacological 
response of the drug is a more appropriate way to determine the extent of intraoral drug 
absorption. 
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2.1.5 Advantages and challenges of intraoral drug delivery 
Intraoral drug administration represents an attractive drug delivery option, since it offers 
several advantages (Table 2.1). In comparison to peroral administration, the intraoral route 
confers some important pharmacokinetic benefits, such as the bypass of first-pass 
metabolism and rapid transport to the systemic circulation, often achieving peak plasma 
concentrations within 10 to 15 minutes after administration (Madhav et al. 2009). In 
addition, intraoral administration is easy, convenient and painless, and therefore it is more 
popular with patients than intravenous injections or administration via other transmucosal 
routes (i.e. the nasal, rectal, vaginal, pulmonary and ocular routes). 
The intraoral administration route also has some disadvantages that are related to the 
anatomical and physiological features of the oral cavity (Table 2.1). Due to the barrier 
properties of the oral epithelium and the short residence time of drug formulations in the 
oral cavity, the intraoral delivery is limited to potent drugs with low molecular weights and 
which have well balanced hydrophilic and lipophilic characteristics in the salivary pH 
(Mathias and Hussain 2010). These requirements are reflected in the drugs that are 
currently on the market as sublingual or buccal formulations; for example glyceryl 
trinitrate, nicotine, fentanyl, buprenorphine and naloxone. With the exception of 
buprenorphine, their molecular weights are less than 350 g/mol, and their log P or log DpH 7 
values range from 1.2 to 2.3 (Moffat et al. 2006). Buprenorphine is somewhat larger and 
more lipophilic, its molecular weight being 467.6 g/mol (free base) and log P being 4.98. All 
these drugs are intended for acute or intermittent use, and their typical single doses are less 
than 2 mg. Another common characteristic of these drugs is that they undergo extensive 
hepatic first-pass metabolism after peroral administration. 
 
Table 2.1. Advantages and challenges of intraoral drug delivery and requirements for the 
intraorally administered drug and the drug delivery system (Rathbone et al. 1994, Shojaei 
1998, Kurosaki and Kimura 2000, Hao and Heng 2003, Goswami et al. 2008, Madhav et al. 
2009, Mathias and Hussain 2010) 
Advantages of intraoral 
drug delivery 
Challenges and limitations 
of intraoral drug delivery 
Requirements for the drug 
and the delivery system 
 Avoidance of presystemic 
metabolism in the liver and  
gut wall 
 Rapid onset of action 
 Avoidance of gastric conditions 
(enzymatic degradation,  
low pH) 
 Low enzymatic activity 
 Robust mucosa that recovers 
fast from damage and stress 
 Good patient acceptability 
 Easy, painless administration 
 Suitable for patients suffering 
from nausea, vomiting or 
swallowing difficulties 
 Water not needed for 
administration 
 Small surface area for 
absorption (~100 cm2) 
 Low permeability compared to 
intestinal absorption 
 Considerable differences in 
permeability between different 
regions of the oral cavity 
 Small volume of saliva 
 Involuntary swallowing of saliva 
 Short residence time in the oral 
cavity (with the exception of 
mucoadhesive formulations) 
 Limited dose of drug 
 Sufficient solubility in saliva 
 Sufficient dissolution rate in 
saliva 
 Sufficient permeability through 
the oral mucosa 
 Sufficient potency and low dose 
 Acceptable size of the delivery 
system 
 Acceptable taste and texture  
 No adverse effects on the teeth 
or oral microflora 
 No irritancy and allergenicity 
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2.2 FAST-DISINTEGRATING OR FAST-DISSOLVING FORMULATIONS FOR 
INTRAORAL DRUG ADMINISTRATION 
2.2.1 Dosage forms for intraoral administration 
Several dosage forms are available for local or systemic drug delivery in the oral cavity. 
Liquid and semisolid dosage forms, including mouthwashes, suspensions, gels and creams, 
are usually employed to exert a local action within the oral cavity (Patel et al. 2011, Sankar 
et al. 2011). An intraoral aerosol spray has been used for the systemic administration of 
glyceryl trinitrate and more recently, insulin (Guevara-Aguirre et al. 2004, Palermo et al. 
2011, Hearnden et al. 2012). Chewing gums can now be considered as traditional dosage 
forms for the systemic administration of nicotine, and they provide an interesting 
opportunity for patient-controlled drug release to be modified by the rate and duration of 
chewing (Madhav et al. 2009). The most commonly used formulations in intraoral 
administration are solid dosage forms, such as tablets, lozenges, patches and wafers. They 
are often used to achieve systemic drug delivery and comprise a wide variety of 
formulation technologies and drug release characteristics. 
Intraorally administrated tablets can be formulated for either immediate or controlled 
release of the active drug. When prolonged drug release is desired, bioadhesive buccal 
tablets or patches can be used (Madhav et al. 2009, Patel et al. 2011, Hearnden et al. 2012). 
These types of formulations adhere to the buccal mucosa and are retained in the oral cavity 
for an extended period of time. The rate and directionality of drug release may be 
controlled e.g. by using multilayered tablet structures or impermeable tablet coatings. 
Immediate release intraoral tablets need to disintegrate and dissolve rapidly, as the 
involuntary swallowing of saliva quickly washes the tablet and the active drug out of the 
oral cavity (Pfister and Ghosh 2005, Hearnden et al. 2012). The terminology related to 
rapidly disintegrating or dissolving intraoral tablets is broad and several terms have been 
used interchangeably in the literature, for example orally disintegrating tablets, orally 
dissolving tablets, orodispersible tablets, mouth-dissolving tablets, fast/rapid disintegrating 
tablets, fast/rapid/quick dissolving tablets and fast/rapid melting tablets. Although the 
terms “orally disintegrating” and “orally dissolving” are sometimes used as synonyms, a 
distinction can be made between them. Orally disintegrating tablets can be defined as solid 
dosage forms that disintegrate in the oral cavity within seconds or minutes, releasing the 
active drug, which disperses and sometimes also partly dissolves in saliva (Ghosh et al. 
2005). The saliva is then swallowed and the drug is absorbed from the gastrointestinal tract, 
although minor pregastric absorption may take place before swallowing. Orally dissolving 
or “melting” tablets, on the other hand, are truly dissolved in saliva, and the drug is 
absorbed into the bloodstream through the oral mucosal membranes. 
The most important requirement for an intraoral immediate release formulation is 
obviously a sufficiently fast disintegration and dissolution rate. Fast-disintegrating and 
fast-dissolving tablets generally undergo disintegration or dissolution in saliva in a time 
span ranging from a few seconds to approximately one minute (Fu et al. 2004, Pfister and 
Ghosh 2005). The European Pharmacopoeia (Ph.Eur. 7th ed.) states that orally 
disintegrating tablets should disintegrate in the oral cavity within three minutes before 
swallowing, whereas FDA defines that they disintegrate usually within a matter of seconds 
(FDA 2008). There are also other important characteristics and requirements for intraorally 
administered dosage forms (Table 2.1). For example, taste-masking of the active drug is 
essential, as the drug will dissolve close to the taste buds (Habib et al. 2000, Fu et al. 2004). 
The formulation should have a smooth texture and a pleasant mouth feel. Ideally, the 
product should also possess adequate mechanical strength to withstand normal packaging 
and handling (Fu et al. 2004). 
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2.2.2 Improvement of the dissolution rate of drugs 
A fast dissolution rate of the drug in saliva is crucial in intraoral drug administration. The 
dissolution process of a drug involves the transfer of molecules from the surface of the solid 
drug into the liquid phase through a stagnant diffusion layer that is formed adjacent to the 
dissolving surface. The dissolution rate of a solid drug can be expressed using the modified 
Noyes-Whitney equation: 
 
(Equation 2.1) 
 
 
where dm/dt is the dissolution rate (change in mass per time), A is the surface area of the 
solid drug available for dissolution, D is the diffusion coefficient of the drug, h is the 
thickness of the diffusion layer, Cs is the saturation solubility of the drug, and C is the 
concentration of the drug in the dissolution medium (Noyes and Whitney 1897, Sinko and 
Singh 2011). With respect to intraoral drug delivery, the most feasible strategies to improve 
the dissolution rate of the drug are increasing the saturation solubility of the drug or 
increasing the surface area of the drug available for dissolution. Some examples of these 
strategies will be discussed below. 
 
Using different polymorphic forms of the drug 
Most drugs are able to crystallize in several polymorphic forms (Florence and Attwood 
2006, Buckton 2007, Sinko and Singh 2011). It is possible that one can obtain different 
polymorphic forms e.g. by melting, rapid cooling or recrystallization from different 
solvents. These polymorphs have the same chemical composition, but they differ from each 
other in their crystal structures and crystal lattice energies. Due to these differences, the 
polymorphic forms also possess different physicochemical properties, such as melting 
point, apparent solubility, dissolution rate, stability, and hygroscopicity. The most stable 
polymorph has the lowest energy, whereas the other, metastable forms have a higher 
energy, and thus also higher apparent solubility and dissolution rate. The disadvantage of 
the use of high-energy polymorphic forms is that they may convert to other metastable 
polymorphic forms or to the most stable, less soluble form during processing and storage. 
Furthermore, the effects of metastable polymorphs on the apparent solubility and 
dissolution rate are usually relatively small: the differences in the apparent solubilities of 
stable and metastable polymorphs are typically less than 2-fold (Pudipeddi and Serajuddin 
2005). For example, Shah et al. (1999) prepared a metastable polymorph of etoposide by 
recrystallization and found that this polymorph possessed 1.9-fold better apparent 
solubility and 1.7-fold intrinsic dissolution rate in comparison to the most stable form.  
 
Using an amorphous form of the drug 
In addition to the different polymorphic forms, drugs may exist in an amorphous form 
(Buckton 2007). The amorphous form of a drug may display short-range molecular order 
between neighbouring molecules, but it lacks a distinguishable three-dimensional crystal 
structure (Hancock and Zografi 1997, Yu 2001). There are several commonly used methods 
to produce amorphous material e.g. cooling from melt, rapid precipitation by freeze- or 
spray-drying, and mechanical activation by milling or grinding (Hancock and Zografi 1997, 
Yu 2001, Kaushal et al. 2004). Due to the absence of a crystal lattice, amorphous materials 
have a higher free energy and molecular motion relative to the crystalline state, leading to 
increased apparent solubility and a faster dissolution rate (Kaushal et al. 2004). However, 
their higher free energy also makes the amorphous forms physically and chemically 
unstable and prone to convert to the more stable crystalline form during storage or 
processing, especially when exposed to heat and humidity (Yu 2001, Kaushal et al. 2004). In 
comparison to the use of different polymorphic forms, conversion to the amorphous state 
generally provides a higher increase in the apparent solubility and in the dissolution rate of 
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the drug (Huang and Tong 2004). For example, Karmwar and coworkers (2012) prepared 
amorphous indomethacin by cryo-milling and observed that its dissolution rate was 
significantly higher (approximately 10-fold) as compared to the crystalline alpha and 
gamma polymorphs of indomethacin. 
 
Micronization or nanosizing of the drug 
Reduction of the particle size of a drug increases its surface area and hence improves the 
dissolution rate. For example, Ning and coworkers (2011) determined the dissolution rate 
of glimepiride from tablets that were prepared using different particle size fractions of the 
drug. When the tablets prepared from coarse glimepiride powder (145 μm) were compared 
to those made from glimepiride that had been micronized down to 10 μm, there was a 
fivefold difference in the dissolved amount of glimepiride at 1 h. The lowest particle size 
that can be obtained with conventional milling techniques is approximately 23 μm, which 
is sometimes not sufficient to improve the dissolution rate (Kawabata et al. 2011). Further 
particle size reduction can be achieved with various nanosizing techniques (Kesisoglou et 
al. 2007). One limitation of micronization is that the resulting materials often have poor 
flow and wetting properties, for example there may be generation of static charges during 
milling which can cause particle agglomeration (Chaumeil 1998, Kaushal et al. 2004). The 
high energy used in the milling processes may also disrupt the crystal lattice of the drug 
and create partially amorphous surfaces, leading to a higher dissolution rate but sometimes 
also to physical and chemical instability (Rasenack et al. 2003). 
 
Formation of salts 
Salt formation with suitable counterions is a widely used method to improve the apparent 
aqueous solubility and dissolution rate of acidic or basic drugs. When the salt dissolves, the 
counterions create a favorable pH change in the diffusion layer that is formed on the 
surface of the dissolving particle (Serajuddin 2007, Kawabata et al. 2011). This change of pH 
increases the apparent solubility of the drug in the diffusion layer, leading to a higher 
dissolution rate relative to the free acid or base form of the drug. For example, salt 
formation with cyclamic acid has increased the apparent aqueous solubility of lamotrigine 
by 19-fold and its intrinsic dissolution rate in water by 4.9-fold (Rahman et al. 2012). The 
most suitable counterion for a particular drug needs to be carefully selected, since different 
salts have different apparent solubilities and dissolution rates. The salt forms also have an 
influence on other important drug properties, such as hygroscopicity, chemical stability, 
crystal form, and toxicity (Bastin et al. 2000). One possible drawback related to the use of 
drug salts is that depending on the pH, they may precipitate back to the more slowly 
dissolving free acid or base form at the administration site (Serajuddin 2007). Another 
limitation is that this approach is only applicable for ionizable drugs. 
 
Solid dispersion technology 
Solid dispersions can be defined as systems, where a drug is homogenously dispersed 
within a carrier matrix (Kaushal et al. 2004). Based on their crystallinity and phase 
composition, solid dispersions can be classified into different types e.g. solid solutions, 
solid suspensions and eutectic mixtures (Craig 2002, Kaushal et al. 2004, Vasconcelos et al. 
2007). The most common carrier materials used in solid dispersions are fully or partially 
amorphous hydrophilic polymers, such as polyethylene glycol, polyvinyl-pyrrolidone, and 
hydroxypropyl methylcellulose (Leuner and Dressman 2000, Vasconcelos et al. 2007). Solid 
dispersions can be prepared by a variety of methods; for example by melting, hot melt 
extrusion, solvent evaporation or supercritical fluid technology (Kaushal et al. 2004, 
Vasconcelos et al. 2007). Solid dispersions enhance the dissolution rate of drugs via several 
mechanisms. Since the drug is homogenously dispersed within the carrier matrix, its 
particle size is maximally reduced to nearly the molecular level (Kaushal et al. 2004). The 
drug is often converted into an amorphous, more rapidly dissolving form during solid 
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dispersion preparation (Vasconcelos et al. 2007). The intimate presence of the hydrophilic 
carrier also improves the wetting of the drug particles (Craig 2002, Kaushal et al. 2004). 
Moreover, the carrier materials may solubilize the drug and thereby increase its apparent 
aqueous solubility (Vasconcelos et al. 2007). However, there are some limitations associated 
with solid dispersions e.g. sensitivity to moisture and possible recrystallization of the 
amorphous materials during processing or storage. The study conducted by Laitinen et al. 
(2009) is a good example of the use of solid dispersion technology. In that experiment, a 
major improvement was achieved in the dissolution rate of perphenazine with a solid 
dispersion containing perphenazine and polyethylene glycol (PEG) 8000 in a 1:5 ratio. At 
non-sink conditions simulating the situation in the oral cavity, perphenazine was fully 
dissolved within one minute from the solid dispersion, whereas pure perphenazine 
achieved only 2% dissolution during 4 min. The work of Shah and coworkers (1995) is 
another example; they investigated a solid dispersion containing etoposide and PEG 8000 
in a 1:10 ratio. In comparison to their other study where a metastable polymorph of 
etoposide showed less than 2-fold dissolution rate compared to unprocessed etoposide 
(Shah et al. 1999), the solid dispersion approach provided a higher increase in the 
dissolution rate. From the solid dispersion, the apparent solubility of etoposide was 
doubled and the intrinsic dissolution rate was 42-fold better as compared to unprocessed 
etoposide. 
 
Cyclodextrin complexation 
The formation of inclusion complexes with cyclodextrins (CDs) has been demonstrated to 
increase the apparent aqueous solubility and dissolution rate of poorly soluble drugs 
(Loftsson and Brewster 1996). More detailed discussion on CDs and examples of their 
effects on the apparent solubility and dissolution rate of drugs can be found in Chapter 2.3. 
2.2.3 Preparation of intraorally fast-disintegrating or fast-dissolving formulations 
Various technologies have been utilized to produce drug formulations that disintegrate or 
dissolve rapidly in the oral cavity. Fast-disintegrating and fast-dissolving tablets are often 
prepared using routine pharmaceutical processes such as freeze-drying, melt extrusion, 
molding and compression (Fu et al. 2004, Goel et al. 2008). In general, the fast disintegration 
of the dosage form requires a rapid ingress of liquid into the formulation when it comes 
into contact with saliva (Goel et al. 2008). This can be achieved by maximizing the porosity 
of the material, and by choosing highly wettable and water-soluble excipients. Saccharides 
and sugar alcohols (e.g. mannitol, xylitol, glucose or sucrose) are widely used in fast-
disintegrating and fast-dissolving formulations, since they have a high aqueous solubility, 
sweet taste and a pleasant mouth feel (Fu et al. 2004). Other typical excipients include 
gelatin, dextrans, dextrins, alginates and microcrystalline cellulose. The disintegration of 
the tablets is often promoted by incorporating disintegrating agents, such as cross-linked 
polyvinylpyrrolidone, modified starches or modified celluloses. Due to the nature of the 
excipients and preparation processes, fast-disintegrating and fast-dissolving formulations 
are often soft, friable and sensitive to moisture, sometimes requiring special packaging to 
protect them from moisture and mechanical stress (Habib et al. 2000). 
The freeze-drying technique involves freezing a solution or suspension containing the 
drug and excipients, after which water is removed by sublimation at reduced pressure. An 
example of the freeze-drying technique is the Zydis® process that was used in the first 
commercialized orally fast-dissolving dosage forms, and is currently the basis for several 
marketed products e.g. Zyprexa® Zydis® (olanzapine; Eli Lilly), Claritin® Reditabs® 
(loratadine; Schering-Plough) and Maxalt®-MLT® (rizatriptan benzoate; Merck & Co.) 
(Seager 1998, Habib et al. 2000, Fu et al. 2004). In this process, the drug is first dissolved or 
dispersed in an aqueous solution containing water-soluble excipients such as saccharides 
and polymers (Seager 1998, Kearney 2002). The suspension is then frozen in preformed 
blister pockets and freeze-dried. The process produces highly porous wafer-like tablets 
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consisting of an open matrix network in which the drug is physically entrapped (Seager 
1998, Habib et al. 2000). Due to the high porosity and possible amorphization of the drug 
and the excipients during the freeze-drying process, these tablets possess superior 
dissolution properties in comparison to other types of fast-disintegrating and fast-
dissolving tablets (Dobetti 2001, Fu et al. 2004). The water-soluble excipients in the porous, 
freeze-dried structure dissolve instantaneously (< 5 s) on contact with saliva, releasing the 
active drug, which is then either dispersed or dissolved in saliva (Seager 1998, Dobetti 2001, 
Kearney 2002). The drawback of the freeze-drying method is that the resulting tablets are 
very fragile and hygroscopic, and thus need to be packaged in special peelable blister 
pockets (Habib et al. 2000, Fu et al. 2004). Another disadvantage is that the freeze-drying 
process is relatively lengthy and expensive. 
Compression methods utilize conventional tableting equipment and processes, which 
have been modified to be more suitable for the preparation of fast-disintegrating or fast-
dissolving tablets (Sastry et al. 2000). For example, the tablets need to be more porous than 
conventional tablets, and superdisintegrants are often required to promote tablet 
disintegration (Fu et al. 2004, Rawas-Qalaji et al. 2006). The benefits of the compression 
methods are convenience, simplicity, and low manufacturing costs (Fu et al. 2004). The 
compressed tablets usually have a high mechanical strength but, on the other hand, their 
disintegration and dissolution rates are slower than those of freeze-dried tablets (Dobetti 
2001). There are some commercial applications using compression methods e.g. the 
Orasolv® and Durasolv® processes. The Orasolv® tablets are prepared by direct compression 
with very low compaction pressure (Habib et al. 2000, Fu et al. 2004). Effervescent agents 
may be utilized to promote fast disintegration. They release gas upon contact with saliva, 
induce salivation and provide a pleasant fizzing sensation. The tablets are not very 
sensitive to moisture, but require special packaging due to their softness and fragility. The 
Durasolv® process involves direct compression of a powder mixture containing non-
directly compressible fillers that have a smaller particle size as compared to directly 
compressible materials (Pather et al. 2002, Fu et al. 2004). The resulting tablets are robust 
but still fast-disintegrating, and they can be packaged in conventional bottles or blisters. 
Examples of marketed fast-disintegrating tablets prepared by compression methods include 
Remeron® SolTabs® (mirtazapine; Organon) and Zomig-ZMT® (zolmitriptan; AstraZeneca) 
which utilize the Orasolv® technology, and Alavert® (loratadine; Pfizer), which is prepared 
by the Durasolv® process. 
The molding methods can be subdivided into compression molding and heat-molding 
techniques (Fu et al. 2004). Both methods utilize water-soluble ingredients, such as 
saccharides. In compression molding, a powder mixture is moistened with a solvent and 
molded into tablets using low compaction forces, after which the solvent is removed by 
drying (Dobetti 2001). In heat-molding, the tablets are molded from a molten carrier matrix, 
in which the drug has been dissolved or dispersed. Molded tablets typically disintegrate 
and dissolve rapidly and they have a pleasant taste due to their high sugar content (Dobetti 
2001, Fu et al. 2004). However, the high costs and low mechanical strength of the tablets 
limit the applicability of these techniques. 
The FlashDose® process is a unique method for preparing fast-disintegrating or fast-
dissolving tablets. In this process, the simultaneous action of flash melting and spinning is 
used to convert a crystalline matrix containing the drug and saccharides into an amorphous 
floss that resembles cotton candy (Habib et al. 2000, Goel et al. 2008). The floss is then 
partially recrystallized to yield a material with a high specific surface area, fast dissolution, 
and good tableting properties (Habib et al. 2000, Dobetti 2001). The matrix is ultimately 
tableted using conventional methods. Tablets utilizing the FlashDose® technology are 
typically soft, friable and moisture-sensitive, requiring specialized packaging (Habib et al. 
2000). Furthermore, the high processing temperature limits the use of the method to 
thermostable ingredients (Goel et al. 2008). The FlashDose® process is currently used in one 
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commercially available product containing tramadol hydrochloride as the active drug 
(Ralivia Flashdose®; Valeant Pharmaceuticals). 
2.3 CYCLODEXTRINS 
2.3.1 Structure and physicochemical properties of cyclodextrins 
Cyclodextrins (CDs) are a family of cyclic oligosaccharides consisting of six (α-CD), seven 
(β-CD), eight (γ-CD) or more α-D-glucopyranose (glucose) units linked together by α-(1,4) 
glucosidic bonds. Natural α-, β- and γ-CDs are produced from starch in an enzymatic 
process using cyclodextrin glucosyl transferase (CGTase) enzymes (Biwer et al. 2002). The 
chair conformation of the glucose subunits confers on CDs the distinctive shape of a 
truncated cone (Figure 2.3), where secondary hydroxyl groups are located at the wider edge 
and primary groups at the narrower edge (Loftsson and Brewster 2010). The hydroxyl 
groups make the outer surface of the molecule hydrophilic, whereas the inner cavity lined 
with skeletal carbons and ethereal oxygens is relatively lipophilic. The polarity of the CD 
cavity has been estimated to be similar to the polarity of a 40% aqueous ethanolic solution 
(Frömming and Szejtli 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. The molecular structure and the conical shape of natural β-cyclodextrin 
 
The three natural CDs are crystalline substances and differ from each other in their 
physicochemical properties, most importantly aqueous solubility (Table 2.2). Although the 
outer surfaces of the CD molecules are hydrophilic, the aqueous solubility of all natural 
CDs is limited, which is attributable to their high crystal lattice energy (Loftsson and 
Brewster 1996). The very low solubility of natural β-CD in water is due to intramolecular 
hydrogen bonding between the secondary hydroxyl groups, which makes the molecular 
structure rigid and impedes hydrogen bonding with surrounding water (Frömming and 
Szejtli 1994). One can substitute the hydroxyl groups e.g. with hydroxyalkyl, methyl or 
sulfoalkyl moieties; this leads to a significant increase in solubility (Table 2.2), since this 
chemical modification not only disrupts the intramolecular hydrogen bonding, but also 
transforms the crystalline compounds into amorphous mixtures of isomeric derivatives 
(Szente and Szejtli 1999). In addition to their higher aqueous solubility, cyclodextrin 
derivatives may have other advantages over natural CDs, such as better complexing 
properties and improved safety in parenteral administration (Irie and Uekama 1997, Szente 
and Szejtli 1999). 
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Table 2.2. Physicochemical properties of natural α-, β- and γ-CDs and the most common CD 
derivatives (Frömming and Szejtli 1994, Dodziuk 2006, Loftsson and Brewster 2010) 
 α-CD β-CD γ-CD HP-β-CD RM-β-CD SBE-β-CD 
Number of glucose units 6 7 8 7 7 7 
Molecular weight (g/mol) 972 1135 1296 1400a 1312a 2162a, b 
Average degree of substitutionc    0.7 1.8 0.91.0 
Inner cavity diameter (pm) 470530 600650 750830 600650 600650 600650 
Solubility (25°C; g/100 ml)       
     in water 14.5 1.85 23.2 > 60 > 50 > 60 
     in ethanol insoluble insoluble > 0.1 > 0.1 n/a n/a 
Melting temperature range (°C) 255260d 255265d 240245d d d d 
Crystal water content (% w/w) 10.2 1315 818    
pKa 12.33 12.20 12.08 n/a n/a n/a 
n/a, not available 
a average molecular weight; b sodium salt; c number of substituted hydroxyl groups in one glucose unit;  
d decomposes 
 
2.3.2 Inclusion complex formation  
The three-dimensional molecular structure of CDs allows the formation of inclusion 
complexes, where a lipophilic guest molecule or moiety with a suitable size and 
stereochemistry can enter into the hydrophobic CD cavity. The formation of an inclusion 
complex does not involve covalent bonding, instead a reversible, dynamic equilibrium 
exists between the free drug, free CD and drug/CD complex. The complex formation 
appears to be driven by a combination of several forces, such as van der Waals forces, 
electrostatic interactions, hydrogen bonding, and charge-transfer interactions (Rekharsky 
and Inoue 1998, Liu and Guo 2002, Brewster and Loftsson 2007). The exclusion of high-
energy water bound in the CD cavity and the release of conformational strain of the CD 
molecule may also play a role in complex formation. 
Inclusion complex formation between a drug and a CD has been often investigated using 
the phase-solubility method, where the concentration of drug is measured as a function of 
the CD concentration  (Higuchi and Connors 1965). An excess of drug is added to a series of 
solutions with increasing CD concentrations, and the solutions are agitated until 
equilibrium is reached. Undissolved drug is removed by filtration or centrifugation, and 
the concentration of the drug is measured in each solution. The phase-solubility diagram is 
constructed by plotting the drug concentrations against the CD concentrations (Figure 2.4). 
Phase-solubility diagrams can be classified into two major types. When the apparent drug 
solubility increases as a function of the CD concentration and soluble complexes are 
formed, the phase-solubility diagrams are defined as A-type. This type of phase-solubility 
profiles can be linear (AL) or show positive (AP) or negative (AN) deviations from linearity. 
B-type phase-solubility diagrams (BS and BI) indicate the formation of complexes with 
limited solubility. B-type phase-solubility behaviour is typical for natural CDs, whereas A-
type phase-solubility diagrams can be observed with both natural CDs and highly water 
soluble CD derivatives. 
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Figure 2.4. Types of phase-solubility diagrams. S0 denotes the solubility of drug in the absence 
of CD. 
 
 
In aqueous solutions, drug/CD complexes are constantly formed and dissociated at a 
very rapid rate, usually in milli- or microseconds, or even less (Stella et al. 1999). This 
dynamic equilibrium can be described by the following equation: 
 
(Equation 2.2) 
  
where D and CD represent free drug and free CD, and D/CD is the inclusion complex. The 
equilibrium constant of the complex formation reaction is Kc, which is also often called the 
stability, association, complexation or binding constant. Most drugs form 1:1 complexes 
with CDs, although the formation of higher order complexes is also possible (Rao and Stella 
2003). The Kc of a 1:1 complex (K1:1) can be calculated using equation 2.3: 
 
(Equation 2.3) 
 
 
where K1:1 is the stability constant for the 1:1-drug/CD complex and [S0] is the solubility of 
the drug in the absence of CD (Higuchi and Connors 1965). The slope value is obtained 
from the linear part of the phase-solubility diagram. The magnitude of K1:1 is usually 
between 0 and 100 000 M-1; however in most cases K1:1 lies in the range of 50 to 2000 M-1 
(Rajewski and Stella 1996, Brewster and Loftsson 2007). 
CDs or drug/CD complexes do not easily permeate through biological membranes and 
therefore, the complexes need to dissociate in the body before the active drug can be 
absorbed (Stella and He 2008). The main driving force for the dissociation of inclusion 
complexes is simple dilution in biological fluids (Stella et al. 1999). There may be other 
mechanisms involved in the dissociation e.g. the binding of the drug to plasma proteins, the 
competitive displacement of the drug from the CD cavity by other molecules, and the 
partition of the drug into tissues that are not accessible to CD (Stella and He 2008). These 
secondary mechanisms may be more important in cases where the fluid volume is low and 
dilution alone is insufficient to cause complex dissociation. 
In addition to the inclusion complexes, the existence of non-inclusion complexes between 
drugs and CDs has been reported. It has been claimed that CDs and drug/CD complexes 
may associate to form micelles or nanoscale aggregates, and that these structures would be 
able to solubilize additional drug molecules (Loftsson et al. 2002, Magnusdottir et al. 2002, 
  )1(0
1:1 slopeS
slopeK


D + CD                            D/CD
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Jansook et al. 2010). The mechanisms for these phenomena are not yet totally clarified, but 
they may involve the formation of hydrogen bonds between drug molecules and the 
hydroxyl groups on the outer surface of the CD molecules (Brewster and Loftsson 2007). In 
addition, amphiphilic inclusion complexes of CDs with hydrophobic drugs may be 
arranged in micellar structures. For example, it has been reported that in aqueous solutions, 
the complexes of β-carotene and β-CD or γ-CD form micelles, in which the hydrophobic 
moieties of β-carotene are located inside the micelle, and the hydrophilic CDs are arranged 
on the outside (Mele et al. 1998). Although it has been estimated that inclusion complexes 
are much more common than their non-inclusion counterparts, both complex types can 
coexist especially in saturated solutions, and non-inclusion complexes may therefore 
contribute to the overall drug solubilization (Brewster and Loftsson 2007). 
Cyclodextrin complexes can be prepared by several methods either in solution or in solid 
state. The most appropriate complexation method for a particular drug/CD complex 
depends on the characteristics of the drug and the CD and the desired properties of the 
complex. On an industrial scale, the complexation yield, process simplicity, cost, and ease 
of scaling up also need to be taken into account (Mura et al. 1999). When CD complexes are 
prepared in solution, an excess of drug is simply added to an aqueous CD solution, and the 
suspension is agitated until equilibrium is reached. Finally, the undissolved drug is 
removed by filtration or centrifugation. If a solid complex is needed, there are several ways 
to remove the solvent e.g. by spray-drying, freeze-drying or vacuum-drying (Veiga et al. 
2001, Fernandes et al. 2002). When complexes are prepared in solution, it must be noted 
that the dried solid product does not only contain the drug/CD complex, but is in fact a 
mixture of the drug/CD complex, uncomplexed drug and uncomplexed CD. The 
proportions of the complexed and uncomplexed species depend on the Kc value (Equation 
2.2). Pure, crystalline drug/CD complexes can be produced by a precipitation method that 
utilizes the B-type phase-solubility behaviour between drugs and natural CDs. The 
advantage of the precipitation method is that it produces a pure, solid complex that does 
not contain either free drug or CD. On the other hand, the solubility of the crystalline 
complex is low, and the method is only applicable to drugs and CDs forming B-type phase-
solubility diagrams. On an industrial scale, drug/CD complexes are often prepared in a 
semisolid medium using the so-called kneading or slurry methods (Frömming and Szejtli 
1994, Hedges 1998, Loftsson and Brewster 2012). In the kneading method, the drug and CD 
are ground together in a minimal amount of solvent, for example water or a mixture of 
water and ethanol (Gil et al. 2004, Kratz et al. 2012). The slurry method involves vigorous 
mixing of a drug/CD suspension, in which a larger volume of solvent is used in comparison 
to the kneading method (Del Valle 2004). In both methods, the resulting paste or slurry is 
dried using an appropriate method.  
2.3.3 Use of cyclodextrins in pharmaceutical applications  
When drugs or other guest molecules form inclusion complexes with CDs, their chemical, 
physical and biological properties can be dramatically different from those of the free guest 
molecule (Rajewski and Stella 1996). This phenomenon has been widely utilized in various 
fields, such as analytical chemistry, biochemistry, pharmacy, agriculture, and food, textile 
or cosmetic industry (Szejtli 1998, Singh et al. 2002, Loftsson and Duchêne 2007). In 
pharmaceutical applications, CDs have been used for a variety of purposes, e.g. to improve 
the apparent aqueous solubility, dissolution rate, chemical, physical or enzymatic stability 
and bioavailability of drugs, to decrease local irritation, and to reduce unpleasant tastes and 
odours of drugs (Davis and Brewster 2004, Challa et al. 2005). Other pharmaceutical 
applications of CDs include the prevention of incompatibilities and converting liquids and 
oils into free-flowing powders (Davis and Brewster 2004). Some hydrophobic CD 
derivatives have also been utilized as carriers in sustained release or delayed release 
formulations (Uekama 2004, Salústio et al. 2011). 
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Safety is an important consideration when CDs are used in pharmaceutical applications. 
CDs are large, hydrophilic molecules that do not readily pass through biological 
membranes (Stella and He 2008). After peroral administration, only small amounts of CDs 
(usually 06%) are absorbed in an intact form (Antlsperger and Schmid 1996, Irie and 
Uekama 1997, Stella and He 2008). The more lipophilic methylated CD derivatives display 
somewhat higher oral bioavailability (612%) (Antlsperger and Schmid 1996). CDs are 
generally resistant to stomach acidic pH as well as to salivary or pancreatic amylases, with 
the exception of natural γ-CD that is digested by the amylases in the upper gastrointestinal 
tract (Antlsperger and Schmid 1996, Munro et al. 2004). Unabsorbed CDs are extensively 
degraded by the colonic microflora (Frömming and Szejtli 1994). In general, CDs are 
considered to be virtually nontoxic in peroral administration, and their adverse effects (i.e. 
transient diarrhea or soft stools) are similar to those of poorly digestible carbohydrates 
(Lina and Bär 2004, Stella and He 2008). The proposed safe daily intake levels for natural 
CDs in peroral administration are 1.9 (α-CD), 0.5 (β-CD), and 14 (γ-CD) g/kg/day 
(Antlsperger and Schmid 1996). In addition, a peroral daily dose of < 16 g (HP-β-CD) and a 
peroral single dose of 12 g (SBE-β-CD) have been reported to be nontoxic (Irie and Uekama 
1997, Gould and Scott 2005, Stella and He 2008). When CDs are administered 
intravenously, they disappear rapidly from the systemic circulation and are excreted 
unchanged via the kidneys (Irie and Uekama 1997, Stella and He 2008). The use of natural 
α-CD and β-CD in intravenous administration is limited, since they are known to 
accumulate in the kidneys, where they can cause cellular and histological changes that 
eventually lead to irreversible renal impairment (Frank et al. 1976, Stella and He 2008). The 
hemolytic activity of α-CD and β-CD is also higher than that of the other CDs (Irie and 
Uekama 1997). Methylated β-CD derivatives have also been found to induce renal toxicity 
due to their ability to interact with cellular lipids and to persist in the kidneys for a 
prolonged time after intravenous administration (Antlsperger and Schmid 1996, Irie and 
Uekama 1997, Stella and He 2008). The CDs most suitable for intravenous administration 
are HP-β-CD, SBE-β-CD and natural γ-CD, which have not been shown to cause 
irreversible renal alterations or any other serious adverse effects (Stella and He 2008). 
However, the use of γ-CD in injectable solutions may be hampered by its tendency to self-
aggregate and precipitate during storage (Szente et al. 1998). HP-β-CD and SBE-β-CD are 
currently found in commercially available intravenous formulations with daily doses as 
high as 14 g (Sporanox® containing itraconazole and HP-β-CD; Janssen Pharmaceutica) or 
16 g (Vfend® containing voriconazole and SBE-β-CD; Pfizer) (Loftsson and Brewster 2010). 
At the moment, five cyclodextrins are listed in pharmacopoeial sources. Natural α-CD 
and β-CD have monographs in the European Pharmacopoeia (Ph.Eur.), the United States 
Pharmacopeia/National Formulary (USP/NF) and the Japanese Pharmaceutical Codex (JPC) 
(Kurkov and Loftsson 2013). Natural γ-CD is included in USP/NF and JPC. HP-β-CD has a 
monograph in USP/NF and Ph.Eur., and SBE-β-CD has recently been included in USP/NF. 
In addition, γ-CD, HP-β-CD and SBE-β-CD have been added to the US Food and Drug 
Administration´s (FDA) list of inactive pharmaceutical ingredients that have already 
appeared in FDA-approved drug products and may thus require a less extensive review 
process the next time they are used in new drug products (FDA 2012a). Furthermore, FDA 
has conferred on natural CDs the “generally recognized as safe” (GRAS) status, allowing 
their use as food additives (FDA 2012b). At the moment, at least 35 CD-containing drug 
products are on the market in different countries (Kurkov and Loftsson 2013). In addition to 
the pharmacopoeially approved CDs, RM-β-CD and HP-γ-CD have been used in some 
commercial products. 
The amount of CD that can be included in a pharmaceutical formulation is limited for a 
variety of reasons. Toxicity and isotonicity must be taken into account in parenterally 
administered formulations, whereas in solid formulations, the effect of CD on the 
formulation bulk mass and volume is often a major challenge (Loftsson and Duchêne 2007, 
Miller et al. 2007). Furthermore, excess CD increases production costs and may decrease 
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drug bioavailability. If a hypothetical drug (Mw 350 g/mol) forms an ideal 1:1 complex with 
HP-β-CD (Mw 1397 g/mol), the bulk mass is increased fivefold assuming that every CD 
molecule is complexed with a drug molecule. However, in practice, the complexation 
efficiency is less than ideal. Various approaches have therefore been devised to improve the 
complexation efficiency, or more accurately, the solubilization efficiency of cyclodextrins 
(Loftsson and Duchêne 2007). For example, drug ionization (Li et al. 1998), or addition of a 
third, auxiliary component such as a cosolvent (Li et al. 1999, He et al. 2003), hydroxy acid 
(Redenti et al. 2000, Mura et al. 2001), amino acid (Mura et al. 2003, 2005), metal ion 
(Yamakawa and Nishimura 2003, Sami et al. 2010), or a water-soluble polymer (Loftsson et 
al. 1994, Ribeiro et al. 2003, Sami et al. 2010), have been found to enhance the complexation 
or solubilization efficiency. These strategies aim to increase either the apparent stability 
constant of the complex (Kc) or the apparent solubility of the drug (S0), or to increase both 
factors simultaneously (Loftsson and Brewster 2012). It has also been postulated that these 
auxiliary substances may enhance the overall drug solubilization by stabilizing CD 
aggregates, micellar structures or other types of non-inclusion complexes. 
2.3.3.1 Improvement of the apparent aqueous solubility and dissolution rate of drugs  
Increasing the apparent aqueous solubility and dissolution rate of drugs is probably the 
most widely utilized application for CDs in pharmacy. It is well known that the apparent 
aqueous solubility of a poorly soluble drug can be increased when it forms an inclusion 
complex with a CD (Loftsson and Brewster 1996). The degree of solubility enhancement 
depends on several factors, such as the type of CD used, the ionization of the drug, the 
complexation efficiency between the drug and the CD, and the presence of other substances 
that may increase or decrease drug complexation. A greater relative increase in solubility is 
generally achieved with drugs having aqueous solubility in the micromolar range as 
compared to drugs with solubilities in the millimolar range or higher.  
The improved dissolution rate of a drug in the presence of CD is due to the increased 
apparent aqueous solubility (Cs in Equation 2.1). Moreover, when solid drug/CD complexes 
are prepared, the resulting powder is often amorphous or less crystalline than the pure 
drug. CDs are also known to improve the wettability of solid substances (Frömming and 
Szejtli 1994, Deroubaix et al. 1995, Patel and Patel 2010). Some examples of the effect of CDs 
on the apparent aqueous solubility and dissolution rate of drugs are presented in Table 2.3.
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Table 2.3. Examples of the use of cyclodextrins in the improvement of apparent aqueous 
solubility and dissolution rate of drugs 
Drug  
(S0)* 
CD  
(conc.) 
Methods Observations Ref. 
Aripiprazole 
(0.009 mM;  
~4 μg/ml) 
HP-β-CD 
(260 mM; 
~36% w/v) 
Solubility was measured in 
pure water. Dissolution of 
the spray-dried complex 
filled in gelatin capsules 
was determined in 0.1 M 
HCl using the USP paddle 
method. 
Apparent aqueous solubility was 
improved by 1080-fold in the 
presence of HP-β-CD. After 10 
min, 80% of drug had dissolved 
from the drug/CD complex, 
whereas only 40% of plain drug 
had dissolved.  
Mihajlovic 
et al. 
2012 
Phenytoin 
(0.02 mg/ml) 
 
RM-β-CD 
(45% w/v) 
Solubility and dissolution 
rate were studied at pH 6. 
Dissolution of the freeze-
dried complex was studied 
using the USP paddle 
method. 
Apparent aqueous solubility was 
improved by 580-fold in the 
presence of RM-β-CD. Pure drug 
reached 5% dissolution during 10 
min and 32% dissolution during 
60 min. In contrast, the drug had 
fully dissolved from the drug/CD 
complex within 10 min. 
Latrofa et 
al. 2001 
Progesterone 
(0.011 mg/ml) 
HP-β-CD 
(300 mM; 
~45% w/v) 
 
Solubility and dissolution 
rate were determined in 
pure water. Dissolution 
study of the freeze-dried 
complex was conducted 
with the USP paddle 
method. 
Apparent aqueous solubility was 
improved by 3600-fold in the 
presence of HP-β-CD. The drug 
dissolved completely in less than 3 
min from HP-β-CD complex. The 
physical mixture of drug and HP-
β-CD showed < 30% dissolution at 
the same time point. The 
dissolution of pure drug was not 
studied. 
Lahiani-
Skiba et 
al. 2006 
Warfarin 
(8.6 μg/ml  
at pH 1.2;  
17.7 μg/ml  
at pH 5.0) 
β-CD 
(1:1 molar 
ratio to 
warfarin) 
Warfarin/β-CD complexes 
were prepared by knead-
ing, coevaporation and 
freeze-drying. Solubility 
and dissolution rate of 
warfarin and the 
complexes were deter-
mined at pH 1.2 or 5.0. 
Dissolution was measured 
using the USP paddle 
method. 
Apparent aqueous solubility was 
improved by 1629-fold (pH 1.2) 
or 1019-fold (pH 5.0) in the 
presence of β-CD. At pH 1.2, the 
times to reach 50% dissolution 
were > 180 min for pure warfarin, 
and 512 min for the warfarin/β-
CD complexes. At pH 5.0, the 
times to reach 50% dissolution 
were 100 min for pure warfarin, 
and < 26.5 min for the 
warfarin/β-CD complexes. 
Zingone 
and 
Rubessa 
2005 
Zolpidem 
(0.25 mg/ml) 
HP-β-CD 
(45% w/v) 
Solubility and dissolution 
rate were determined in 
pure water. Dissolution of 
the freeze-dried complex 
was measured using the 
USP paddle method. 
Apparent aqueous solubility was 
improved by 43-fold in the 
presence of HP-β-CD. Pure drug 
achieved only 28% dissolution 
within 10 min and 57% dissolution 
within 60 min. In contrast, the 
drug had fully dissolved from the 
drug/CD complex in 10 min. 
Trapani et 
al. 2000  
* S0, experimentally determined solubility in the absence of CD as reported in the reference 
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2.3.3.2 Cyclodextrins in the taste-masking of drugs 
Most orally administered drugs have a very bitter, even an extremely bitter taste, which is a 
problem especially in pediatric patients (Szejtli and Szente 2005, Cram et al. 2009). The 
bitter taste is observed when the drug dissolves in saliva and interacts with so-called 
gatekeeper proteins that are located in the taste buds of the tongue. Only dissolved 
substances can be tasted, but even virtually insoluble drugs may elicit unpleasant taste 
sensations already at ppm concentration levels. 
In pharmaceutical applications, a wide variety of techniques are available for taste-
masking of bitter drugs. The simplest and most common approach is to use flavours or 
sweeteners (Sohi et al. 2004, Ayenew et al. 2009). However, their efficacy is limited in the 
case of very bitter or highly water-soluble drugs administered at high doses, and therefore 
they are often used along with other taste-masking techniques, such as coating or 
granulation with hydrophilic polymers, or the use of ion-exchange resins that release the 
drug in the gastrointestinal tract. However, these technologies are not suitable for intraoral 
administration, where the drug needs to be released and dissolved quickly in saliva.  
Cyclodextrins have been used successfully in the taste-masking of bitter drugs (Table 
2.4). When CDs form inclusion complexes with bitter-tasting drugs, the strongly hydrated 
outer surface of the complex prevents the binding of the drug to the taste receptors (Szejtli 
and Szente 2005). In addition, CDs have a slightly sweet taste that may contribute to their 
taste-masking effect. The degree of taste-masking has been found to correlate with the 
stability constant of the inclusion complex (Szejtli and Szente 2005, Ono et al. 2011). 
However, with respect to intraoral drug administration, it must be noted that a high 
stability constant and a large excess of CD may hamper drug release from the complex in 
the small volume of saliva and thus decrease drug absorption through the oral mucosal 
membranes. A high amount of CD may also increase the size of the formulation making it 
too large for intraoral administration.  
In some cases, the most optimal taste-masking can be achieved using a combination of 
CD complexation and some other taste-masking technique. For example, β-CD alone did 
not significantly decrease the bitterness and astringency of (+)-catechin, a health-promoting 
flavonoid incorporated into functional foods and beverages (Gaudette and Pickering 2012). 
However, effective taste-masking could be achieved when β-CD was used together with 
sweeteners, such as sucrose or rebaudioside A. In some studies, ternary complexes 
containing a drug, a CD and a water-soluble polymer have been found to decrease the 
bitterness of drugs better than the corresponding binary complexes. Patel and Vavia (2008) 
investigated the taste-masking of famotidine in healthy volunteers and found that the 
ternary complex of famotidine, β-CD and hydroxypropyl methylcellulose had a very good, 
even excellent taste, while the taste of the binary famotidine/β-CD complex was rated 
somewhere between poor and fair. Similarly, Mady and coworkers (2010a) reported that 
the ternary complex of famotidine, SBE-β-CD and povidone K30 provided better taste-
masking than the binary drug/SBE-β-CD system, although the difference was not as 
prominent as that described in the study of Patel and Vavia (2008). 
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Table 2.4. Examples of the use of cyclodextrins in the taste-masking of drugs 
Drug CD(s) Dosage form Observations Reference 
Cetirizine 
 
β-CD Solution Thirteen volunteers tasted a solution 
containing cetirizine (1 mg/ml) and β-CD 
in a 1:5 molar ratio. The volunteers rated 
the solution as not bitter (n=5), slightly 
bitter (n=7) or moderately bitter (n=1). 
The taste of the pure drug solution 
(strongly bitter) was used as a reference.  
Stojanov et 
al. 2011 
Famotidine SBE-β-
CD  
Solution Twelve volunteers evaluated a solution 
containing the drug (0.6 mg/ml) and SBE-
β-CD in a 1:1 molar ratio to be very 
slightly bitter (n=4) or slightly bitter 
(n=8). The taste of the pure drug solution 
(very strongly bitter) was used as a 
reference. 
Mady et al. 
2010a 
Famotidine CM-β-
CD 
Orally fast-
disintegrating 
tablet 
Eight volunteers evaluated the taste of 
tablets that contained either famotidine 
(20 mg), or ternary famotidine/CM-β-
CD/povidone K 30 complex (equivalent to 
20 mg of famotidine). The complex 
contained CM-β-CD in a 1:1 molar ratio to 
famotidine, and 1% povidone K30. Tablets 
containing the ternary complex were 
tasteless (n=2) or slightly bitter (n=6). 
Tablets containing the free drug were 
bitter (n=3) or strongly bitter (n=5). 
Mady et al. 
2010b 
Ginsenosides 
(Panax ginseng) 
γ-CD Solution 0.09% γ-CD significantly reduced the 
bitter taste of ginseng (0.052%) as rated 
by a panel of twelve volunteers. 
Tamamoto et 
al. 2010 
Midazolam α-CD  
β-CD  
γ-CD 
Solution The investigators tasted solutions 
containing 5 mM of midazolam, 10 mM of 
CD and 40 mM of citric acid. α-CD did not 
affect the taste, whereas β-CD and γ-CD 
significantly decreased the bitterness of 
midazolam. 
Marcon et al. 
2009 
Oxyphenonium 
bromide 
 
β-CD Solution Five volunteers rated the bitterness of a 
solution containing the drug (4 mM) and 
β-CD (1% w/v) to 0.2 in a scale 05, 
where 0=no bitter taste and 1=very 
slightly bitter. The bitterness of plain drug 
solution was rated at 3.7. 
Funasaki et 
al. 2006 
Cetirizine, di-
chlorpheniramine,  
diphenhydramine, 
epinastine and 
hydroxyzine 
α-CD 
β-CD  
γ-CD  
HP-β-
CD 
Solution Seven volunteers observed the bitterness 
of the drugs (1 or 5 mM) to be greatly 
reduced in the presence of β-CD and HP-
β-CD (1030 mM), whereas α-CD and γ-
CD (10-30 mM) were less efficient. Degree 
of taste-masking correlated with the CD 
concentration and the stability constants 
of the complexes. 
Ono et al. 
2011 
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2.3.3.3 Cyclodextrins in intraoral drug formulations 
The ability of CDs to increase the apparent aqueous solubility and dissolution rate and to 
mask the bitter taste of drugs makes them interesting excipients for intraoral drug 
formulations. To date, CDs have been used in a few commercially available drug products 
administered in the oral cavity, including both sublingual tablets and chewable tablets. A 
well-known example of a CD-containing sublingual tablet is the Nicorette® Microtab 
(McNeil / Johnson & Johnson). The irritating, astringent taste of nicotine prevents its direct 
use in intraoral formulations, but complexation with β-CD masks the unpleasant taste and 
allows the preparation of a sublingual dosage form (Szejtli 2004). Other examples of drugs 
available as CD-containing sublingual tablets include prostaglandin E2 (Prostarmon E, 
Ono, Japan) and glyceryl trinitrate (Nitropen; Nihon Kayaku) (Loftsson and Brewster 2010). 
β-CD has also been used in chewable tablets containing cetirizine (Cetritzin, Losan Pharma) 
or in a preparation with a combination of diphenhydramine and chlortheophylline (Stada-
Travel, Stada). 
The use of CDs in intraoral drug formulations also poses some challenges. Since CDs or 
drug/CD complexes do not easily pass through the oral mucosal membranes, the drug 
needs to be released from the complex by dilution in saliva (Stella et al. 1999). The low 
volume of saliva and the short residence time of formulations in the oral cavity may lead to 
insufficient complex dissociation and thus to decreased bioavailability. Another issue is the 
effect of CDs on the formulation size. It has been estimated that the upper size limit of a 
buccal tablet is approximately 250 mg, and since other excipients are also needed, not more 
than 150 mg of a solid drug/CD complex can be included in the tablet (Loftsson 2002). Due 
to these limitations, the use of CDs for drug solubilization in intraoral formulations is not 
feasible in cases where the complexation efficiency of the drug with the CD is low or the 
dose of the drug is high. 
The safety of CDs in intraoral administration can be evaluated on the basis of the peroral 
and local safety of CDs. As discussed earlier in Chapter 2.3.3, most CDs have been found to 
be safe for peroral administration even at high doses. The local effects of CDs on the oral 
mucosa have been studied using a human oral epithelial cell culture model (TR146) or 
excised porcine buccal mucosa. Natural β-CD and HP-β-CD (14 mg/ml) as well as natural 
γ-CD (12 mg/ml) were found to exert only minor, if any, toxic effects on the TR146 cells 
(Pedersen et al. 1998, Jacobsen et al. 1999). A 24-h exposure of TR146 cells to a 10% RM-β-
CD solution caused a slight reduction in cell viability and some inflammatory effects, 
whereas 2% or 5% RM-β-CD solutions did not evoke any damage even after repeated 
exposures over a 5-day period (Boulmedarat et al. 2005). Thus, RM-β-CD was considered to 
be a safe excipient for intraoral administration at concentrations below 5%. When porcine 
buccal mucosa was exposed to inclusion complexes of omeprazole and β-CD or methyl-β-
CD (CD concentration approximately 1 mg/ml), the lactate dehydrogenase assay revealed 
no signs of cytotoxicity (Figueiras et al. 2009). In addition, viability studies and histological 
evaluations have indicated that the mucosa remained viable after a three-hour incubation 
with the complex solutions. In light of these findings, it may be assumed that CDs are not 
likely to cause significant toxicity in intraoral administration, especially considering the 
short residence time of the intraorally dissolving formulations in the oral cavity. 
In vitro studies have been conducted to assess the effect of CDs on drug release from 
intraorally administered formulations or on drug permeation across the oral mucosal 
membrane. CD complexation has been shown to improve the in vitro release e.g. of 
miconazole from a chewing gum (Jacobsen et al. 1999), omeprazole (Figueiras et al. 2010) or 
piroxicam (Jug and Becirevic-Lacan 2004) from a mucoadhesive buccal tablet, and 
flufenamic acid from a mucoadhesive buccal film (Mura et al. 2010). In all cases, the 
improved release characteristics were attributed to the increased apparent aqueous 
solubilities and better dissolution rates of the drugs in the presence of CDs. CDs have also 
been observed to improve the flux or Papp of drugs across excised porcine buccal mucosa 
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(Cappello et al. 2006, Figueiras et al. 2009, 2010). This improvement is usually due to the 
increased apparent aqueous solubility of the drug, leading to a higher concentration 
gradient across the membrane. CDs also facilitate the diffusion of drugs across unstirred 
water layers that represent aqueous diffusion barriers at membrane surfaces (Masson et al. 
1999, Loftsson and Brewster 2011). It has also been postulated that some CDs could act as 
permeation enhancers. For example, methylated CDs are more lipophilic and surface active 
than other CDs and may thus promote drug permeation by extracting and solubilizing cell 
membrane components (Babu and Pandit 2004, Figueiras et al. 2010). However, the 
possibility that CDs may act as permeation enhancers seems to be contradicted by the 
frequent observation that excess CD does not improve, but instead hampers, the 
permeation of drugs across cell membranes (Zuo et al. 2000, Cappello et al. 2006, Loftsson 
and Brewster 2011).  
The use of CDs in intraoral drug formulations has also been investigated in vivo (Table 
2.5). In most of these studies, the intraoral administration of drug/CD complexes has 
resulted in higher absolute bioavailability than the peroral administration of the drugs. In 
addition, some studies indicated that CD complexation increased the intraoral absorption 
of drugs in comparison to the uncomplexed drug. However, in some of these in vivo 
studies, the interpretation of the results has been complicated by experimental difficulties, 
such as incomplete dissolution or the swallowing of the formulation. All in all, the in vivo 
results indicate that intraorally administered CD formulations need to be carefully 
designed in order to optimize the dissolution and drug release properties. It must also be 
noted that the results obtained using animal models are likely to underestimate the 
performance of similar formulations in humans, since in many in vivo studies, the drug 
doses given to the animals have been relatively high in comparison to the human 
therapeutic doses. The area of oral mucosa and the volume of saliva are larger in humans 
and therefore, one could assume that better dissolution and improved absorption of drugs 
from CD-containing formulations should be achieved. 
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Table 2.5. Examples of the in vivo performance of cyclodextrin-containing intraoral drug 
delivery systems 
Drug CD Methods Observations Ref. 
Cannabidiol β-CD Cannabidiol was given to rabbits 
perorally and sublingually as an 
ethanolic solution, and sub-
lingually as a solid cannabidiol/ 
β-CD complex.  
Sublingual administration of the solid 
cannabidiol/β-CD complex increased 
the absorption of cannabidiol when 
compared to peroral administration 
of an ethanolic cannabidiol solution. 
The highest absorption was achieved 
with a sublingual ethanolic solution. 
Mannila 
et al. 
2007 
Clomipramine HP-β-
CD 
Clomipramine was given to rats 
perorally and sublingually in a 
saline solution, and sublingually 
in a saline solution that also 
contained HP-β-CD, mannitol 
and methyl cellulose. 
After peroral administration, the F% 
of clomipramine was 30%. After 
sublingual administration of the 
clomipramine solutions, the F% 
values were 36% without HP-β-CD 
and 57% with HP-β-CD. 
Yoo et al. 
1999 
Danazol HP-β-
CD 
Danazol/HP-β-CD complex was 
given 1) to rats buccally and 
perorally as an aqueous solution 
and 2) to dogs buccally in a 
rapidly dissolving adhesive 
patch and perorally in hard 
gelatin capsules. 
In rats, buccal administration of the 
danazol/HP-β-CD complex increased 
the F% of danazol as compared to 
the peroral administration of the 
same complex. In dogs, the 
pharmacokinetic parameters of 
danazol were similar after peroral 
and buccal administration of the 
danazol/HP-β-CD complex. 
Badawy 
et al. 
1996 
Danazol SBE-
β-CD 
Solid danazol/SBE-β-CD 
complex was given to dogs 
perorally in capsules and 
buccally in mucoadhesive 
tablets. The dogs were also 
given commercially available 
danazol capsules perorally. 
After peroral administration, the F% 
of danazol was 2% from commer-
cially available danazol capsules and 
64% from the danazol/SBE-β-CD 
complex capsules. After buccal 
administration of the danazol/SBE-β-
CD complex, the F% was 25%. 
Jain et al. 
2002 
Testosterone γ-CD Solid testosterone/γ-CD 
complex was given to one 
human volunteer sublingually in 
a tablet form and perorally in a 
hard gelatin capsule. The 
complex was also administered 
as a peroral solution. 
Sublingual administration of the 
testosterone/γ-CD complex tablet 
yielded much higher serum levels of 
testosterone than peroral admin-
istration of the same complex in 
solid or liquid form. 
Pitha et 
al. 1987 
Δ9-tetrahydro-
cannabinol 
(THC) 
RM-β-
CD 
THC was given to rabbits 
perorally and sublingually. With 
both administration routes, THC 
was given as an ethanolic 
solution and as a THC/ 
RM-β-CD complex solution. 
The F% values of THC were 12% 
from the sublingual THC/RM-β-CD 
solution, 4% from the peroral 
THC/RM-β-CD solution, 4% from the 
sublingual ethanolic THC solution, 
and 1% from the peroral ethanolic 
THC solution. 
Mannila 
et al. 
2005 
Δ9-tetrahydro-
cannabinol 
(THC) 
β-CD THC was administered to 
rabbits perorally as an ethanolic 
solution or sublingually as a 
solid THC/β-CD complex. 
The F% values of THC were 1.3% 
after peroral administration of the 
ethanolic THC solution and 16% 
after sublingual administration of the 
solid THC/β-CD complex. 
Mannila 
et al. 
2006 
F%, absolute bioavailability 
26 
 
 
3 Aims of the Study 
The general objective of this study was to investigate the use of cyclodextrins in fast-
dissolving formulations for intraoral administration. Cyclodextrins were used to improve 
the apparent aqueous solubility and dissolution rate of drugs, and to prepare taste-masked 
formulations suitable for pediatric use. Perphenazine and midazolam were used as model 
drugs.  
 
The specific aims of the study were as follows: 
 
1. To develop and validate a sensitive and selective gas chromatographic-mass 
spectrometric method for the analysis of perphenazine from rabbit plasma. 
 
2. To prepare fast-dissolving formulations of perphenazine and to investigate the 
sublingual absorption of perphenazine in rabbits. 
 
3. To investigate the effect of storage on the physical and chemical stability and 
on the dissolution rate of a fast-dissolving, amorphous perphenazine/β-CD 
complex. 
 
4. To prepare liquid and solid taste-masked cyclodextrin formulations of 
midazolam and to investigate the sublingual absorption of midazolam in 
rabbits. 
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4 Development and Validation of a GC-MS Method for 
Quantitative Determination of Perphenazine in Rabbit 
Plasma After Sublingual Administration1 
Abstract. Perphenazine is a phenothiazine-type antipsychotic that is a potential candidate 
for sublingual administration due to its extensive first-pass metabolism. In this study, a gas 
chromatographic–mass spectrometric method was developed for the quantification of 
perphenazine in rabbit plasma after sublingual administration. The plasma samples were 
purified by mixed-mode solid phase extraction with good recovery (> 83%). The method 
was linear (r2 > 0.99) over a range of 2–64 ng/ml, with a lower limit of quantification of 
2 ng/ml. The accuracy was 100 ± 4%, and the within-day and between-day precisions were  
< 6.8% RSD and < 14% RSD, respectively. Perphenazine was stable in stock solutions and 
plasma. This method was successfully applied for analysing perphenazine in plasma after 
sublingual administration to rabbits. 
                                                          
1 Adapted with permission of Elsevier from: Turunen E, Lehtonen M, Järvinen T, Jarho P. Development and validation 
of a gas chromatographicmass spectrometric method for quantitative determination of perphenazine in rabbit plasma 
after sublingual administration. Journal of Chromatography B 872: 5157, 2008. 
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4.1 INTRODUCTION 
Perphenazine (Figure 4.1) is a potent phenothiazine-type antipsychotic which can be used 
in the treatment of schizophrenia, anxiety and severe nausea or vomiting (Hartung et al. 
2005). The oral bioavailability of perphenazine is relatively poor due to its extensive hepatic 
first-pass metabolism (Balant-Gorgia and Balant 1987, Hartung et al. 2005). Intraoral drug 
delivery via the sublingual and buccal membranes is an effective means to bypass the first-
pass effect and thus to increase the drug's bioavailability (Rathbone 1996). The intraoral 
administration route offers also many other benefits for drug delivery, such as rapid onset 
of action, ease of use and improved patient compliance. 
Sublingual and buccal drug absorptions are often investigated in rabbits, as the oral 
cavities of rabbits and humans have histological similarities (Dali et al. 2006). In these 
absorption studies, a sensitive method of analysis is required if one wishes to quantify 
drugs from plasma, since the volume of plasma that can be collected from a rabbit is 
relatively small and the drug concentrations expected in the samples are often low. There 
are several methods available for determining perphenazine and other phenothiazine-type 
antipsychotics from human plasma, urine or oral fluid, e.g. liquid chromatography with 
ultraviolet (Mandal and Ace 1993, Marumo et al. 2005, Mercolini et al. 2007, Pedernera et al. 
2007), coulometric (Tjaden et al. 1976, Foglia et al. 1995, Luo et al. 1997), fluorescence 
(Ponder and Stewart 1995) or mass spectrometric detection (Kratzsch et al. 2003), gas 
chromatography with electron capture detection (ECD) (Larsen and Naestoft 1975, Cooper 
et al. 1979), nitrogen detection (Javaid et al. 1981, Ulrich 1995) or mass spectrometric 
detection (McKay et al. 1983, Miller et al. 1995, Ventura et al. 2002, Pujadas et al. 2007), as 
well as capillary electrophoresis coupled with chemiluminescence (Lara et al. 2006) or 
ultraviolet-visible detection (Lara et al. 2005). Radioimmunoassays have also been applied 
in the determination of phenothiazines from plasma (Midha et al. 1981, Rasky et al. 1992). 
In addition to sensitivity, the United States Food and Drug Administration's (FDA) 
guideline about bioanalytical method validation stresses the importance of the selectivity of 
the quantitative analytical method (FDA 2001). Most of the above-mentioned analytical 
methods are very sensitive, but their ability to differentiate the analytes of interest from 
other sample components cannot be undoubtedly proved. Mass spectrometric detection 
allows simultaneous quantification and reliable identification of the analytes based on the 
monitoring of target and qualifier ions in either the single ion monitoring (single 
quadrupole MS) or multiple reaction monitoring mode (MS/MS). Furthermore, mass 
spectrometry is also one of the most sensitive analytical methods available. 
Plasma samples need to be adequately purified before they are injected into a GC–MS 
instrument. Previous studies have reported several sample preparation techniques for 
perphenazine and related substances, including liquid–liquid extraction (LLE) (Larsen and 
Naestoft 1975, Tjaden et al. 1976, Cooper et al. 1979, Javaid et al. 1981, McKay et al. 1983, 
Foglia et al. 1995, Ulrich 1995, Miller et al. 1995, Luo et al. 1997, Pedernera et al. 2007) and 
solid phase extraction (SPE) (Ponder and Stewart 1995, Ventura et al. 2002, Kratzsch et al. 
2003, Marumo et al. 2005, Lara et al. 2005, Lara et al. 2006, Mercolini et al. 2007, Pujadas et 
al. 2007) . Being a multi-step process, LLE is often extremely time-consuming and laborious. 
It also requires large quantities of organic solvents and frequently results in poor extraction 
recovery and incomplete sample purification (Franke and de Zeeuw 1998, Hennion 1999, 
Pedernera et al. 2007). The use of SPE usually improves the analyte recovery and also 
results in cleaner extracts compared to LLE. When perphenazine or related substances have 
been extracted from plasma, urine or oral fluid using SPE, recoveries have been reported 
ranging from 71% to 107% (Ponder and Stewart 1995, Ventura et al. 2002, Kratzsch et al. 
2003, Marumo et al. 2005, Lara et al. 2005, Lara et al. 2006, Mercolini et al. 2007, Pujadas et 
al. 2007), whereas the recoveries after LLE have varied between 30% and 93% (Tjaden et al. 
1976, Cooper et al. 1979, Javaid et al. 1981, Foglia et al. 1995, Ulrich 1995, Miller et al. 1995, 
Luo et al. 1997). Moreover, the time required for sample purification by SPE is often shorter 
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than with LLE, and thus a larger number of samples can be processed in a single working 
day. 
In the present study, a GC–MS method with electron impact ionization (EI) was 
developed for the quantification of perphenazine in rabbit plasma, as GC–MS–EI is known 
to offer excellent chromatographic separation as well as a high degree of sensitivity and 
selectivity. The validity of the analytical method was confirmed according to the FDA 
guideline (FDA 2001). In addition, the suitability of mixed-mode SPE for preparing very 
clean extracts with good recovery was demonstrated for the first time for perphenazine in 
both human and rabbit plasma samples. The present method has been used in the 
development of novel fast-dissolving formulations of perphenazine intended for sublingual 
delivery, which is a novel route of administration for this drug. 
 
 
 
Figure 4.1. Sample preparation and GC–MS analysis of perphenazine and fluphenazine (internal 
standard, I.S.): solid phase extraction (Step 1), silylation (Step 2) and fragmentation in MS 
(Step 3). 
4.2 EXPERIMENTAL 
4.2.1 Materials 
Perphenazine (≥99%) and fluphenazine dihydrochloride (≥99%) were purchased from 
Sigma–Aldrich (Steinheim, Germany). Pyridine (≥99.8%, GC-grade), 1-trimethyl-
silylimidazole (TMSI, 97%), trifluoroacetic anhydride (TFAA) and bis(trimethylsilyl)-
trifluoroacetamide (BSTFA; 1% trimethylchlorosilane (TMCS)) were supplied by Sigma–
Aldrich (Steinheim, Germany). Medetomidine (Domitor®) was purchased from Orion 
(Espoo, Finland) and ketamine (Ketaminol®) was purchased from Intervet International 
B.V. (Boxmeer, The Netherlands). All other reagents were of analytical grade. Strata™ X-C 
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cation mixed-mode polymer SPE cartridges were purchased from Phenomenex (Torrance, 
California, USA). Human plasma was obtained from The Finnish Red Cross Blood Service 
(Helsinki, Finland). New Zealand white rabbits were purchased from The National 
Laboratory Animal Center (Finland). The rabbits were allowed to eat commercial food 
pellets and drink water ad libitum, except during the first 5 h of each test, when they were 
under anaesthesia. All procedures with animals were reviewed and approved by the 
Animal Ethics Committee of the University of Kuopio. 
4.2.2 Standard solutions 
Stock solutions (1 mg/ml) of perphenazine and fluphenazine dihydrochloride (internal 
standard, I.S.) were prepared using methanol as a solvent. Working solutions of 
perphenazine were diluted in methanol at concentrations of 20–640 ng/ml. Fluphenazine 
dihydrochloride was diluted in methanol to a working solution of 100 ng/ml. All solutions 
were stored at −20 °C. 
Calibration and quality control (QC) standards were freshly prepared on the day of 
analysis. A total of 50 μl of the I.S. working solution and 50 μl of one of the calibration or 
QC standard working solutions were mixed in a test tube and evaporated to dryness under 
a nitrogen stream at 40 °C, after which 500 μl of analyte-free human plasma was added. 
Standards were then mixed for 20 s, equilibrated at room temperature (22 ± 2 °C) for 30 min 
and treated similarly as the plasma samples (Section 4.2.3). The calibration standards were 
prepared at six perphenazine concentrations: 2, 4, 8, 16, 32 and 64 ng/ml of plasma. At least 
four calibration standards were used for obtaining the calibration curve. The quality control 
samples were prepared at concentrations of 2, 10 and 40 ng/ml of plasma. 
Reference standards were prepared by mixing 50 μl of the I.S. working solution and 50 
μl of one of the QC working solutions in a test tube. The samples were evaporated to 
dryness, derivatized and analyzed. The concentrations of the reference standards were 2, 10 
and 40 ng/ml. When the extraction recoveries were determined, reference standards (10 
ng/ml) were also prepared using an alternative method, in which extracted analyte-free 
plasma was spiked with perphenazine and I.S. 
4.2.3 Sample preparation 
Frozen plasma samples were first thawed unassisted to room temperature (22 ± 2 °C). A 
total of 50 μl of the I.S. working solution was evaporated to dryness under a nitrogen 
stream at 40 °C, after which 500 μl of plasma sample was added. Samples were mixed for 
20 s and equilibrated for 30 min at room temperature. After equilibration, they were 
acidified with 20 μl of 2 M HCl, diluted using 500 μl of 100 mM potassium dihydrogen 
phosphate buffer (pH 5.5) and centrifuged at 3000 rpm for 5 min. 
SPE cartridges (Strata™ X-C) were preconditioned with 2 ml of methanol and 
equilibrated with 2 ml of water. The samples were then loaded under vacuum and washed 
with 1 ml of 2% (v/v) formic acid and 2 ml of methanol. After the washes, the solid phase 
material was aspirated to dryness for 30 s. Finally, the samples were eluted with 2 ml of 5% 
(v/v) ammonia in methanol. 
4.2.4 Derivatization procedures 
The standard solutions or methanolic extracts obtained from SPE were evaporated to 
dryness under a nitrogen stream at 40 °C. The trimethylsilyl derivatives were prepared 
using 50 μl of TMSI and 50 μl of pyridine. The samples were then kept at 70 °C for 30 min 
and analyzed after they had cooled to room temperature. 
During the method development, two alternative derivatization methods were also 
investigated: trimethylsilylation by bis(trimethylsilyl)trifluoroacetamide (BSTFA) and 
acetylation by trifluoroacetic anhydride (TFAA). Trimethylsilylation by BSTFA was 
performed by treating the evaporation residues with 50 μl of BSTFA and 50 μl of pyridine. 
The samples were kept at 70 °C for 60 min, evaporated to dryness and dissolved in 100 μl of 
toluene. The acetylated derivatives were prepared using 200 μl of a derivatizing mixture 
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that contained 2 ml of dichloromethane, 200 μl of TFAA and 60 μl of pyridine. The 
solutions were mixed for 10 s, equilibrated for 30 min and then evaporated to dryness. The 
evaporation residues were dissolved in 1 ml of toluene, 1 ml of water was added, and the 
solutions were mixed. After 1 min equilibration, the toluene layer was transferred to 
another test tube and the water phase was washed with 1 ml of toluene. Finally, the 
combined toluene phases were evaporated to dryness, and the evaporation residues were 
dissolved in 200 μl of toluene. 
4.2.5 Instrumentation 
The Agilent GC–MS system consisted of a gas chromatograph 6890N, autosampler 7683 
and mass detector 5973N (Palo Alto, California, USA). Agilent Enhanced ChemStation 
software (version C.00.01.08) was used for data processing. A cross-linked 5% phenyl 
methyl siloxane capillary column (HP-5MS; 30 m × 0.25 mm i.d. × 0.25 μm film thickness) 
(Agilent Technologies; Palo Alto, California, USA) was used with helium as the carrier gas 
(1.0 ml/min, column head pressure 14.99 psi). Sample injection (1 μl) was performed in the 
pulsed splitless mode, in which an inlet pressure of 30 psi was maintained for 1.5 min. The 
initial oven temperature of 180 °C was held for 1 min, increased by 30 °C/min to 300 °C 
which was then maintained for 11 min (total run time 16 min). The temperatures at the 
inlet, interface, ionization source and quadrupole were 250, 290, 230 and 150 °C, 
respectively. Electron impact ionization was used with an ionization energy of 70 eV. MS 
was operated in the selected ion monitoring (SIM) mode with a dwell time of 50 ms. The 
ions monitored were as follows: perphenazine m/z 246.0, 372.2 and 475.2, fluphenazine 
dihydrochloride m/z 280.0, 406.2 and 509.2, respectively. The area ratio of 246.0/280.0 was 
used for quantification, whereas the other ions were used as qualifiers. 
4.2.6 Validation of the method 
The validity of the analytical method was confirmed according to the FDA guideline by 
investigating selectivity, linearity, accuracy, precision, recovery and stability of the analyte 
(FDA 2001). All statistical tests were performed using Microsoft Excel® 2002 software. 
The selectivity of the method was confirmed by analysing analyte-free human and rabbit 
plasma for interfering peaks at the retention times of perphenazine and I.S. Rabbit plasma 
was collected prior to perphenazine administration as well as from rabbits that did not 
receive perphenazine. Linearity was determined using calibration standards at 
concentrations of 2, 4, 8, 16, 32 and 64 ng/ml. Three replicate analyses were performed at 
each concentration. The lower limit of quantification (LLOQ) was defined as the lowest 
concentration at which the determination was accurate and precise. The suitability of 
human plasma for the preparation of calibration curve and QC standards was investigated 
by comparing peak areas of quality control samples at concentrations of 5 and 40 ng/ml 
with analyte-free human or rabbit plasma as sample matrix. The similarity between the two 
plasma matrices was investigated by F-test followed by t-test (p < 0.05 considered 
statistically significant). 
Within-day precision and accuracy were studied at concentrations of 2, 10 and 40 ng/ml 
by comparing five parallel samples at each concentration. To determine the between-day 
precision, three similar determinations were performed on different analytical days. 
Precision was defined at each concentration level as the relative standard deviation (%RSD) 
of calculated sample concentrations. Accuracy was determined by comparing the calculated 
concentrations to the nominal concentrations of the analyte. Extraction recoveries of 
perphenazine and I.S. were determined by comparing the analyte peak areas in quality 
control standards (10 ng/ml, n=4) and in the corresponding reference standards prepared 
either by spiking extracted analyte-free plasma with perphenazine and I.S. or by mixing the 
standard solutions, evaporating them to dryness and derivatizing the evaporation residues 
(Section 4.2.2). 
The stability of perphenazine in plasma was evaluated by determining the short-term 
stability (24 h at room temperature, 22 ± 2 °C), freeze and thaw stability (three freeze-thaw 
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cycles) and long-term stability (3 months at −80 °C). The stock solution stability (2 weeks at 
−20 °C) as well as the post-preparative stability of the analyte (24 h in the autosampler of 
the GC–MS) were also studied. Quality control samples (n=3) at concentrations of 2 and 40 
ng/ml were analyzed after each storage period, and the concentrations were compared to 
the corresponding results before storage. The short-term stability was also determined at 5 
ng/ml. 
4.2.7 In vivo sublingual absorption of perphenazine 
The rabbits were anaesthetized using ketamine (25 mg/kg) and medetomidine (0.5 mg/kg). 
Perphenazine was administered to rabbits sublingually (1 mg/kg) as a micronized (< 15 μm) 
powder. Blood samples were withdrawn either from a central artery or from a marginal 
vein of the ear before perphenazine administration and 10–480 min after administration. 
Blood samples were centrifuged (3300 g for 5 min) at room temperature (22 ± 2 °C), after 
which the plasma layer was collected and frozen immediately. The samples were stored at 
−80 °C until analysis. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Optimization of the method 
In gas chromatography, derivatization is used to improve the chromatographic properties, 
volatility, detectability and stability of analytes and sample matrix components (Segura et 
al. 1998). In GC–ECD and GC–MS analyses, perphenazine and fluphenazine have typically 
been analyzed as trimethylsilylated (O-TMS) derivatives (Figure 4.1) prepared by a reaction 
of the analytes with, e.g. N-methyl-N-trimethylsilyl trifluoroacetamide (MSTFA) (Ventura 
et al. 2002, Pujadas et al. 2007), N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) (Miller et 
al. 1995) or N,O-bis(trimethylsilyl)acetamide (BSA) (Larsen and Naestoft 1975, Cooper et al. 
1979, McKay et al. 1983). Derivatization of perphenazine and fluphenazine by acetylation 
has also been reported (Javaid et al. 1981). 
In the present study, two derivatization methods were investigated: trimethylsilylation 
by TMSI or BSTFA and acetylation by trifluoroacetic acid (TFAA). Acetylated derivatives of 
perphenazine and I.S. were found to be unstable as they were readily hydrolyzed in acidic 
conditions. Moreover, the peak areas of the acetylated derivatives were too small to detect 
low perphenazine concentrations, and therefore trimethylsilylation was chosen for analyte 
derivatization. TMSI was found to be a superior silylating agent because of the higher 
stability of the derivatives and the lower variation between parallel samples in comparison 
to derivatives prepared using BSTFA (data not shown). In addition, the peak areas were 
somewhat larger when TMSI was used. TMSI reacts readily with hydroxyl groups but 
leaves aliphatic amino groups unaffected, whereas BSTFA is able to silylate both hydroxyl 
and amino groups (Knapp 1979). As the molecular structures of perphenazine and 
fluphenazine contain only one hydroxyl group but several tertiary amino groups which 
BSTFA may attack, the derivatization reaction between TMSI and the analytes is more 
quantitative and repeatable than the silylation reaction with BSTFA. 
Figure 4.1 shows the fragment ions observed after electron impact ionization of the O-
TMS derivatives of perphenazine and I.S. The base peaks (m/z 246 for perphenazine-O-TMS 
and m/z 280 for fluphenazine-O-TMS) resulted from the cleavage of the bond between the 
first two methylene groups adjacent to the phenothiazine ring ([M-C13H9ClNS]+ and [M-
C14H9F3NS]+ for perphenazine-O-TMS and fluphenazine-O-TMS, respectively). Ions 
corresponding to the breakdown of the silyl group with one methylene group ([M-
C4H11OSi]+) were also abundant (m/z 372 for perphenazine-O-TMS and m/z 406 for 
fluphenazine-O-TMS). In addition, other fragments with lower relative intensities were 
detected, corresponding to the cleavages depicted in Figure 4.1. Molecular ions were 
present at m/z values of 475 (perphenazine-O-TMS) and 509 (fluphenazine-O-TMS) (McKay 
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et al. 1983, Ventura et al. 2002, Pujadas et al. 2007). All the ions selected for SIM detection 
have relatively high masses, which reduces the background noise and thus improves 
method specificity. 
In order to maximize the sensitivity and robustness of the method, dynamic mass 
calibration was performed to define the exact m/z values being monitored in the SIM mode. 
Data was acquired using ions spaced 0.1 atomic mass unit apart around the expected 
nominal masses of the ions used in the quantification and as qualifiers. The most abundant 
masses (m/z 246.0, 372.2 and 475.2 for perphenazine-O-TMS and m/z 280.0, 406.2 and 509.2, 
for fluphenazine-O-TMS) were then selected for SIM detection. 
During the early phases of method development, inlet liners packed with silanized glass 
wool were used. However, low peak areas and carryover were observed as the analytes 
mostly remained in the glass wool material and did not appear to reach the GC column. 
With these liners, the relative peak areas of perphenazine and I.S. were only 11% and 33%, 
respectively, when compared to the peak areas obtained using inlet liners without glass 
wool packing. In addition to the increase in the analyte peak areas, the use of empty inlet 
liners also reduced analyte carryover. In earlier studies, the glass wool material has been 
reported to decrease the detectability of some compounds, e.g. theophylline (Saka et al. 
2007) and nitroaromatic compounds (Emmrich et al. 2001) as the glass wool either adsorbs 
or decomposes the analytes. In the present study, the use of empty inlet liners substantially 
increased the sensitivity of the method. Therefore, the analytes could be more precisely 
quantified at lower concentrations, since there was no analyte retention on the glass wool 
packing. On the other hand, the absence of glass wool packing clearly affected the method 
robustness, and careful sample purification and instrument maintenance were thus needed 
to ensure reliable results. 
4.3.2 Selectivity 
The selectivity of the method was studied using analyte-free human plasma and analyte-
free rabbit plasma collected prior to perphenazine administration or from rabbits that had 
not received perphenazine. The chromatograms were free of interfering peaks at the 
retention times of I.S. (9.6 min) and perphenazine (13.8 min). Figure 4.2 shows 
representative chromatograms of analyte-free plasma, QC and reference standards (10 
ng/ml) and a rabbit plasma sample (14.7 ng/ml) collected after sublingual administration of 
micronized perphenazine. 
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Figure 4.2. Chromatograms from analyte-free plasma (A), a reference standard prepared by 
mixing the standard solutions, evaporating them to dryness and derivatizing the evaporation 
residues (10 ng/ml) (B), analyte-free plasma spiked with I.S. and perphenazine (10 ng/ml) (C), 
and a rabbit plasma sample (14.7 ng/ml) collected after sublingual administration of 
perphenazine (D). 
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4.3.3. Precision, accuracy and extraction recovery 
The data on precision and accuracy are summarized in Table 4.1. The within-day and 
between-day precisions of the determinations were acceptable (< 14% RSD) at all 
concentrations studied. The accuracy of the analyses was also well within the acceptance 
limits as all calculated concentrations were within 4% of the nominal concentrations. 
 
Table 4.1. Stability of perphenazine in plasma during sample preparation and storage (n=3) 
   
Nominal 
concentration 
of perphenazine 
Recovery % (RSD) 
Short-term 
stability  
(24 h at room 
temperature) 
Long-term 
stability 
(3 months  
at -80 °C) 
Freeze-thaw 
stability 
(3 freeze-thaw 
cycles) 
Post-preparative 
stability 
(24 h in the 
autosampler) 
2 ng/ml 90 (0.4) 104; 107a 89; 113a 100b 
5 ng/ml 105 (5.5) N.D. N.D. N.D. 
40 ng/ml 107; 117a 84 (13) 80 (15) 105b 
a n=2; b n=1 
N.D. = not determined 
 
Extremely clean extracts are required to ensure the sensitivity of the GC–MS analyses at 
low drug concentrations, especially when inlet liners without glass wool packing are being 
used. SPE is an efficient sample preparation method that is known to produce very pure 
extracts with excellent recoveries. Several stationary phase materials have been used in 
extracting perphenazine or other phenothiazine drugs from different biological matrices 
e.g., reversed phase sorbents of different alkyl chain lengths (Marumo et al. 2005, Mercolini 
et al. 2007), hydrophilic–lipophilic balanced polymeric sorbents (Lara et al. 2005, Lara et al. 
2006) and mixed-mode polymeric stationary phases that combine cation exchange and 
reversed phase properties (Ventura et al. 2002, Kratzsch et al. 2003, Pujadas et al. 2007). In 
this study, mixed-mode SPE was chosen as the sample preparation method. Mixed-mode 
phase materials have been reported to offer superior selectivity and sample purity in 
comparison to standard reversed phase sorbents. In addition to reversed phase interactions, 
they act via cationic retention mechanisms that allow efficient elution of interfering 
substances using strong organic solvents (Mills et al. 1993, Clauwaert et al. 1996, Landis 
2007). This clearly improves the robustness and usability of the analytical method, as 
cleaner samples reduce the need for instrument maintenance procedures and thus make 
possible longer analysis periods.  
In the present study, a pronounced matrix effect was observed, leading to extraction 
recovery values that exceeded 100%. In order to compare the extraction recoveries, 
reference standards were prepared in two different ways: either by simply mixing, 
evaporating and derivatizing the methanolic standard solutions, or by spiking extracted 
analyte-free plasma with perphenazine and I.S., followed by evaporation and 
derivatization. In the reference standards prepared in methanol, the analyte peak areas 
were significantly smaller than those observed in the reference standards prepared in 
extracted analyte-free plasma. A similar difference was observed when extracted QC 
standards in phosphate buffer (pH 5.5) were compared to corresponding extracted QC 
standards in human or rabbit plasma. The mean calculated extraction recoveries (n=4) for 
the reference standards prepared in methanol were 190% (7% RSD) for I.S. and 140% (6% 
RSD) for perphenazine. In contrast, with the reference standards prepared in extracted 
analyte-free plasma, the mean extraction recoveries were 88% (7% RSD) for I.S. and 83% 
(6% RSD) for perphenazine. The effect of plasma matrix components on the 
chromatographic properties was clearly observed especially for perphenazine, as the 
reference standards prepared in methanol showed increasing peak tailing (Figure 4.2B) and 
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decreasing detector response after a few days of analysis. These results indicate that the 
plasma matrix components improve the chromatographic properties of the analytes and 
facilitate their evaporation and ionization during the GC–MS analysis (Bernal et al. 1997, 
Jimenez et al. 1998). 
4.3.4 Linearity and lower limit of quantification 
The calibration curves were linear (r2 > 0.99) over the entire concentration range of 2–64 
ng/ml. The slope and intercept of the calibration curve (n=3) were 0.476 (0.451–0.501) and 
−0.066 (−0.082–0.068), respectively (mean; 95% confidence interval). The LLOQ of the 
method was 2 ng/ml, which was suitable for monitoring plasma concentrations during the 
in vivo studies. The suitability of human plasma for the preparation of calibration curve and 
QC standards was investigated by comparing quality control samples with analyte-free 
human or rabbit plasma as sample matrix. No statistically significant differences were 
found between the peak areas of I.S. and perphenazine in rabbit and human plasma, and 
thus the use of human plasma in the calibration and QC standards was justified. 
4.3.5 Stability 
The stability of perphenazine during sample preparation and storage was investigated at 2, 
5 and 40 ng/ml (Table 4.1). The concentrations of perphenazine remained within 20% of the 
initial concentrations under all conditions studied. Perphenazine was also found to be 
stable in stock solutions, as the QC standard concentrations remained above 98% of the 
initial concentrations during the 14-day storage at −20 °C. The stability of perphenazine was 
thus considered sufficient for the analytical application. 
4.3.6 In vivo sublingual absorption of perphenazine 
In the in vivo experiment, the absorption of perphenazine was investigated after its 
sublingual delivery, which is a novel route of administration for this drug. Mean plasma 
concentrations (n=4) of perphenazine after its sublingual administration as a solid, 
micronized powder are plotted in Figure 4.3. The perphenazine concentrations of the 
individual rabbit plasma samples ranged from 2.6 to 51 ng/ml, with the highest 
concentrations being observed between 1.5 and 6 h after perphenazine administration. In 
every experiment, almost all of the plasma concentrations were higher than 10 ng/ml, and 
concentrations lower than 5 ng/ml were only observed at the first time points in some 
experiments. 
 
  
 
Figure 4.3. Perphenazine concentrations in rabbit plasma after sublingual administration of plain 
micronized perphenazine (1 mg/kg) (n=3–4; mean ± sem). 
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4.4 CONCLUSIONS 
A sensitive GC–MS method was developed for the determination of perphenazine in rabbit 
plasma. The selectivity, linearity, accuracy and precision of the method as well as the 
stability of the analytes were found to be sufficient to allow reliable analyses of plasma 
samples. A new mixed-mode SPE procedure resulting in very clean extracts with good 
recovery was developed for perphenazine in human and rabbit plasma. The present 
method was successfully applied in measuring the concentrations of perphenazine in rabbit 
plasma after sublingual administration of the drug. The method can also be utilized in the 
determination of perphenazine in human plasma. 
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5 Fast-dissolving Sublingual Solid Dispersion and 
Cyclodextrin Complex Increase the Absorption of 
Perphenazine in Rabbits2 
Abstract 
Objectives: The sublingual administration route as well as solid dispersion formation with 
PEG 8000 and complexation with β-cyclodextrin (β-CD) were investigated as ways for 
improving the absorption of perphenazine, a poorly water-soluble drug subjected to 
substantial first-pass metabolism. 
Methods: The absorption of perphenazine was studied in rabbits after sublingual 
administration of perphenazine/PEG solid dispersion, solid perphenazine/β-CD complex 
and plain micronized perphenazine, as well as after peroral administration of an aqueous 
perphenazine solution. Solid formulations were prepared by freeze-drying 
(perphenazine/PEG solid dispersion) or spray-drying (perphenazine/β-CD complex). 
Key findings: The value for area under the curve from 0 to 360 min (AUC0–360 min) of 
perphenazine after peroral administration was only 8% of the AUC0–360 min value obtained 
after intravenous administration, while the corresponding values for the sublingually 
administered formulations were 53% (perphenazine/PEG solid dispersion), 41% 
(perphenazine/β-CD complex) and 64% (micronized perphenazine). There are three 
possible mechanisms to explain these results: avoidance of first-pass metabolism; good 
sublingual absorption of perphenazine; and rapid dissolution rate of perphenazine from the 
studied formulations. 
Conclusions: With sublingual administration, the drug has to dissolve rapidly in a small 
volume of saliva. Based on the present absorption studies in rabbits, the solid dispersion 
preparation and cyclodextrin complexation were postulated to be useful ways to attain 
successful sublingual administration of perphenazine. Good sublingual absorption was also 
achieved by micronization of perphenazine. As far as we are aware, this paper is one of the 
first to evaluate the sublingual administration of a solid dispersion in vivo. 
                                                          
2 Adapted with permission of John Wiley & Sons from: Turunen E, Mannila J, Laitinen R, Riikonen J, Lehto VP, Järvinen 
T, Ketolainen J, Järvinen K, Jarho P. Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the 
absorption of perphenazine in rabbits. Journal of Pharmacy and Pharmacology 63: 1925, 2011. 
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 5.1 INTRODUCTION 
The oral cavity is a promising route of administration for drugs that are susceptible to 
hepatic first-pass metabolism (Goswami et al. 2008, Mathias and Hussain 2010). In addition 
to the possibility of avoiding the first-pass effect, sublingual administration often provides 
a rapid onset of drug action since the oral mucosa is highly vascularized. Sublingual drug 
delivery is also well accepted by patients, and it offers an easy and convenient means to 
administer drugs to individuals suffering from swallowing difficulties, nausea or vomiting 
(Song et al. 2004). However, the sublingual absorption of many drugs is limited, since in 
order to pass through the sublingual and buccal membranes, the drug has first to dissolve 
rapidly in the small volume of saliva present in the mouth before it is removed from the site 
of absorption by swallowing (Mathias and Hussain 2010). This represents a challenge to the 
sublingual administration of poorly soluble or slowly dissolving drugs or drugs with high 
therapeutic doses. 
The model drug used in this study was perphenazine, a potent phenothiazine-type 
antipsychotic that is used in the treatment of schizophrenia, anxiety and severe nausea or 
vomiting (Hartung et al. 2005). Although perphenazine is well absorbed after peroral 
administration, its bioavailability is limited by a substantial hepatic first-pass effect, making 
it a potential candidate for sublingual delivery. However, the poor aqueous solubility of 
perphenazine (less than 150 μg/ml at pH 6.8) would be predicted to hamper its sublingual 
administration (Laitinen et al. 2009). 
Various methods can be applied to increase the apparent aqueous solubility and 
dissolution rate of poorly soluble drugs. For example, cyclodextrin complexation (Brewster 
and Loftsson 2007), solid dispersion preparation (van Drooge et al. 2004b, Shinde et al. 
2008, Dhumal et al. 2009) and the use of micronized, microcrystalline or amorphous drugs 
(Rasenack et al. 2003, Blagden et al. 2007, Vogt et al. 2008) have been reported as useful 
methods to produce rapidly dissolving formulations of poorly soluble drugs. Although 
numerous in vitro studies have highlighted the potential of different formulation 
approaches to resolve problems in sublingual administration, only a few studies have been 
conducted to demonstrate their performance in vivo. Some earlier studies have reported 
increased bioavailability for drugs that are administered sublingually as cyclodextrin-
containing formulations (Badawy et al. 1996, Yoo et al. 1999, Jain et al. 2002, Mannila et al. 
2005). With solid dispersions, on the other hand, the potential for sublingual delivery has so 
far been demonstrated mainly in vitro, based on their fast dissolution rates and other 
favourable characteristics (van Drooge et al. 2004b, Sammour et al. 2006, Shah and Mashru 
2008, Laitinen et al. 2009), and as far as we are aware, very little data of their performance in 
vivo has been published (Shephard et al. 2001). In this study, the sublingual absorption of a 
solid dispersion in rabbits has been reported. In addition, the effects of cyclodextrin 
complexation and micronization on the sublingual absorption of perphenazine have been 
described. 
5.2 EXPERIMENTAL 
5.2.1 Materials 
Perphenazine was purchased from Sigma-Aldrich (Steinheim, Germany). α-Cyclodextrin 
(α-CD, Alpha W6 Pharma), β-cyclodextrin (β-CD, Cavamax W7 Pharma), γ-cyclodextrin (γ-
CD, Cavamax W8 Pharma), hydroxypropyl-β-cyclodextrin (HP-β-CD, Cavasol W7 Pharma) 
and randomly methylated β-cyclodextrin (RM-β-CD, Cavasol W7 M) were obtained from 
Wacker Chemie (Burghausen, Germany). PEG 8000 (polyethylene glycol) was purchased 
from Sigma-Aldrich (Steinheim, Germany). All other reagents were of analytical grade. 
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5.2.2 Analytical methods 
High performance liquid chromatography (HPLC) was used for the determination of 
perphenazine concentration during the phase-solubility and dissolution studies. In the 
phase-solubility studies of perphenazine and PEG, the HPLC determinations were 
performed using the method described earlier (Laitinen et al. 2009). In all other HPLC 
determinations, an Agilent 1100 HPLC system (Agilent Technologies Inc., Waldbronn, 
Karlsruhe, Germany) was used for the quantification of perphenazine. The HPLC system 
consisted of a binary pump, a vacuum degasser, an automated injector system autosampler, 
a UV-detector, an HPLC column oven and analyst software Agilent ChemStation for LC 
Systems. The separation was performed with a LiChroCART Purospher RP-18e column 
(125 × 4 mm, 5 μm) (Merck KGaA, Germany). The mobile phase consisted of acetonitrile 
and 0.1% trifluoroacetic acid in water, 35:65 (v/v). The detector wavelength was 254 nm, 
flow rate was 1.0 ml/min, column temperature was 25°C, and injection volume was 10 μl. 
The HPLC method was validated in terms of linearity, repeatability and the lower limit of 
quantification. Before the HPLC analyses, the samples were filtered (0.45 μm, Millex-HV, 
low protein binding Durapore PVDF, Millipore Corporation, Ireland). 
The concentration of perphenazine in rabbit plasma samples was determined using a gas 
chromatographic-mass spectrometric method. Before the analysis, the samples were 
purified using solid phase extraction. These procedures have been described in detail 
elsewhere (Chapter 4) (Turunen et al. 2008). 
5.2.3 Phase-solubility studies 
The effects of various cyclodextrins and PEG on the apparent aqueous solubility of 
perphenazine were investigated using the phase-solubility method (Higuchi and Connors 
1965). The phase-solubility experiments with perphenazine and PEG have been described 
elsewhere (Laitinen et al. 2009). In the case of β-CD, an excess amount of perphenazine was 
added to aqueous phosphate buffer solutions (0.16 m, pH 8.0, ionic strength 0.50) 
containing 0, 0.25, 0.5, 1 or 1.5% (w/v) of β-CD (n=3). With α-CD, γ-CD and HP-β-CD, the 
cyclodextrin concentrations were 0, 1, 2.5, 5 and 10% (w/v) (n=1). The drug/cyclodextrin 
suspensions were protected from light and shaken at room temperature for three days to 
attain equilibrium. The pH of the suspensions was maintained at 8.0 using aqueous HCl or 
NaOH solutions. After equilibration, the samples were filtered (0.45 μm) and analysed by 
HPLC. 
The phase-solubility diagrams of perphenazine were prepared by plotting the 
perphenazine concentrations as a function of cyclodextrin and PEG concentration. The 
apparent stability constant (K1:1) between perphenazine and β-CD was calculated using 
equation 5.1: 
 
      (Equation 5.1) 
 
 
where K1:1 is the apparent stability constant for the 1:1-perphenazine/β-CD complex and [S0] 
is the experimentally determined intrinsic solubility of perphenazine (mol/l). The slope 
value was obtained from the phase-solubility diagram (concentrations expressed as mol/l) 
(Higuchi and Connors 1965). No stability constant was calculated for the solid dispersion, 
as the use of equation 5.1 presumes that the observed solubility increase is due to the 
formation of a complex between the drug and the solubilizer. 
5.2.4 Preparation and characterization of the solid formulations 
Three solid formulations were prepared for these in vivo studies: plain micronized 
perphenazine; a perphenazine/β-CD complex; and a perphenazine/PEG solid dispersion. 
Perphenazine was micronized by manually passing it through a 15 μm sieve mesh. The 
solid perphenazine/β-CD complex was prepared by adding an excess amount of 
perphenazine to an aqueous 1% (w/v) β-CD solution. The suspension was protected from 
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1:1 slopeS
slopeK


41 
 
 
light and stirred for three days at room temperature. The pH of the solution was adjusted to 
8.0 and held constant during the equilibration by adding aqueous HCl or NaOH, when 
necessary. After stirring, the suspension was filtered (0.45 μm) to remove undissolved 
perphenazine. The solution was then spray-dried using a Büchi Mini-Spray Dryer B-191 
(Büchi Labortechnik AG, Flawil, Switzerland) under the following conditions: atomizer air 
flow rate 600 Nl/h, inlet temperature 160°C, outlet temperature 96°C and feed rate 5 
ml/min. The solid dispersion of perphenazine with PEG was prepared by freeze-drying an 
aqueous 0.1 M HCl solution containing perphenazine and PEG in a 1/5 weight ratio, as 
described earlier (Laitinen et al. 2009). The perphenazine contents of the perphenazine/β-
CD complex and perphenazine/PEG solid dispersion powders were determined by HPLC. 
Freeze-drying of the perphenazine/PEG solid dispersion and spray-drying of the 
perphenazine/β-CD complex produced solid powders containing 0.21 ± 0.006 mg (0.52 ± 
0.02 μmol) or 0.15 ± 0.003 mg (0.38 ± 0.01 μmol) perphenazine per 1 mg PEG or β-CD, 
respectively (mean ± sd, n=3–4). 
The particle size and morphology of the perphenazine/β-CD complex were examined by 
scanning electron microscopy (XL30 ESEM TMP microscope, FEI Company/Oy Philips Ab, 
Czech Republic) using an acceleration voltage of 15 kV, spot size of 3 and working distance 
of 12 mm. Before analysis, the sample was sputter-coated with gold for 2.5 min (Advanced 
Sputter Coater II-E5100, Polaron Equipment Ltd, Watford, UK; voltage 2.5 kV, current 20 
mA). The perphenazine/PEG solid dispersion was photographed similarly, with the 
exception that the acceleration voltage was 20 kV (Laitinen et al. 2009). 
The crystal structures of perphenazine, β-CD and PEG in the formulations were 
examined by X-ray powder diffractometry (XRPD). The XRPD measurements were 
performed with a Bragg–Brentano θ/2θ reflection geometry based diffractometer (Philips 
PW1820, PW1830 and PW1710) using Ni filtered Cu Kα (40 kV/50 mA) radiation. The 
samples were measured between the angular range of 3–30° using 0.04° steps and a 3 s 
counting time per step. 
5.2.5 Dissolution studies 
Dissolution studies (n=3–6) were performed at room temperature in 20 ml disposable 
plastic syringes using 5.0 ml of a dissolution medium that contained 2% (w/v) RM-β-CD in 
a 0.16 M phosphate buffer (pH 6.5, ionic strength 0.5). RM-β-CD was added to the 
dissolution medium to maintain sink conditions for perphenazine. The syringe was 
equipped with a syringe tip filter (0.45 μm), and a piece of filter paper was placed on the 
bottom of the syringe to prevent the solid particles from sedimenting into the syringe tip. A 
magnetic stirring bar was placed in the syringe, and the solutions were agitated at 
approximately 100 rev/min. An accurately weighed amount of unprocessed perphenazine 
(0.92–1.06 mg), micronized perphenazine (0.89–1.11 mg), perphenazine/β-CD complex 
(6.94–7.07 mg) or perphenazine/PEG solid dispersion (5.10–6.01 mg) was carefully dropped 
into the dissolution medium. The test was terminated at the designated time point by 
rapidly filtering a small amount of the solution into a test tube. Samples were taken at 0.25, 
0.5, 1, 2, 5, 10, 15, 20 and 30 min. Each time point was performed in a separate syringe. The 
perphenazine contents of the samples were analysed by HPLC. 
5.2.6 Pharmacokinetic studies in rabbits 
Seven male New Zealand white rabbits (3.3–4.4 kg) were purchased from HB Lidköpings 
Kaninfarm (Lidköping, Sweden). Water and standard commercial food pellets were freely 
available, except during the first 6 h of each experiment, when the rabbits were under 
anaesthesia. All procedures with animals were reviewed and approved by the Animal 
Ethics Committee of the University of Kuopio. 
In all pharmacokinetic studies, the rabbits were anaesthetized using ketamine (25 mg/kg; 
Ketaminol, Intervet International B.V., Boxmeer, the Netherlands or Ketalar, Pfizer, Espoo, 
Finland) and either medetomidine (0.5 mg/kg; Domitor, Orion, Espoo, Finland) or a 
combination of medetomidine (0.1 mg/kg) and midazolam (10 mg/kg; Dormicum, Roche, 
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Espoo, Finland). The rabbits were positioned on a table and their lower jaws were 
supported in the horizontal position. Perphenazine (1 mg/kg) was administered to rabbits 
intravenously, perorally or sublingually. 
For the intravenous administration of perphenazine, an aqueous 10% (w/v) HP-β-CD 
solution containing 1 mg/ml perphenazine was prepared (pH 8). The solution was made 
isotonic using NaCl and filtered through a sterile membrane filter (pore size 0.2 μm; 
Schleicher & Schuell, Dassel, Germany). The perphenazine/HP-β-CD solution (1 ml/kg) was 
injected directly into a marginal ear vein. The peroral formulation contained 1 mg/ml 
perphenazine in an aqueous 0.1 M HCl solution (pH 1). The solution (1 ml/kg) was 
administered to the gastrointestinal tract via catheterization, followed by rinsing with 2–3 
ml 0.9% NaCl solution. For the sublingual administration, the tongue of the rabbit was 
carefully lifted using tweezers and appropriate amounts of the solid formulations were 
placed under the tongue. The weighed amounts for micronized perphenazine, 
perphenazine/β-CD complex and perphenazine/PEG solid dispersions were 4.04–4.76, 
29.28–32.58 and 18.06–23.41 mg, respectively. The wetting of the solid formulations was 
ensured by administering 50 μl 0.9% NaCl solution under the tongue every 2 min after 
delivering the sublingual formulation, over 30 min. 
Blood samples were collected into Venoject tubes (Terumo, Leuven, Belgium) from either 
a central artery or a marginal vein of the ear before perphenazine administration and 10–
480 min after administration. Blood samples were centrifuged (3300g for 5 min), after which 
the plasma layer was collected and frozen immediately. The samples were stored at −80°C 
until analysis. 
The maximum plasma concentrations of perphenazine (Cmax) as well as the time at which 
maximum concentration was reached (tmax) were obtained directly from the time vs plasma 
concentration profiles. The area under the curve from 0 to 360 min (AUC0–360 min) was 
determined for perphenazine from the time vs concentration plot using the linear 
trapezoidal method. For the intravenous administration, the perphenazine concentrations 
at 0 min were extrapolated using the WinNonlin program (Version 5.0.1). The elimination 
rate constant (kel), elimination half-life (t½), clearance (CL), volume of distribution (VSS) and 
AUC0–∞ value of perphenazine were determined individually for each rabbit from the 
intravenous data by the WinNonlin program. 
Surprisingly, some rabbits died either during the anaesthesia or soon after the 
experiment. Examination of one such rabbit by a veterinary surgeon suggested that the 
cause of death was of cardiovascular origin, perhaps either a fatal drop in blood pressure or 
cardiac arrhythmias. We believe that the cause of death was not due to any of the 
perphenazine formulations but instead, due to the sensitivity of this strain of rabbit to the 
anaesthetic drugs, especially medetomidine. This assumption was supported by the fact 
that the deaths were not related to any particular perphenazine formulation and in some 
cases, they occurred even before there was any administration of the formulations. 
However, it must be emphasized that medetomidine has been used successfully in our 
earlier studies with other rabbit strains (Mannila et al. 2007). To prevent the blood pressure 
decline, midazolam was added to the anaesthetic combination and the dose of 
medetomidine could thus be reduced. In addition, the rabbits were given atipamezole (0.1–
0.25 mg/kg; Antisedan, Orion, Espoo, Finland) two hours after perphenazine 
administration to reverse the effect of medetomidine. During the anaesthesia, the rabbits 
were also given 100 ml 0.9% NaCl solution as an intravenous infusion lasting 
approximately 30 min. Since these actions did not entirely prevent the deaths of the rabbits, 
it was decided to prematurely terminate this series of in-vivo experiments before all 
intended experiments were completed. Therefore, the number of parallel observations was 
lower with some formulations (n=2–5) 
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5.2.7 Statistical analysis 
In the dissolution and absorption studies of perphenazine, a nonparametric Kruskall–
Wallis test was used to evaluate the statistical differences between the tested formulations. 
The post hoc test was then used to test the significance of the differences of the means (Siegel 
and Castellan Jr. 1988). The level of statistical significance (p) was designated as 0.05. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Phase-solubility studies 
The apparent aqueous solubility of perphenazine was determined in the presence of PEG 
and various cyclodextrins. The best complexation of the tested cyclodextrins was achieved 
with β-CD. Perphenazine exhibited linear AL-type phase-solubility behaviour in the 
presence of β-CD (Figure 5.1), the apparent stability constant (K1:1) of the complex being 
9300 ± 1300 (mean ± sd; n=3). With PEG, the apparent aqueous solubility of perphenazine 
also increased in a linear manner (Figure 5.2) (Laitinen et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Phase-solubility diagram of perphenazine at pH 8 in the presence of β-cyclodextrin. 
Values are given as mean ± sd; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Phase-solubility diagram of perphenazine at pH 6.8 in the presence of PEG. Values 
are given as mean ± sd; n=3. 
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5.3.2 Preparation and characterization of solid formulations 
In XRPD analyses, a characteristic X-ray diffraction pattern was observed for unprocessed 
perphenazine, confirming that the drug was in the crystalline state (Figure 5.3a). The 
diffractogram of micronized perphenazine showed nonsystematic changes in the intensity 
of the diffraction peaks as well as a minor increase in the background intensity when 
compared with unprocessed perphenazine. These changes could be attributed to a smaller 
particle size and the more symmetric particle morphology, which increased the density of 
the XRPD powder sample and diminished the preferred orientation of the crystals, 
respectively (Figure 5.3b). The spray-dried perphenazine/β-CD complex was completely 
amorphous, as no characteristic diffraction peaks for perphenazine or β-CD were observed 
(Figure 5.3c). As described earlier, the diffractograms for the freeze-dried 
perphenazine/PEG solid dispersion also showed total amorphization of perphenazine, 
while PEG remained, at least partly, in its crystalline form (Figure 5.3d) (Laitinen et al. 
2009). The scanning electron micrographs showed that the spray-dried perphenazine/β-CD 
complex consisted of spherical particles with a relatively small particle size (< 20 μm). The 
solid dispersion particles, on the other hand, were larger and had a flaky appearance, 
typical of freeze-dried materials (Laitinen et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. X-ray diffraction patterns. (a) Unprocessed perphenazine; (b) micronized (< 15 μm) 
perphenazine; (c) spray-dried perphenazine/β-cyclodextrin complex; and (d) freeze-dried 
perphenazine/PEG solid dispersion. 
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5.3.3 Dissolution studies 
The dissolution studies were performed at pH 6.5, which lies in the pH range of saliva (5.8–
7.4) (Mathias and Hussain 2010). The dissolution rates of unprocessed perphenazine, 
micronized perphenazine, perphenazine/β-CD complex and perphenazine/PEG solid 
dispersion are shown in Table 5.1. Even though sink conditions prevailed, unprocessed 
perphenazine was completely dissolved only after more than 20 min. In contrast, 
micronization, cyclodextrin complexation and solid dispersion formation all increased the 
dissolution rate of perphenazine, and 100% dissolution of perphenazine was achieved in  
5 min or less from all of these formulations. Based on the Noyes–Whitney equation, it can 
be assumed that increased dissolution rate of micronized perphenazine was due to the 
decreased particle size of the drug. With the perphenazine/β-CD complex, the improved 
dissolution rate was mainly attributable to the increased apparent aqueous solubility of 
perphenazine. In the case of the perphenazine/PEG solid dispersion, the molecular level 
mixing between perphenazine and PEG as well as the formation of an amorphous 
perphenazine dihydrochloride salt were found to be the main factors improving the 
dissolution rate (Laitinen et al. 2009). 
 
 
Table 5.1. Dissolution behaviour of unprocessed perphenazine, micronized (< 15 μm) 
perphenazine, perphenazine/β-cyclodextrin complex and perphenazine/PEG solid dispersion. All 
formulations corresponded to 1 mg perphenazine. An aqueous phosphate buffer solution  
(0.16 M, pH 6.5, ionic strength 0.05) containing 2% (w/v) randomly methylated β-cyclodextrin 
was used as the dissolution medium to maintain sink conditions. 
 
Time  
(min) 
Unprocessed 
perphenazine 
Mean ± sd (n=3) 
Micronized 
perphenazine 
Mean ± sd (n=3-6) 
Perphenazine/ 
β-CD complex 
Mean ± sd (n=4) 
Perphenazine/PEG 
solid dispersion 
Mean ± sd (n=3) 
0.25 8 ± 1 35 ± 15 72 ± 17* 74 ± 8* 
0.5 13 ± 3 62 ± 15 57 ± 6 80 ± 4* 
1 21 ± 8 83 ± 21 82 ± 14 92 ± 10 
2 41 ± 8 79 ± 16 93 ± 12* 88 ± 13 
5 62 ± 6 114 ± 1* 105 ± 2 102 ± 3 
10 78 ± 15 106 ± 6 110 ± 9 107 ± 5 
15 80 ± 16 102 ± 3 111 ± 4 101 ± 19 
20 92 ± 7 99 ± 4 101 ± 3 102 ± 8 
30 100 ± 11 101 ± 3 106 ± 4 113 ± 4 
*Dissolved amount was significantly different from the dissolved amount of unprocessed 
perphenazine (Kruskall–Wallis test with a post hoc test, p < 0.05). 
 
5.3.4 Pharmacokinetic studies in rabbits 
Sublingual drug absorption can be studied in vivo using various animal models, such as 
rabbits, dogs, pigs and monkeys (Dali et al. 2006). All these species have a non-keratinized 
sublingual mucosa that closely resembles human sublingual and buccal tissue. In this 
study, the rabbit was chosen as the animal model due to its convenient size, easy handling 
and lower cost in comparison with larger animals. In addition, the suitability of the rabbit 
model for determining the sublingual absorption of various weakly basic drugs has been 
demonstrated in earlier reports (Odou et al. 1999, Dali et al. 2006). 
The plasma profiles after intravenous administration of perphenazine suggested first-
order pharmacokinetics with distinct distribution and elimination phases. A two-
compartment intravenous bolus model with first-order elimination was used for 
determining the pharmacokinetic parameters for each rabbit. The values for kel, CL, VSS, t½ 
46 
 
 
and AUC0–∞ of perphenazine were 0.005 ± 0.002 min-1, 200 ± 36 l/min, 37 ± 19 l, 151 ± 81 min 
and 18 630 ± 1920 ng/ml × min, respectively. 
Figure 5.4 shows the mean plasma concentrations of perphenazine after sublingual 
administration of micronized perphenazine, perphenazine/β-CD complex and 
perphenazine/PEG solid dispersion as well as after peroral administration of an aqueous 
perphenazine solution. The values of Cmax, tmax and AUC0–360 min for perphenazine from these 
formulations are summarized in Table 5.2. The AUC0–∞ values and absolute bioavailabilities 
were not calculated for the sublingual and peroral formulations, as to minimize the 
duration of anaesthesia the experiments were concluded shortly after achieving the 
maximum plasma concentration. When perphenazine was administered perorally, its 
AUC0–360 min value was 8% of the AUC0–360 min value after intravenous administration of 
perphenazine. With sublingual administration, the corresponding values were 53% 
(perphenazine/PEG solid dispersion), 41% (perphenazine/β-CD complex) and 64% 
(micronized perphenazine). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. The mean plasma concentrations of perphenazine (1 mg/kg) in rabbits after 
sublingual administration of micronized (< 15 μm) perphenazine (▲) (4.0–4.8 mg), 
perphenazine/β-cyclodextrin complex (♦) (29.3–32.6 mg) and perphenazine/PEG solid 
dispersion (◊) (18.1–23.4 mg), and after peroral administration of an aqueous perphenazine 
solution (□) (3.3–4.1 ml). Values are mean ± sem; n=3–5.  
 
The results indicated that the absorption of perphenazine could be enhanced using the 
sublingual administration route instead of peroral administration. Cyclodextrin 
complexation and solid dispersion formation did not improve the sublingual absorption of 
perphenazine in comparison with simple micronization of the drug. A possible explanation 
for this observation was the difference in the bulk volumes of the three formulations 
studied. As the dose of perphenazine was always 1 mg/kg, the average amounts of 
micronized perphenazine, perphenazine/β-CD complex and perphenazine/PEG solid 
dispersion powders given sublingually to 4-kg rabbits were approximately 4, 31 and 21 mg, 
respectively. The volume of saliva in the oral cavity of a rabbit is very small, and the better 
absorption of plain micronized perphenazine could thus be attributed to its smaller bulk 
volume, resulting in faster wetting in saliva and closer contact with the oral mucosa. The 
rabbit model may, however, underestimate the absorption of the cyclodextrin complex and 
solid dispersion formulations in humans, as both the volume of saliva and area of the oral 
mucosa are larger in the human mouth, whereas the dose of perphenazine given to rabbits 
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in this study corresponded to a typical single peroral dose of perphenazine for an adult 
human. In the case of the perphenazine/β-CD complex, it was also possible that the dilution 
of the complex in the small volume of saliva was not sufficient to allow the drug to be 
released from the complex, as the stability constant between perphenazine and β-CD was 
relatively high (Stella et al. 1999). 
 In practice, with micronized powders, the small particle size and possible formation of 
highly energetic amorphous surfaces may pose problems for the stability and processability 
of the drug (Elamin et al. 1995). Therefore, solid dispersion preparation and cyclodextrin 
complexation seem to be more suitable techniques when poorly soluble drugs are 
formulated for sublingual administration. 
 
Table 5.2. Values of Cmax, tmax and AUC0–360 min for perphenazine after intravenous administration 
of an aqueous perphenazine/hydroxypropyl-β-cyclodextrin solution, peroral administration of an 
aqueous perphenazine solution and sublingual administration of micronized perphenazine, solid 
perphenazine/β-cyclodextrin complex and perphenazine/PEG solid dispersion in rabbits. 
 
Route of 
administration 
Formulation n Cmax  
(ng/ml) 
median (range) 
tmax  
(min) 
median (range) 
AUC0-360min 
(ng/ml×min) 
mean ± sd 
Intravenous Aqueous perphenazine/ 
HP-β-CD solution 
3 690 (522–1388)a 0a 12920; 13730b 
Peroral Aqueous perphenazine 
solution 
4 10.9 (4.3–38.6) 120 (10–180) 1090 ± 877 
Sublingual Micronized perphenazine 4 36.1 (21.2–51.1) 165 (90–360) 8650 ± 3590c, * 
 Perphenazine/β-CD 
complex 
5 24.7 (15.4–35.4) 180 (60–360) 5530 ± 1730 
 Perphenazine/PEG solid 
dispersion 
4 35.1 (30.6–38.3) 180 (60–180) 7070 ± 1120* 
a extrapolated value 
b n=2 
c n=3 
* significantly different from the AUC0-360 min value of perorally administered aqueous perphenazine 
solution (Kruskall-Wallis test with a post hoc test, p < 0.05) 
5.4 CONCLUSIONS 
For sublingual delivery, the drug needs to dissolve rapidly in a small volume of saliva. In 
this study, solid dispersion preparation and cyclodextrin complexation were investigated 
as ways to achieve sublingual administration of perphenazine in rabbits. When compared 
with peroral administration of an aqueous perphenazine solution, the absorption of 
perphenazine could be enhanced by the sublingual administration of a perphenazine/PEG 
solid dispersion and a solid perphenazine/β-CD complex. Good sublingual absorption was 
achieved using micronized perphenazine. 
48 
 
 
6 Effect of Storage on the Dissolution Rate of a Fast-
dissolving Perphenazine/beta-cyclodextrin Complex 3 
Abstract 
Objective: In general, the chemical and physical stability of amorphous cyclodextrin 
complexes and how storage affects their dissolution rate have not been widely reported. 
The aim of this study was to evaluate the solid-state stability of a fast-dissolving 
perphenazine/beta-cyclodextrin (β-CD) complex, which has been found to be well absorbed 
after sublingual administration to rabbits. In addition, the dissolution rate of plain β-CD in 
crystalline and amorphous forms was determined.  
Methods: The amorphous perphenazine/β-CD complex powders were prepared by spray-
drying and freeze-drying, and their stability was examined after storage at 40 °C, 75% 
relative humidity (RH) or at room temperature, 60% RH for up to 82 days.  
Key findings: Perphenazine was found to be chemically stable in all samples. The dissolution 
rate of perphenazine remained practically unchanged at both storage conditions, although 
partial crystallization was observed in both spray-dried and freeze-dried samples at 40 °C, 
75% RH. Interestingly, it was also observed that the dissolution rates of crystalline and 
amorphous β-CD were similar.  
Conclusion: The results suggest that CD complexation may represent a suitable alternative 
for preparing intraorally dissolving formulations, since the fast dissolution rate of the drug 
was maintained even though changes in the crystal structure were observed during storage. 
                                                          
3 Adapted with permission of John Wiley & Sons  from: Turunen E, Korhonen O, Lehto VP, Kauppinen A, Ahtiainen H, 
Järvinen K, Jarho P. Effect of storage on the dissolution rate of a fast-dissolving perphenazine/beta-cyclodextrin 
complex. Journal of Pharmacy and Pharmacology, in press. 
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6.1 INTRODUCTION 
In our earlier study (Chapter 5), it was shown that complexation with β-cyclodextrin (β-
CD) improved the apparent aqueous solubility and dissolution rate of perphenazine 
(Turunen et al. 2011). In addition, the sublingual administration of the rapidly dissolving, 
amorphous perphenazine/β-CD complex to rabbits resulted in better absorption of 
perphenazine than peroral administration of an aqueous perphenazine solution.  
Fully or partially amorphous drug/CD complexes are commonly formed when solid 
complex powders are prepared e.g. by spray-drying and freeze-drying. These materials 
usually exhibit higher apparent aqueous solubilities and dissolution rates in comparison to 
crystalline materials but on the other hand, they may be physically and chemically unstable 
with a tendency to crystallize during processing, storage or dissolution (Yu 2001, Kaushal et 
al. 2004). The solid-state stability of amorphous drug/CD complexes and the effect of 
possible solid state changes on their dissolution rate have not been widely studied. In 
addition, the dissolution properties of the amorphous forms of natural CDs have not been 
previously reported. Thus, the aim of the present study was to investigate the effect of 
storage on the physical and chemical stability and dissolution rate of a fast-dissolving, 
amorphous perphenazine/β-CD complex. Solid perphenazine/β-CD complex powders were 
prepared by spray-drying and freeze-drying, and stored at 40 °C, 75% relative humidity 
(RH) or at room temperature (2123 °C), 60% RH for up to 82 days. Plain β-CD was also 
investigated in its crystalline and amorphous forms to elucidate the effect of crystallization 
on its dissolution rate. 
6.2 EXPERIMENTAL 
6.2.1 Materials 
Perphenazine was purchased from Sigma-Aldrich (Steinheim, Germany). Beta-cyclodextrin 
(β-CD, Cavamax® W7 Pharma) and randomly methylated beta-cyclodextrin (RM-β-CD, 
Cavasol® W7 M) were purchased from Wacker-Chemie GmbH (Burghausen, Germany). All 
other reagents were of analytical grade. 
6.2.2 Preparation and characterization of amorphous perphenazine/β-CD complex and 
physical mixture of perphenazine and β-CD 
Solid perphenazine/β-CD complexes were prepared by spray-drying and freeze-drying. An 
excess amount of perphenazine was added to an aqueous 1% (w/v) β-CD solution. The 
suspension was protected from light and stirred for 3 days at room temperature (2123 °C). 
The pH of the solution was adjusted to 8.0 and held constant during the equilibration by 
adding a small amount of aqueous HCl, when necessary. After stirring, any undissolved 
perphenazine was removed by filtration (0.45 μm). The resulting solution was then split 
into two portions, one of which was spray-dried and the other was freeze-dried, as 
described below. 
Spray-drying was performed with a Büchi Mini-Spray Dryer B-191 (Büchi Labortechnik 
AG, Flawil, Switzerland) under the following conditions: atomizer air flow rate 600 l/h, 
inlet temperature 160 °C, outlet temperature 9698 °C and feed rate 4.7 ml/min. Freeze-
drying was conducted with a laboratory scale freeze-dryer LyoStar II (SP Scientific Inc., 
Stone Ridge, NY, USA). The beaker flasks containing the sample solutions were loaded 
onto the bottom shelf of the freeze-dryer. The following process conditions were used: (1) 
cooling 2.5 °C/min from +25 °C to -30 °C with 30 min equilibration steps at +5 °C and -5 °C; 
(2) primary drying was performed in two steps, firstly at -20 °C for 15 h and subsequently 
at 0 °C for 9 h; (3) heating 0.2 °C/min to secondary drying temperature of +30 °C with a 
holding time of 2 h. Both primary and secondary drying were carried out under a chamber 
pressure of 200 mTorr. 
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The residual moisture of the spray-dried and freeze-dried perphenazine/β-CD powders 
was determined before storage by coulometric Karl Fischer titration using a Mettler Toledo 
C30 titrator with a Mettler AJ100 analytical balance (Mettler Toledo, Greifensee, 
Switzerland). The moisture contents of the spray-dried and freeze-dried perphenazine/β-
CD powders were 5.06 ± 0.19% and 4.42 ± 0.14%, respectively (mean ± sd, n=9). 
The perphenazine content of the solid perphenazine/β-CD complexes was determined in 
triplicate by a high performance liquid chromatographic (HPLC) method which will 
described in the Chapter 6.2.3. The sample powders were accurately weighed and dissolved 
in 5.0 ml of the mobile phase, after which the solutions were filtered (0.45 μm) and 
analyzed. The spray-dried and freeze-dried complexes contained 0.20 ± 0.01 mg and 0.18 ± 
0.01 mg perphenazine per 1.00 mg of β-CD (mean ± sd, n=3).  
In addition to the perphenazine/β-CD complex, a physical mixture of perphenazine and 
β-CD was prepared by manually mixing perphenazine and β-CD in a 1:5 weight ratio. The 
perphenazine content of the physical mixture was verified by HPLC to be 0.20 ± 0.02 mg 
perphenazine per 1.00 mg of β-CD (mean ± sd, n=3). 
6.2.3 Stability-indicating HPLC method 
A stability-indicating high performance liquid chromatographic (HPLC) method was 
developed for determining the concentrations of perphenazine in the chemical stability and 
dissolution studies. The Agilent 1100 system (Agilent Technologies Inc., Waldbronn, 
Karlsruhe, Germany) consisted of a binary pump, a vacuum degasser, an autosampler 
(Hewlett Packard 1050, Hewlett Packard, Waldbronn, Germany), and a variable 
wavelength UV detector (Hewlett Packard 1050). A reversed-phase column (Zorbax Eclipse 
Plus C18, 3.0 x 100 mm, 3.5 μm, Agilent Technologies Inc., Wilmington, DE, USA) was used 
for the separation of perphenazine. The isocratic mobile phase consisted of acetonitrile and 
0.1% (v/v) trifluoroacetic acid in water (37:63 v/v). The injection volume was 1 μl, flow rate 
0.5 ml/min, and detection wavelength 254 nm. The retention time of perphenazine was 2.4 
min (total run time 3.5 min). The range of the HPLC method was 9–97 μg/ml. 
The ability of the HPLC method to separate the possible degradation products from 
perphenazine was verified with forced degradation of perphenazine. Perphenazine 
solutions were analyzed after subjecting them to oxidation (3% or 30% (v/v) H2O2) and light 
for up to two hours at room temperature (2123 °C). The peaks of the degradation products 
appeared at 1.0 min and 1.1 min and were well resolved from the peak of perphenazine (2.4 
min) (Figure 6.1). 
6.2.4 Stability study 
The stability study was performed under two accelerated storage conditions. The samples 
were individually weighed in open glass tubes and placed in desiccators at either 40 °C, 
75% relative humidity (RH) or at room temperature (2123 °C), 60% RH. The relative 
humidities were achieved by placing either a saturated NaCl solution (75% RH) or a 
saturated NaBr solution (60% RH) at the bottom of tightly closed desiccators. During the 
storage, the samples were protected from light with aluminum foil. The samples were 
analyzed before storage, and after storage periods of 2, 4, 8 or 12 weeks. 
6.2.4.1 Chemical stability 
The chemical stability determinations (n=3) were performed for perphenazine (0.941.32 
mg), the physical mixture of perphenazine and β-CD (5.746.20 mg), the spray-dried 
perphenazine/β-CD complex (5.796.23 mg) and the freeze-dried perphenazine/β-CD 
complex (5.756.29 mg). The previously weighed samples were dissolved in 3 ml of 0.1% 
trifluoroacetic acid in water. The amount of perphenazine in each sample was then 
analyzed by HPLC and compared to the amount of perphenazine at the beginning of the 
study. 
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Figure 6.1. The UV chromatograms (λ = 254 nm) of perphenazine and its degradation products: 
(a) no degradation, (b) partial degradation after 5 min in a 1:1 mixture of perphenazine 
solution and 3% H2O2 solution, and (c) full degradation after 10 min in a 1:1 mixture of 
perphenazine solution and 30% H2O2 solution 
 
6.2.4.2 Physical stability 
X-ray powder diffractometry (XRPD) was used to detect any possible crystallization of 
perphenazine or β-CD from the spray-dried and freeze-dried perphenazine/β-CD 
complexes. The perphenazine/β-CD complex samples (n=1) were analyzed at the beginning 
of the study as well as during storage. The XRPD measurements were performed with a 
Bragg–Brentano θ/2θ reflection geometry based diffractometer (Bruker D8 Discover, 
Karlsruhe, Germany) using Ni filtered Cu Kα (40 kV/40 mA) radiation. The samples were 
measured between the angular range of 550° using  0.01° steps and a 0.1-s counting time 
per step. The sample holder was rotated at 30 rpm. 
Differential scanning calorimetry (DSC) was used to monitor for possible crystallization 
of perphenazine from the spray-dried and freeze-dried perphenazine/β-CD complex 
powders during the storage. The analysis was performed using a Mettler Toledo DSC 823e 
apparatus (Greifensee, Switzerland) with a refrigerated cooling accessory (Mettler Toledo, 
METT-FT900 Julabo, Greifensee, Switzerland) and an autosampler (TS0801RO Sample 
Robot, Mettler Toledo). The samples (n=2) were first held at 25 °C for 0.5 min and then 
heated at 80 °C for 2 h to remove the residual moisture, followed by cooling at -50 °C (15 
min). The samples were then heated from -50 °C to 250 °C at 10 °C/min during the actual 
measurement. The DSC cell was purged with nitrogen at 50 ml/min. Temperature and heat 
flow were calibrated using indium, lead, zinc and highly purified water as reference 
standards. The samples (3.216.6 mg) were weighed with an analytical balance (Sartorius 
SE2, Sartorius AG, Göttingen, Germany) and analyzed in sealed 40 μL aluminum pans 
(Mettler Toledo) with a pierced lid. The results were analyzed with STARe software 
(Mettler Toledo). 
6.2.4.3 Dissolution rate of perphenazine before and after storage 
The dissolution rate of perphenazine (n=3) from the spray-dried and freeze-dried 
perphenazine/β-CD complexes was determined before and after storage. In addition, the 
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dissolution rates of unprocessed perphenazine and the physical mixture of unprocessed 
perphenazine and unprocessed β-CD were determined at the beginning of the study. The 
dissolution studies were performed at room temperature (2123 °C) using the method 
described earlier (Turunen et al. 2011). A total of 5.0 ml of dissolution medium was 
measured into a 20 ml plastic syringe equipped with a syringe tip filter (0.45 μm). A piece 
of filter paper was placed on the bottom of the syringe to prevent the solid particles from 
sedimenting into the syringe tip. A magnetic stirring bar was placed in the syringe, and the 
solutions were agitated at approximately 100 rev/min. The dissolution medium contained 
2% (w/v) randomly methylated β-CD (RM-β-CD) in 0.16 M phosphate buffer solution (pH 
6.5, ionic strength 0.5). RM-β-CD was added to the dissolution medium in order to 
maintain sink conditions for perphenazine. An accurately weighed amount of 
perphenazine (0.911.62 mg), physical mixture (5.026.17 mg), spray-dried perphenazine/β-
CD complex (5.756.39 mg) or freeze-dried perphenazine/β-CD complex (5.716.29 mg) 
was carefully placed into the dissolution medium. Samples were taken at 0.25, 0.5, 1, 2, and 
5 min. Each time point was analyzed separately. The perphenazine contents of the samples 
were determined by HPLC. 
6.2.5 Preparation and characterization of plain amorphous β-CD 
Amorphous β-CD was prepared by spray-drying an aqueous 1% (w/v) β-CD solution. 
Spray-drying was performed as described above for the perphenazine/β-CD complex. The 
spray-dried powder was examined by XRPD and scanning electron microscopy (n=1) using 
methods reported in detail earlier (Turunen et al. 2011). The dissolution rates of 
unprocessed, crystalline β-CD and spray-dried, amorphous β-CD in water (n=4) were 
studied under sink conditions using the experimental setup described above for the 
perphenazine/β-CD complex. Samples were taken at 10 s, 30 s, and 1, 2, 3, 4 and 5 min. The 
concentrations of β-CD were measured using an HPLC method with pulsed amperometric 
detection, as described earlier (Toropainen et al. 2008). Briefly, the analysis was performed 
with the Agilent 1100 system (Agilent Technologies Inc., Waldbronn, Karlsruhe, Germany) 
connected to an ESA Coulochem III detector (ESA Inc., Chelmsford, MA, USA). A Zorbax 
SB-Phenyl column (4.6 mm × 150 mm, 5 μm, Agilent Technologies, USA) was used for the 
separation of β-CD. The isocratic mobile phase consisted of acetonitrile and water (7:93 
v/v). The injection volume was 20 μl, flow rate 0.65 ml/min, and column temperature 30 °C. 
A post-column addition of 0.5 M NaOH solution (0.65 ml/min) was used to adjust the pH of 
mobile phase (pH > 12) in order that it would be suitable for the pulsed amperometric 
detection of β-CD. The range of the HPLC method was 0.6–121 μg/ml. 
 
6.2.6 Statistical methods 
The effect of storage time, storage conditions and the formulations on the chemical stability 
of perphenazine was evaluated using a three way analysis of variance (ANOVA) followed 
by a post hoc test (IBM SPSS Statistics, version 21, IBM Corp., Armonk, NY, USA). The effect 
of storage time and storage conditions on the dissolved amount of perphenazine in either 
spray-dried or freeze-dried perphenazine/β-CD complex was examined using a two way 
ANOVA followed by a post hoc test. A level of p < 0.05 denoted statistical significance in all 
cases. 
6.3 RESULTS AND DISCUSSION 
6.3.1 Chemical stability 
CDs have been claimed to increase the chemical stability of several drugs both in solution 
and in the solid state (Frömming and Szejtli 1994). However, it has also been reported that 
CDs can accelerate the solid state degradation of drugs through the absorption of 
atmospheric humidity (Frömming and Szejtli 1994, Loftsson and Brewster 1996). 
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Furthermore, the amorphous state of a solid drug/CD complex may promote drug 
degradation: for example, the oxidative degradation of ziprasidone was observed to be 
much higher in freeze-dried, amorphous ziprasidone/CD complexes than in crystalline 
ziprasidone/CD systems (Hong et al. 2011). 
The main degradation pathway of perphenazine is oxidation to perphenazine sulfoxide, 
although the drug can also undergo dechlorination when exposed to light (Li et al. 2005). In 
the present study, a stability-indicating HPLC method was used to determine the possible 
degradation of perphenazine during storage (n=3). At the last time point of the storage (81 
days), the amount of perphenazine was within 92109% of the original amount of 
perphenazine in all samples studied (Table 6.1). During the stability study, no peaks of the 
degradation products were observed in any of the chromatograms. The stability of 
perphenazine was not affected by the storage time or the storage conditions (three way 
ANOVA with a post hoc test, p > 0.05). The statistical analysis, however, showed that the 
amounts of perphenazine in the unprocessed perphenazine samples (range 90104% during 
the study) and spray-dried perphenazine/β-CD complex samples (9498%) during the 
storage differed from the amounts of perphenazine measured for the freeze-dried 
perphenazine/β-CD complex (101111%) and the physical mixture (92113%). 
Although the results indicated that perphenazine remained chemically stable during 
storage, it must be noted that the storage time was shorter than the time required according 
to the the International Conference on Harmonisation (ICH) guidance for the stability 
testing of new drug substances and products (i.e. 6 months at 40 °C/75% RH and 12 months 
at 25 °C/60% RH) (ICH, 2003). Therefore, more extensive stability studies would be 
required before a drug product containing the perphenazine/β-CD complex could be 
commercialized. 
 
Table 6.1. Chemical stability of unprocessed perphenazine, physical mixture of perphenazine 
and β-CD, spray-dried perphenazine/β-CD complex and freeze-dried perphenazine/β-CD 
complex during storage at 40 °C, 75% RH or at room temperature (2123 °C), 60% RH. Values 
are % of the amount of perphenazine at t=0 (mean ± sd, n=3). 
Days in 
storage 
Unprocessed 
perphenazine 
Physical  
mixture 
Spray-dried 
complex 
Freeze-dried 
complex 
Storage at 40 °C, 75% RH 
0 100 100 100 100 
13 90 ± 7 105 ± 15 98 ± 3 111 ± 2 
27 104 ± 8 108 ± 8 95 ± 0.5 108 ± 3 
56 99 ± 3 96 ± 7 97 ± 5 107 ± 3 
81 100 ± 4 109 ± 9 95 ± 2 105 ± 4 
Storage at room temperature, 60% RH 
0 100 100 100 100 
13 93 ± 5 113 ± 11 96 ± 5 108 ± 4 
27 94 ± 3 107 ± 9 96 ± 1 108 ± 2 
56 101 ± 6 105 ± 14 97 ± 2 106 ± 2 
81 98 ± 7 92 ± 4 94 ± 1 101 ± 2 
 
6.3.2 Physical stability 
Spray-dried and freeze-dried perphenazine/β-CD complex powders (n=1) were examined 
by X-ray powder diffractometry (XRPD) to determine whether there had occurred any 
changes in their crystal structures during storage. At the beginning of the study, the spray-
dried complex was fully amorphous, as indicated by the absence of diffraction peaks 
(Figures 6.2c and 2d). The freshly prepared freeze-dried complex, on the other hand, was 
not completely amorphous (Figures 6.2e and 6.2f). After 15 days of storage at 40 °C, 75% 
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RH, crystallization was observed in both spray-dried and freeze-dried complex powders 
(Figures 6.2c and 6.2e). The crystallinity of the freeze-dried complex also increased during 
storage at room temperature (2123 °C), 60% RH (Figure 6.2f), whereas under these 
conditions, the spray-dried complex remained amorphous throughout the study (Figure 
6.2d). The diffraction peaks in the crystallized samples did not completely correspond to 
the characteristic diffractions of unprocessed perphenazine or β-CD. Thus, it was clear that 
the crystallized complex had a crystal structure which differed from its crystalline 
components. The structure of the recrystallized form was independent of the storage 
conditions or the production method. Furthermore, the diffractogram of the crystalline 
form resembled the diffractogram of the dodecanol/β-CD complex (reported diffraction 
lines in the entry PDF 017-1016 in the Powder Diffraction File database (International 
Centre for Diffraction Data, 2005)), suggesting that different complexes might have 
corresponding crystal structures. In addition, the existence of a new metastable polymorph 
of perphenazine could not be ruled out. However, no reports of any other polymorphic 
forms of perphenazine were found in either relevant databases or the literature. 
In addition to the XRPD analysis, differential scanning calorimetry (DSC) was employed 
to determine the possible crystallization of perphenazine during its storage. In all samples 
studied, the thermograms were free of any melting endotherms that would be indicative of 
the presence of crystalline perphenazine or its possible polymorphic forms (data not 
shown), suggesting that the crystallized material observed with XRPD was not 
perphenazine. It was not possible to study the crystallization of amorphous β-CD with 
DSC, since β-CD does not have a definite melting point, but it undergoes thermal 
decomposition before melting at temperatures above 250 °C (Trotta et al. 2000, Song et al. 
2008, Tabary et al. 2011). In addition, the glass transition of amorphous β-CD could not be 
observed with DSC, since this has been postulated to occur at approximately 290 °C, which 
is above the thermal degradation temperature of β-CD (Tabary et al. 2011). 
6.3.3 Dissolution rate of perphenazine before and after storage 
Since the fast-dissolving perphenazine/β-CD complexes are intended for intraoral drug 
delivery, the dissolution studies were carried out at pH 6.5, which corresponds to the pH of 
saliva (5.87.4) (Mathias and Hussain 2010). Figure 6.3 shows the dissolution rates of 
unprocessed perphenazine, the physical mixture of perphenazine and β-CD, the spray-
dried perphenazine/β-CD complex and the freeze-dried perphenazine/β-CD complex 
before storage (n=3). Perphenazine was fully dissolved from the spray-dried and freeze-
dried perphenazine/β-CD complexes within 2 min, whereas unprocessed perphenazine and 
the physical mixture reached 55% and 78% dissolution during 5 min, respectively. The 
dissolution of perphenazine from the spray-dried and the freeze-dried perphenazine/β-CD 
complexes before and after storage is summarized in Table 6.2. The results indicate that 
although partial crystallization had occurred during storage (Figure 6.2), the dissolution 
profiles of perphenazine remained practically unchanged in all samples throughout the 12-
week storage period. The statistical analysis indicated that at some time points in the 
dissolution studies, the dissolved amount of perphenazine after storage was different from 
the dissolved amount at the beginning of the study (two way ANOVA followed by a post 
hoc test, p < 0.05) (Table 6.2). However, the dissolved amounts of perphenazine from both 
spray-dried and freeze-dried complexes were still clearly higher than those found for 
unprocessed perphenazine and the physical mixture of perphenazine and β-CD (Figure 
6.3). 
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Figure 6.2. X-ray patterns of unprocessed perphenazine (a), unprocessed β-CD (b), (c) spray-
dried perphenazine/β-CD complex stored at 40 °C, 75% RH, (d) spray-dried perphenazine/β-CD 
complex stored at room temperature (2123 °C) and 60% RH, (e) freeze-dried perphenazine/β-
CD complex stored at 40 °C, 75% RH, and (f) freeze-dried perphenazine/β-CD complex stored 
at room temperature, 60% RH (n=1). The time points for the stored samples were (i) before 
storage, (ii) 15 days, (iii) 29 days, (iv) 58 days, and (v) 83 days. 
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Figure 6.3. Dissolution curves of unprocessed perphenazine (Δ), physical mixture of 
perphenazine and β-CD (▲), spray-dried perphenazine/β-CD complex (○) and freeze-dried 
perphenazine/β-CD complex (●) before storage (mean ± sd, n=3). All samples corresponded to 
1 mg of perphenazine. The experiment was done at 2123 °C and pH 6.5 under sink conditions. 
 
When intraorally fast-dissolving drug formulations are considered, it is critical that the 
rapid dissolution rate of the drug is maintained during storage. In addition to CD 
technology, the solid dispersion approach has been investigated as a potential way to 
prepare fast-dissolving formulations for intraoral administration (van Drooge et al. 2004a, 
Laitinen et al. 2009, 2010).Unfortunately, the poor physical stability of amorphous solid 
dispersions may sometimes limit their properties in drug delivery. For example, the 
initially fast dissolution rate of perphenazine from freeze-dried solid dispersions containing 
polyvinylpyrrolidone (PVP) was found to decline back to the level of crystalline 
perphenazine during four weeks’ storage at 40 °C, ~5% RH (Laitinen et al. 2010). In another 
study, amorphous spray-dried powders containing nifedipine and either hydroxypropyl-β-
CD (HP-β-CD) or PVP were examined after their storage at 60 °C, 75% RH (Uekama et al. 
1992). After 14 days’ storage, crystallization of nifedipine had occurred in both powders. In 
the HP-β-CD system, the dissolution rate of nifedipine and its oral absorption in dogs after 
storage remained similar to those observed with the freshly prepared, amorphous 
nifedipine/HP-β-CD complex. In contrast, with the PVP system, the dissolution rate and 
oral absorption of nifedipine were significantly reduced during the 2-week storage period. 
These observations could be attributed to the differences in the crystal growth of nifedipine. 
A small crystal size was maintained in the HP-β-CD system throughout the storage period, 
whereas in the PVP system, the size of the nifedipine crystals increased markedly over 
time. Based on these observations and the results of the present study, it may be concluded 
that CD technology may represent a suitable approach for preparing fast-dissolving 
formulations, where the fast dissolution of drug is maintained during storage. However, it 
must also be noted that although the solid state changes had no major impact on the 
dissolution performance of the perphenazine/β-CD complex, more detailed 
characterization of the other physical properties of the complex powder would be needed 
in the development of the final dosage form. 
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Table 6.2. Dissolution of perphenazine from spray-dried or freeze-dried perphenazine/β-CD 
complex before and after storage at 40 °C, 75% RH or at room temperature (2123 °C), 60% 
RH. Values are % dissolved ± sd (n=3). All samples corresponded to 1 mg of perphenazine. The 
experiment was done at pH 6.5 under sink conditions. 
 
 Dissolved (%) 
Days in 
storage 
0.25 min 0.5 min 1 min 2 min 5 min 
Spray-dried complex stored at 40 °C, 75% RH  
0 51 ± 4 62 ± 21 70 ± 4 95 ± 8 92 ± 3 
15 65 ± 4  85 ± 10 87 ± 9 93 ± 4 95 ± 1 
28 60 ± 11 85 ± 12 90 ± 3 97 ± 3 95 ± 2 
57 54 ± 13 78 ± 8 84 ± 7 85 ± 4 92 ± 2 
82 66 ± 15 69 ± 6 91 ± 3 86 ± 8a 90 ± 3a 
      
Spray-dried complex stored at room temperature, 60% RH 
0 51 ± 4 62 ± 21 70 ± 4 95 ± 8 92 ± 3 
14 42 ± 14b 75 ± 5 87 ± 1 91 ± 4 93 ± 2 
28 31 ± 6b 65 ± 5 84 ± 12 98 ± 2 98 ± 2 
56 49 ± 4b 72 ± 13 78 ± 4 90 ± 8 91 ± 1 
82 44 ± 4b 56 ± 4 75 ± 12 87 ± 6a 89 ± 2a 
      
Freeze-dried complex stored at 40 °C, 75% RH 
0 86 ± 3 90 ± 2 87 ± 15 105 ± 2 106 ± 5 
15 67 ± 1a 85 ± 2 95 ± 5 101 ± 3 102 ± 1 
28 75 ± 9a 93 ± 4 95 ± 3 101 ± 5 101 ± 2 
57 77 ± 9a 88 ± 1 94 ± 6 96 ± 2a 94 ± 4a 
82 76 ± 12a 78 ± 6a 92 ± 3 93 ± 7a 95 ± 6a 
Freeze-dried complex stored at room temperature, 60% RH 
0 86 ± 3 90 ± 2 87 ± 15 105 ± 2 106 ± 5 
14 72 ± 5a 84 ± 7 91 ± 7 102 ± 2 90 ± 6a,b 
28 71 ± 8a 90 ± 7 102 ± 4 104 ± 3 109 ± 1 
56 77 ± 13a 82 ± 3 91 ± 6 97 ± 5a 97 ± 2a 
82 66 ± 11a 69 ± 17a 86 ± 5 92 ± 2a 92 ± 3a 
a Significantly different from the % dissolved at t=0 (two way ANOVA followed by a post hoc 
test, p < 0.05) 
b Significantly different from the % dissolved after storage at 40 °C, 75% RH (two way ANOVA 
followed by a post hoc test, p < 0.05) 
 
6.3.4 Preparation and characterization of plain amorphous β-CD 
Spray-drying converted crystalline β-CD into a fully amorphous form, as indicated by a 
halo X-ray diffraction pattern and the absence of characteristic diffraction peaks of β-CD 
(data not shown). The scanning electron micrographs showed that spray-drying had 
changed the morphology of the β-CD particles from regular-shaped crystals to small, 
spherical particles, which are typical for spray-dried materials (Figure 6.4). The dissolution 
behaviour of unprocessed and spray-dried β-CD in water at sink conditions (n=4) is shown 
in Figure 6.5. Interestingly, the dissolution profiles of crystalline and amorphous β-CD were 
practically identical, indicating that the amorphization of β-CD does not confer any 
dissolution advantage over the crystalline form. This also explains why the partial 
recrystallization of the perphenazine/β-CD complex during the storage did not affect the 
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dissolution rate of perphenazine: as the release of perphenazine from the dissolved 
complex can be considered to be instantaneous, the rate limiting step is the dissolution of β-
CD. It is also possible that the similar dissolution profiles of crystalline and amorphous β-
CD could be attributed to solution-mediated phase transformation during dissolution, 
leading to the crystallization of amorphous β-CD upon contact with water (Greco and 
Bogner 2012). In addition, visual observation suggested that the wettability of amorphous 
β-CD was poorer than that of crystalline β-CD, since the amorphous powder remained 
floating on the surface of the dissolution medium for a longer period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Scanning electron micrographs of a) unprocessed β-CD and b) spray-dried β-CD. 
Scale bars: a) 200 μm and b) 10 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Dissolution curves of unprocessed, crystalline β-CD (Δ) and spray-dried, amorphous 
β-CD (▲) in water under sink conditions (mean ± sd, n=4) 
 
 
Although several studies have described the formation of amorphous drug/β-CD 
complexes by spray-drying or freeze-drying (for example Soliman et al. 1997, Ribeiro et al. 
2003, Pralhad and Rajendrakumar 2004, Sinha et al. 2005, Zingone and Rubessa 2005, Hong 
et al. 2011), the amorphous state of natural β-CD itself has not been widely characterized. In 
a recent study, Tabary and coworkers (2011) amorphized crystalline β-CD by high-energy 
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planetary milling and estimated its glass transition temperature (Tg) by extrapolation of the 
Tgs of co-milled, amorphous molecular alloys containing β-CD and methylated β-CD at 
different ratios. The Tg of β-CD was found to be approximately 292 °C, which is above its 
thermal degradation temperature, thus making it impossible to determine by direct 
methods. As far as we are aware, no other extensive studies dealing with the physical 
characterization of amorphous β-CD have been published. In addition, the effect of the 
amorphous state on the dissolution rate of β-CD has not been previously described.  
When solid CD complexes are prepared by spray-drying or freeze-drying a drug/CD 
solution, the resulting powders contain not only the drug/CD complex, but also some 
uncomplexed drug and CD. Since the complexation efficiency between drugs and CDs is 
usually less than ideal, solid CD formulations may contain a significant amount of 
uncomplexed CD (Loftsson and Brewster 2012). The results of the present study indicate 
that even though the uncomplexed amorphous β-CD in a spray-dried or freeze-dried 
formulation may crystallize during storage, its dissolution properties would not be 
significantly affected. Furthermore, the fast dissolution rate of perphenazine was 
maintained in the perphenazine/β-CD system even though partial crystallization could be 
observed with storage, indicating that the possible crystallization of amorphous β-CD does 
not hamper its ability to improve the dissolution rate of a poorly soluble drug. 
6.4 CONCLUSIONS 
The stability of amorphous perphenazine/β-CD complexes prepared by spray-drying and 
freeze-drying was studied at 40 °C, 75% relative humidity (RH) and at room temperature 
(2123 °C), 60% RH for up to 82 days. Perphenazine was found to be chemically stable 
throughout the study. Although partial recrystallization was observed in both the spray-
dried and the freeze-dried perphenazine/β-CD powders during storage, the dissolution rate 
of perphenazine from the complexes remained practically unchanged throughout the 
study. This was attributed to the similar dissolution rates of crystalline and amorphous 
forms of β-CD. Thus, the present results indicate that cyclodextrin technology may 
represent a useful option for obtaining fast-dissolving formulations for intraoral drug 
administration, since the performance of the formulation appears to be insensitive to 
changes in the structure caused by the stress conditions of the storage environment. 
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7 Effect of Hydroxypropyl-beta-cyclodextrin and Sucrose 
on the Sublingual Absorption of Midazolam in Rabbits4 
Abstract. Sublingually administered midazolam is commonly used for premedication of 
pediatric patients. However, the irritating taste and low aqueous solubility of midazolam 
complicate its sublingual use. Cyclodextrin complexation can be used to improve both the 
taste and apparent aqueous solubility of drugs, but based on earlier studies, the 
complexation efficiency of midazolam is relatively low. In the present study, the 
complexation of midazolam with hydroxypropyl-beta-cyclodextrin (HP-β-CD) was 
investigated in the presence of various excipients. The apparent aqueous solubility of 
midazolam improved significantly when HP-β-CD was used together with sucrose. Sucrose 
alone did not increase the solubility of midazolam. In addition, sucrose increased the 
apparent stability constant of the midazolam/HP-β-CD complex. The pharmacokinetics of 
midazolam in different dosage forms was investigated in rabbits (dose 1 mg/rabbit) after 
intravenous administration of midazolam solution and after sublingual administration of 
midazolam solution, midazolam/HP-β-CD/sucrose solution or midazolam/HP-β-
CD/sucrose powder. Midazolam displayed rapid sublingual absorption (mean tmax ≤ 30 min 
from the liquid formulations and 60 min from the solid formulation) with high absolute 
bioavailability (> 68%) from all evaluated formulations. Based on the results, HP-β-CD and 
sucrose can be utilized together to prepare more concentrated and palatable midazolam 
formulations for sublingual administration in pediatric patients. 
                                                          
4 Adapted with permission of Elsevier from: Kaartama R, Turunen E, Toljamo K, Kokki H, Lehtonen M, Ranta VP, 
Savolainen J, Järvinen K, Jarho P. The effect of hydroxypropyl-beta-cyclodetrin and sucrose on the sublingual 
absorption of midazolam in rabbits. European Journal of Pharmaceutics and Biopharmaceutics 81: 178183, 2012. 
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7.1 INTRODUCTION 
Midazolam (Figure 7.1) is a psychoactive benzodiazepine drug that has anxiolytic, sedative, 
anticonvulsant, sleep inducing, and muscle relaxant properties (Krauss and Green 2006). 
Due to its favorable pharmacokinetic and pharmacodynamic properties, i.e., prompt onset 
and short duration of action, midazolam is commonly used as a premedication for children 
before medical procedures or general anesthesia. However, when administered perorally, 
the extensive hepatic first-pass metabolism limits the absolute bioavailability of midazolam 
to only 30–50% (Greenblatt et al. 1984, Reed et al. 2001). Since it is advisable to avoid 
intravenous and intramuscular injections or rectal administration in pediatric use, less 
invasive administration routes are preferred, such as sublingual, buccal or nasal delivery. 
By administering midazolam sublingually, buccally, or nasally, the first-pass effect can be 
avoided, and not only a more rapid onset of action but also higher plasma levels of 
midazolam can be achieved with absolute bioavailabilities ranging from 60% to 92% 
(Schwagmeier et al. 1998, Knoester et al. 2002, Dale et al. 2006, Wermeling et al. 2009, 
Haschke et al. 2010). However, since midazolam often evokes pain, irritation, and a burning 
sensation in the nose, sublingual or buccal administration of midazolam is believed to be a 
better alternative in children (Karl et al. 1993, Krauss and Green 2006). 
At the moment, midazolam preparations intended for sublingual or buccal 
administration in pediatric anesthesia are not commercially available, and injectable 
midazolam solutions are therefore often used for this purpose (Marcon et al. 2009). One 
major drawback related to the use of injectable solutions is the bitter taste of midazolam 
that may cause the children to spit the drug solution out of their mouths. Thus, new taste-
masked formulations are clearly needed to facilitate the sublingual and buccal 
administration of midazolam. In fact, the European Medicines Agency has identified 
midazolam as one of the drugs that require new formulations and administration routes for 
pediatric use (EMA 2006b). 
Various beverages, juices, and sugar-containing flavored syrups have been used to make 
midazolam more palatable (Pandit et al. 2001, Khalil et al. 2003, Isik et al. 2008, Shah et al. 
2009). Another possibility to achieve taste masking of midazolam is to use cyclodextrin 
complexation. Marçon et al. (2009) studied the use of cyclodextrins in peroral solutions of 
midazolam and observed that natural beta-CD (β-CD) and gamma-CD (γ-CD) significantly 
decreased the bitter taste of midazolam and also increased its apparent aqueous solubility. 
However, the cyclodextrin complexation efficiency of benzodiazepines is often low and 
large amounts of cyclodextrins are therefore needed to solubilize them, and this can lead to 
problems such as increased volume and excessive size of the pharmaceutical preparation 
(Loftsson et al. 2001). Various strategies have been devised to improve the cyclodextrin 
complexation of drugs: for example, small amounts of alpha hydroxy acids, amino acids, or 
water-soluble polymers have been added to the formulation in order to increase the 
stability constants of the drug/cyclodextrin complexes (Loftsson et al. 1994, Redenti et al. 
2000, Mura et al. 2003). 
In the present study, cyclodextrin complexation was used to develop palatable 
midazolam formulations for sublingual administration in pediatric patients. The 
complexation of midazolam with hydroxypropyl-beta-cyclodextrin (HP-β-CD) was 
investigated in the presence of different excipients, including alpha hydroxy acids, amino 
acids, and saccharides. As cyclodextrin complexation may affect the absorption of drugs, 
the sublingual absorption of midazolam was evaluated in rabbits after the administration of 
a commercial injectable midazolam solution as well as liquid and solid formulations 
containing midazolam, HP-β-CD and sucrose. In order to determine the absolute 
bioavailability of midazolam from the sublingually administered formulations, midazolam 
solution was also injected intravenously to the rabbits. 
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Figure 7.1. The molecular structure and the reversible ring opening reaction of midazolam 
7.2 EXPERIMENTAL 
7.2.1 Materials 
Midazolam hydrochloride (≥98%) was purchased from Titan Pharma (Mumbai, India). 
Injectable midazolam solution (5 mg/ml; Dormicum®) was obtained from Roche (Espoo, 
Finland). Hydroxypropyl-beta-cyclodextrin (HP-β-CD) was purchased from Wacker 
Chemie (Burghausen, Germany). Sucrose and sorbitol were purchased from MP 
Biomedicals Inc. (Solon, Ohio, USA). Galactose, trehalose, mandelic acid, alanine, aspartic 
acid, glutamic acid, serine, and phenylalanine were obtained from Sigma–Aldrich 
(Steinheim, Germany). Maltose, arginine, lysine, methionine, and proline were obtained 
from Fluka (Buchs, Switzerland), and mannitol, tartaric acid, and glycine from Riedel-de 
Haën (Seelze, Germany). Glucose was purchased from ICN Biomedicals, Inc. (Ohio, USA), 
citric acid from J.T. Baker (Deventer, Holland) and glutamine from Merck (Darmstadt, 
Germany). All other reagents were of analytical grade. 
7.2.2 HPLC method 
High-performance liquid chromatography (HPLC) was used to determine the midazolam 
concentrations during the solubility studies. The HPLC 1100 system (Agilent Technologies 
Inc., Waldbronn, Karlsruhe, Germany) consisted of a binary pump, a vacuum degasser, an 
autosampler, a thermostatted column oven, and a UV detector. A reversed-phase column 
(Zorbax SB-C18, 4.6 × 150 mm, 5 μm, Agilent Technologies Inc., Little Falls, Wilmington, 
USA) was used for the separation of midazolam. The isocratic mobile phase consisted of 
acetonitrile and phosphate buffer (20 mM, pH 7.2) (65:35 v/v). The injection volume was 10 
μl, flow rate 1.0 ml/min, column temperature 28 °C and detection wavelength 240 nm. 
7.2.3 GC–MS method 
A gas chromatographic–mass spectrometric (GC–MS) method with negative chemical 
ionization was used to measure the concentrations of midazolam and its main metabolite, 
1-hydroxymidazolam (1-OH-midazolam) in rabbit plasma. Before the GC–MS analysis, the 
plasma samples were purified by mixed-mode solid-phase extraction. These procedures 
have been described in detail elsewhere (Kaartama et al. 2011). 
7.2.4 Solubility studies 
The effect of various excipients together with HP-β-CD on the apparent aqueous solubility 
of midazolam was determined at pH 5.0 (n=2). The excipients used were alpha hydroxy 
acids (citric acid, tartaric acid, lactic acid, and mandelic acid), amino acids (alanine, aspartic 
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acid, arginine, glutamic acid, glutamine, glycine, lysine, methionine, phenylalanine, 
proline, and serine), and saccharides (glucose, galactose, lactose, sucrose, maltose, 
trehalose, mannitol, and sorbitol). The cyclodextrin/excipient solutions were prepared by 
dissolving 5% (w/v) (35 mM) of HP-β-CD and an equimolar amount of one of the excipients 
in an aqueous acetate buffer solution (0.16 M, pH 5.0, ionic strength 0.5). An excess amount 
of midazolam hydrochloride was added to each cyclodextrin/excipient solution and the 
suspensions were shaken at 21–23 °C for 3 days in order to attain equilibrium. The pH of 
the solutions was measured daily and maintained at 5.0 using aqueous HCl or NaOH 
solutions. After equilibration, the samples were filtered (0.45 μm) and analyzed by HPLC. 
The effect of the sucrose concentration on the complexation of midazolam with HP-β-CD 
was studied at pH 5.0 using 20% (w/v) of HP-β-CD and 0%, 10%, 25% or 50% (w/v) of 
sucrose in an aqueous acetate buffer solution (0.16 M, pH 5.0, ionic strength 0.5) (n=4). In 
addition, the intrinsic solubility of midazolam (S0) and the solubility of midazolam in a 50% 
(w/v) sucrose solution were determined. The samples were prepared, equilibrated and 
analyzed as described earlier in this section. A nonparametric Kruskall–Wallis test was 
used to evaluate the statistical differences between the midazolam concentrations in 20% 
HP-β-CD solutions with or without sucrose. The post hoc test was then used to test the 
significance of the differences of the means (Siegel and Castellan Jr. 1988). The level of 
significance (p) was 0.05. 
The phase-solubility profile of midazolam with HP-β-CD was determined at pH 5.0 in 
the presence or in the absence of 50% (w/v) sucrose (n=2) using the method of Higuchi and 
Connors (Higuchi and Connors 1965). An excess amount of midazolam was added to 
aqueous acetate buffer solutions (0.16 M, pH 5.0, ionic strength 0.5) containing 0%, 2.5%, 
5%, 10%, 15% or 20% (w/v) of HP-β-CD and either 0% or 50% (w/v) of sucrose. The samples 
were prepared, equilibrated, and analyzed as described earlier. The phase-solubility 
diagrams were prepared by plotting the midazolam concentrations (mol/l) as a function of 
the HP-β-CD concentration (mol/l). The apparent stability constants were calculated using 
the equation 5.1 (Section 5).  
7.2.5 Preparation of sublingual formulations 
Two midazolam formulations containing HP-β-CD and sucrose were prepared for 
sublingual administration to rabbits in the pharmacokinetic studies. A liquid formulation 
was prepared by dissolving midazolam (10 mg/ml), HP-β-CD (20% w/v), and sucrose (50% 
w/v) in an acetate buffer (20 mM, pH 5, ionic strength 0.15). For a solid formulation, a 
solution containing 2 mg/ml of midazolam, 4% w/v of HP-β-CD, and 10% w/v of sucrose 
was prepared using an acetate buffer (20 mM, pH 5, ionic strength 0.15) as a solvent. The 
solution was freeze-dried using a Thermo Savant ModulyoD 230 dryer (FTS® Systems Inc., 
New York, USA). After freeze-drying, the resulting powder was sieved (150 μm). The 
amounts of midazolam in both formulations were accurately determined by HPLC (n=3). 
The formulations were stored in tightly closed containers at +4 °C and used within 30 days. 
Both formulations were found to be stable under the storage conditions (data not shown). 
7.2.6 Pharmacokinetic studies in rabbits 
The animal studies were reviewed and approved by the Animal Ethics Committee in 
Finland and performed in accordance with the standards of EC Directive 86/609/EEC. The 
male New Zealand white rabbits used in the study were obtained from HB Lidköpings 
Kaninfarm (Lidköping, Sweden). The rabbits weighed 3.4–4.2 kg at the beginning of the 
study. Water and commercial food pellets were freely available except during the 4 h study 
periods when the rabbits were under anesthesia. The rabbits were anesthetized using 
ketamine (15 mg/kg; Ketalar, Pfizer, Espoo Finland), medetomidine (0.25 mg/kg; Domitor, 
Orion Pharma, Espoo, Finland), and fentanyl citrate (0.05 mg/rabbit) – fluanisone (1.5 
mg/rabbit) solution (Hypnorm, Janssen Pharmaceutica, Beerse, Belgium). The anesthetized 
rabbits were kept warm with towels and lamps and infused with 0.9% NaCl solution. When 
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midazolam was administered sublingually, the lower jaws of the rabbits were supported in 
the horizontal position. 
A total of eight rabbits were used in the pharmacokinetic studies. Each midazolam 
formulation was administered to four rabbits with a wash-out time of three weeks. The 
dose of midazolam was always 1 mg/rabbit. Three different sublingual formulations of 
midazolam were used: (1) injectable midazolam solution (Dormicum®; 5 mg/ml) (200 
μl/rabbit), (2) midazolam/HP-β-CD/sucrose solution (100 μl/rabbit), and 3) midazolam/HP-
β-CD/sucrose powder (85 mg/rabbit). To determine the absolute bioavailability, the rabbits 
were also given midazolam solution (Dormicum®; 5 mg/ ml) as an intravenous injection 
(200 μl/rabbit).  
Blood samples (2 ml) were collected into Venoject tubes (Terumo, Leuven, Belgium) at 0, 
2, 5, 10, 15, 30, 60, 120, 180, and 240 min from either a central artery (90% of the samples) or 
a marginal vein (10% of the samples) of the ear. The samples were centrifuged for 10 min at 
20 °C (3700 g), after which the plasma layer was collected and stored at -80 °C until 
analysis. All samples were analyzed by GC–MS within four weeks. 
The pharmacokinetic parameters for midazolam were calculated with the WinNonlin 
program (version 5.0.1, Pharsight Corporation, Mountain View, CA, USA) using a 
noncompartmental model. The area under the time–concentration curve from 0 to 240 min 
(AUC0–240min), AUC from zero extrapolated to infinity (AUC0–∞), maximum plasma 
concentration (Cmax), time to reach maximum plasma concentration (tmax), and terminal 
elimination half-life (t1/2) were calculated for evaluating the absorption of midazolam. After 
intravenous administration, the Cmax values were determined by extrapolating the 
midazolam concentrations to 0 min. In addition, the elimination rate constant (kel), 
clearance (CL) and volume of distribution at steady state (VSS) after intravenous 
administration of midazolam were determined. The absolute bioavailability of midazolam 
(F%) was calculated by comparing the AUC0–∞ values of midazolam after sublingual 
administration to the AUC0–∞ values obtained after intravenous injection. A nonparametric 
Kruskall–Wallis test was used to evaluate the statistical differences between the Cmax, tmax, 
AUC0–240min, and AUC0–∞ values of the tested formulations. The post hoc test was then used to 
evaluate the significance of the differences of the means (Siegel and Castellan Jr. 1988). The 
level of significance (p) was 0.05. 
7.3 RESULTS AND DISCUSSION 
7.3.1 Solubility studies 
The aqueous solubility of midazolam (pKa 6.15) at a given pH depends not only on its 
ionization state, but also on the reversible pH-dependent opening of its benzodiazepine 
ring structure (Loftsson et al. 2001). The ring-opening of midazolam (Figure 7.1) is an 
equilibrium reaction: at pH values below 2, the more hydrophilic open-ring structure 
prevails, while at pH values above 4, the ring is completely closed, making the molecule 
more lipophilic (Loftsson et al. 2001, Zhang et al. 2002). At pH 3.3, which is the pH of the 
commercial injectable solution, it is estimated that 80–85% of the midazolam molecules are 
in the closed-ring form (Gerecke 1983). In the present study, all solubility experiments were 
performed at pH 5.0, at which midazolam is mostly in its ionized, closed-ring form. At this 
pH, cyclodextrins are not likely to affect the ring-closing equilibrium of midazolam: 
previous studies have shown that cyclodextrins seem to stabilize the open-ring form at low 
pH, but do not change the equilibrium at pH values above 4 (Loftsson et al. 2001).  
The apparent aqueous solubility of midazolam was determined in the presence of 5% 
(w/v) (35 mM) HP-β-CD and equimolar amounts of several excipients (Figure 7.2). When 
sucrose was present in the HP-β-CD solution, the apparent solubility of midazolam was 
nearly doubled when compared to its apparent solubility in plain 5% (w/v) HP-β-CD 
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solution. The alpha hydroxy acids, amino acids, and other saccharides tested did not 
increase the apparent solubility of midazolam in the presence of HP-β-CD. 
The effect of sucrose concentration on the apparent aqueous solubility of midazolam was 
examined in more detail at a constant HP-β-CD concentration (Figure 7.3). The apparent 
solubility of midazolam was increased rather linearly as a function of the sucrose 
concentration. In a 20% (w/v) HP-β-CD solution with no sucrose, the apparent aqueous 
solubility of midazolam was improved 30-fold compared to its intrinsic solubility (S0). 
When 50% (w/v) sucrose was present in the 20% HP-β-CD solution, the apparent solubility 
of midazolam was 68-fold higher as compared to S0. In all solutions containing HP-β-CD 
and 10%, 25%, or 50% (w/v) sucrose, the apparent solubility of midazolam was higher than 
in the solution containing only HP-β-CD. On the other hand, plain 50% (w/v) sucrose had 
only a minor effect on the solubility of midazolam (1.2-fold compared to S0). The solubility-
enhancing effect of HP-β-CD and sucrose was therefore synergistic, as their combined effect 
on the solubility of midazolam was larger than the sum of their independent effects. A 
similar synergistic effect was also observed when natural gamma-cyclodextrin (γ-CD) was 
used instead of HP-β-CD (data not shown). 
 
 
Figure 7.2. The apparent solubility of midazolam at pH 5.0 in the presence of 5% (w/v)  
(35 mM) HP-β-CD without any excipient (dotted bar) and with equimolar amounts (35 mM) of 
various saccharides (light gray bars), alpha hydroxy acids (white bars), and amino acids (dark 
gray bars) (mean ± range, n=2). 
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Figure 7.3. The apparent solubility of midazolam at pH 5.0 in the presence of 20% (w/v) HP-β-
CD and 0%, 10%, 25%, or 50% (w/v) sucrose (mean ± sd; n=4). The intrinsic solubility of 
midazolam and the solubility in the presence of 50% sucrose without HP-β-CD are also 
presented. An asterisk (*) indicates that the apparent solubility of midazolam was significantly 
higher when compared to the apparent solubility in 20% (w/v) HP-β-CD solution without 
sucrose (Kruskall–Wallis test with a post hoc test, p < 0.05). 
 
The phase-solubility diagrams of midazolam and HP-β-CD with and without 50% (w/v) 
sucrose are presented in Figure 7.4. In both cases, midazolam showed linear AL-type phase-
solubility behavior. The apparent stability constant of the complex was higher when 
sucrose was present: the stability constant values in the absence and in the presence of 
sucrose were 259 M-1 and 387 M-1, respectively. 
 
 
Figure 7.4. The phase-solubility diagrams of midazolam and HP-β-CD at pH 5.0 with (■) and 
without (○) 50% (w/v) sucrose (mean; n=2).  
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The solubility-enhancing effect of sucrose and HP-β-CD may be attributable to various 
mechanisms. Similar synergistic solubilization has been extensively reported in the 
literature for systems containing a drug, a cyclodextrin, and a small amount of some 
excipient, such as an alpha hydroxy acid, an amino acid, or a water-soluble polymer 
(Redenti et al. 2000, Loftsson et al. 2001, Mura et al. 2003). In some cases, the intrinsic 
solubility of the drug increases in the presence of an excipient, e.g., due to salt formation 
(Redenti et al. 2000). The excipient may also stabilize the drug/cyclodextrin complex via 
electrostatic interactions and hydrogen bonds or promote the complexation of the drug by 
increasing the negative enthalpy change in the system (Loftsson et al. 1994, Redenti et al. 
2000). In addition to inclusion complexation, cyclodextrins can also solubilize drugs via 
non-inclusion mechanisms, such as self-association and the formation of micelle-like 
structures (Loftsson et al. 2004). Especially with the relatively large amounts of sucrose 
used in this study, it is possible that some non-inclusion phenomena could be involved in 
the solubilization of midazolam. 
The effect of sucrose on the cyclodextrin complexation of drugs can also be related to its 
ability to change the ordering of the surrounding water molecules. Sugars and sugar 
alcohols are known to act as water structure forming agents that strengthen the 
intermolecular hydrogen bonding of water molecules and thereby increase the degree of 
ordering in the water (Müller and Albers 1991, Pedersen 1993, Pioger et al. 1998). The 
increased ordering of water lowers the entropy of the system, and therefore, the intrinsic 
solubility and cyclodextrin complexation of the drug often decrease in the presence of these 
substances. However, positive effects have also been observed: for example, when 0.5 M 
fructose was added to a solution containing ergocalciferol and 1.5% (w/v) β-CD, the 
apparent aqueous solubility of ergocalciferol was 30-fold higher than its solubility in a 
solution containing only 1.5% (w/v) β-CD (Hüttenrauch et al. 1985).  
7.3.2 Preparation of sublingual formulations 
In the present study, liquid and solid midazolam formulations containing HP-β-CD and 
sucrose were prepared for sublingual administration. Earlier research has shown that the 
unpleasant taste of midazolam can be effectively masked by complexation with natural 
beta-CD (β-CD) and gamma-CD (γ-CD) (Marcon et al. 2009). HP-β-CD has also been 
successfully used in the taste masking of bitter-tasting substances, such as various 
antihistaminic drugs (Ono et al. 2011). The safety profile of HP-β-CD is very good for both 
peroral and parenteral administration (Gould and Scott 2005), which makes it a feasible 
excipient for incorporation into pediatric formulations. Sucrose is a widely used sweetening 
agent in pharmaceutical preparations (Sohi et al. 2004), and thus, in the present midazolam 
formulations, it is likely to contribute to masking the unpleasant taste of midazolam. 
In this study, the apparent aqueous solubility of midazolam could be significantly 
enhanced by the combined use of HP-β-CD and sucrose (Figure 7.3). This permitted the 
preparation of a more concentrated midazolam solution as compared to the commercially 
available injectable solution. HP-β-CD and 50% (w/v) sucrose also clearly increased the 
viscosity of the midazolam solution. Both of these properties are useful in sublingual 
administration, as a small volume of viscous solution is more likely to remain in the oral 
cavity without being accidentally swallowed. It must be noted that although the highest 
apparent solubility of midazolam was achieved with 50% (w/v) sucrose, improvements in 
the solubility were observed already at lower sucrose concentrations. This may be of 
importance when solid formulations are prepared, in which the amount of excipients must 
often be restricted in order to reduce the bulk mass and volume of the formulation. 
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7.3.3 Pharmacokinetic studies in rabbits 
The sublingual absorption of midazolam was evaluated using the rabbit as the animal 
model. The rabbit is considered to be a suitable animal model for studying the sublingual 
absorption of various drugs, including midazolam due to its convenient size, ease of 
handling, and the nonkeratinized oral mucosa that closely resembles human sublingual 
and buccal tissues (Odou et al. 1999, Dali et al. 2006). 
The plasma concentration profile of midazolam after intravenous administration is 
presented in Figure 7.5. The pharmacokinetic parameters of midazolam (Table 7.1) were 
determined using a noncompartmental bolus model. The elimination rate constant (kel), 
clearance (CL), and volume of distribution at steady state (VSS) after intravenous 
administration of midazolam were 0.008 ± 0.003 min-1, 0.14 ± 0.02 l/min, and 14 ± 5 l, 
respectively. 
The main pharmacologically active metabolite of midazolam, 1-OH-midazolam, is 
formed when the imidazole ring of midazolam is oxidized by cytochrome P450-3A 
enzymes (Levy et al. 2002). The biological activity of the 1-OH-metabolite is about 10% of 
that of midazolam. The plasma concentrations of 1-OH-midazolam after intravenous 
administration are presented in Figure 7.5. 
 
 
Figure 7.5. The mean plasma concentrations of midazolam (●) and 1-OH-midazolam (□) after 
intravenous administration (mean ± sem; n=4). The dose of midazolam was 1 mg. 
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Table 7.1. Pharmacokinetic parameters of midazolam in rabbits after intravenous administration 
of injectable midazolam solution (Dormicum®) and after sublingual administration of injectable 
midazolam solution (Dormicum®), midazolam/HP-β-CD/sucrose solution and midazolam/HP-β-
CD/sucrose powder (n=4). The dose of midazolam was 1 mg. Median and range are given for 
Cmax, tmax and t1/2 . Mean and standard deviation are given for AUC0-240 min and  AUC0-∞ min. Mean 
is given for F%. 
 Midazolam 
solution 
(Dormicum®) 
Midazolam 
solution 
(Dormicum®) 
Midazolam/ 
HP-β-CD/ 
sucrose solution 
Midazolam/ 
HP-β-CD/ 
sucrose powder 
Route of 
administration 
Intravenous Sublingual Sublingual Sublingual 
     
Cmax (ng/ml) 314 (240470)a 63 (5582) 40 (2557) 29 (2438)* 
tmax (min) 0a 23 (1530) 30 (3060) 60 (3060) 
t1/2  (min) 88 (67144) 83 (7291) 75 (50208) 77 (51114) 
AUC0-240 min 
(ng/ml×min) 
6260 ± 1110 7840 ± 1770 4250 ± 1160 4150 ± 1100 
AUC0-∞ min 
(ng/ml×min) 
7250 ± 1210 9210 ± 2440 5660 ± 2140 4960 ± 1600 
F (%)  127 78 68 
a extrapolated value  
* Significantly different from the Cmax value of injectable midazolam solution (Kruskall-Wallis 
test with a post hoc test, p < 0.05) 
 
Figure 7.6 shows the plasma concentration profiles of midazolam and 1-OH-midazolam 
after sublingual administration. The pharmacokinetic parameters of midazolam after 
sublingual administration are summarized in Table 7.1. The results indicate that midazolam 
was rapidly absorbed after sublingual administration. Detectable plasma concentrations of 
midazolam were achieved within ≤5 min with all three formulations. All sublingually 
administered formulations of midazolam were well absorbed: the mean absolute 
bioavailabilities were ≥78% for the liquid formulations and 68% for the solid formulation. 
The good sublingual absorption observed in this study is in agreement with earlier 
studies. For example, an absolute bioavailability of approximately 100 ± 50% was reported 
when fast-disintegrating tablets of midazolam were administered sublingually to rabbits 
(Odou et al. 1999).  Furthermore, a mean bioavailability of 74.5% was achieved in healthy 
volunteers after buccal administration of a midazolam solution (Schwagmeier et al. 1998). 
In the present study, there were no statistically significant (p < 0.05) differences between the 
AUC values of the three sublingual formulations (Table 7.1). However, a statistically 
nonsignificant trend was observed, in which the absolute bioavailabilities after sublingual 
administration decreased in the following order: injectable midazolam solution > 
midazolam/HP-β-CD/sucrose solution > midazolam/HP-β-CD/sucrose powder. There are 
several possible explanations for these results e.g. the slow dissociation of the 
midazolam/HP-β-CD complexes and the slow dissolution of the midazolam/HP-β-
CD/sucrose powder in the small volume of saliva that is present in the oral cavity of the 
rabbit. 
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Figure 7.6. The mean plasma concentrations of midazolam (A) and 1-OH-midazolam (B) after 
sublingual administration of injectable midazolam solution (●), midazolam/HP-β-CD/sucrose 
solution (□), and midazolam/HP-β-CD/sucrose powder (▲) (mean ± sem; n=4). The dose of 
midazolam was 1 mg. 
 
Based on the results, it is concluded that midazolam is well absorbed in rabbits after 
sublingual absorption of formulations containing HP-β-CD and sucrose. In humans, both 
the volume of saliva and the area of the oral mucosa are notably larger than in rabbits. A 
larger volume of saliva would probably promote faster dissolution of the solid complex and 
dissociation of the midazolam/HP-β-CD complex, leading to even better absorption of 
midazolam. Clinical studies will be needed to evaluate the sublingual absorption of 
midazolam/HP-β-CD/sucrose systems in humans and to assess their taste properties and 
patient acceptance. 
7.4 CONCLUSIONS 
In summary, the present study provides evidence that when HP-β-CD and sucrose were 
used together, the apparent solubility of midazolam was significantly increased as 
compared to solutions containing HP-β-CD only. When administered to rabbits, both liquid 
and solid formulations containing midazolam, HP-β-CD, and sucrose displayed rapid and 
good sublingual absorption. This synergistic solubilization with HP-β-CD and sucrose can 
therefore be utilized in the preparation of more concentrated, better palatable midazolam 
formulations for sublingual administration. 
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8 General Discussion and Future Prospects 
Intraoral administration has traditionally been utilized to achieve a rapid onset of drug 
action or to increase the bioavailability of drugs that undergo extensive hepatic first-pass 
metabolism or gastrointestinal degradation after peroral administration (Goswami et al. 
2008, Mathias and Hussain 2010). Intraoral delivery also provides some important benefits 
for the patients: the administration is non-invasive and painless, and the dosage forms are 
easy and convenient to use. In particular, intraorally fast-disintegrating and fast-dissolving 
dosage forms are gaining popularity, since they are suitable for patient groups that have 
difficulties in swallowing conventional tablets and capsules (Pfister and Ghosh 2005). 
Furthermore, since intraorally fast-dissolving formulations disintegrate and dissolve in the 
mouth without any additional water, they are convenient for busy, travelling patients or for 
patients who have no access to potable water. 
Despite its many advantages, the intraoral administration route has also some serious 
limitations. The multilayered structure of the oral epithelium functions as a barrier that 
protects the underlying tissues from the entry of potentially harmful exogenous substances 
(Goswami et al. 2008). Therefore, the oral epithelium is not as permeable as the simple 
columnar epithelium present in the intestine that is specialized for absorption of substances 
such as nutrients and water. Another challenge is the continuous production and 
involuntary swallowing of saliva, which may wash the dosage form from the oral cavity 
before the drug has had time to be absorbed, possibly leading to decreased and variable 
bioavailability (Patel et al. 2011). The residence time of a drug in the oral cavity could be 
prolonged by developing mucoadhesive dosage forms that adhere to the oral mucosa and 
release the drug over an extended period of time, usually several hours (Song et al. 2004). 
However, if immediate drug release is desired, the drug needs to dissolve sufficiently 
quickly to allow rapid absorption through the oral mucosa. Since the amount of saliva in 
the oral cavity is very low (< 1 ml) (Lagerlöf and Dawes 1984), the solubility and dissolution 
properties of the drug may limit its intraoral absorption. 
CDs have been used in pharmaceutical applications for a variety of purposes, such as 
improving the solubility, dissolution rate and stability of drugs, or masking the unpleasant 
taste or smell of drug substances (Davis and Brewster 2004). These possibilities could also 
be utilized in the development of intraorally administered formulations, as sufficiently fast 
dissolution rate and acceptable taste of the drug can be considered as critical properties in 
intraoral delivery. However, since CDs and drug/CD complexes do not readily pass 
through mucosal membranes, the drug needs to be released from the complex before it can 
be absorbed into the bloodstream (Stella and He 2008). The dissociation of the complex is 
mainly driven by its dilution in biological fluids and therefore, the release of the drug from 
the complex into the small volume of saliva may become a limiting factor for drug 
absorption. 
In this work, two model drugs were used for studying the use of CDs in intraoral 
applications. Perphenazine is an antipsychotic drug that is used for psychiatric disorders, 
such as schizophrenia and anxiety, but also for the treatment of severe nausea and vomiting 
(Hartung et al. 2005). Midazolam is an anxiolytic, sedative benzodiazepine that has many 
therapeutic uses e.g. to induce sleep, to treat seizures, or to relieve anxiety before medical 
procedures in adult and pediatric patients (Krauss and Green 2006). Both perphenazine and 
midazolam could benefit from intraoral delivery, since their bioavailability after peroral 
administration is low and variable due to their extensive hepatic first-pass metabolism. 
Their typical single doses in peroral administration are relatively low (215 mg), indicating 
that they are potent enough to permit the preparation of a reasonably sized intraoral 
formulation. However, since both perphenazine and midazolam are poorly soluble in 
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water, it is evident that their intraoral absorption could be limited by slow and incomplete 
dissolution in saliva. In addition, the intensely bitter taste of midazolam is known to 
complicate its intraoral use, especially in pediatric patients (Marcon et al. 2009).  
One needs a sensitive analytical method in order to reliably quantify drugs from plasma 
samples during in vivo absorption studies. In the first part of the present study, a gas 
chromatographic-mass spectrometric (GC-MS) method offering excellent selectivity and 
sensitivity was developed and validated for the determination of perphenazine from rabbit 
or human plasma. In addition, a mixed-mode solid phase extraction method was developed 
for the purification of the plasma samples before the GC-MS analysis. The purification 
procedure was efficient and resulted in very clean extracts with good recoveries. The 
method was successfully used in the subsequent absorption experiments in rabbits. 
In the present study, the effects of complexation with β-CD and solid dispersion 
formation with PEG on the apparent aqueous solubility and dissolution rate of 
perphenazine were investigated. Both β-CD and PEG improved the apparent solubility of 
perphenazine. Perphenazine was completely dissolved from the CD complex and the solid 
dispersion in five minutes or less, whereas the full dissolution of unprocessed 
perphenazine required 2030 minutes. An increased dissolution rate was also achieved, 
when perphenazine was simply micronized by passing the drug through a 15 μM sieve. 
The sublingual administration of micronized perphenazine, solid perphenazine/β-CD 
complex and perphenazine/PEG solid dispersion to rabbits resulted in 58-fold better 
absorption (AUC0-360 min) of perphenazine as compared to perorally administered 
perphenazine solution, indicating that the first-pass effect could be possibly avoided by 
using the sublingual administration route, and that perphenazine was well absorbed from 
the powders containing β-CD or PEG.  
In the case of midazolam, complexation with HP-β-CD was utilized in this study to mask 
the unpleasant taste of the drug, and to increase its apparent aqueous solubility. Intraorally 
administered midazolam solution is commonly used for premedication of pediatric 
patients, but its bitter and irritating taste often causes the children to refuse to take the 
medication. At the moment, one buccal midazolam solution is commercially available 
(Buccolam®, ViroPharma) (Jevon 2012). However, the product is only approved for the 
treatment of prolonged epileptic seizures in children, and since it is used in acute 
emergency situations, it does not contain any flavours or other taste-masking excipients to 
make the solution more palatable (Summary of Product Characteristics; Buccolam®). In the 
absence of approved commercial alternatives, intraoral administration of a bitter-tasting 
injectable midazolam solution has been commonly used in pediatric premedication 
(Marcon et al. 2009). Based on the study by Marcon et al. (2009), it is known that the bitter 
taste of midazolam can be masked by CD complexation. However, since the complexation 
efficiency of benzodiazepines is generally low (Loftsson et al. 2001), various excipients were 
investigated in this study to find out if the solubilization of midazolam with HP-β-CD 
could be further improved. Interestingly, it was observed that the apparent aqueous 
solubility of midazolam was markedly increased when HP-β-CD was used in combination 
with sucrose. The intraoral absorption of midazolam was investigated in rabbits after 
sublingual administration of commercial injectable midazolam solution, midazolam/HP-β-
CD/sucrose solution and midazolam/HP-β-CD/sucrose powder. Midazolam was rapidly 
absorbed from all three formulations, with absolute bioavailabilities of ≥ 68%, suggesting 
that the synergistic co-solubilizing effect of HP-β-CD and sucrose could be utilized to 
prepare more concentrated and palatable midazolam formulations with good intraoral 
absorption.  
As stated above, one of the main challenges associated with the use of CDs in intraorally 
dissolving formulations is the possibility for insufficient dissociation of the drug/CD 
complex in a small volume of saliva. In the present study, the apparent stability constant of 
the perphenazine/β-CD complex was clearly higher (9300 M-1) than that of the 
midazolam/HP-β-CD complex (259 M-1 without sucrose and 387 M-1 in the presence of 50% 
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(w/v) sucrose). When the plasma concentration profiles after the sublingual administration 
of the perphenazine/β-CD powder and the midazolam/HP-β-CD/sucrose powder are 
compared (Figures 5.4 and 7.6), it is evident that midazolam was absorbed more rapidly 
than perphenazine, indicating that the slower dissociation of the perphenazine/β-CD 
complex may have reduced the absorption of perphenazine. However, it must be noted that 
also plain micronized perphenazine was slowly absorbed, perhaps suggesting that the 
retention of perphenazine in the oral mucosal membranes may have contributed to the 
slow absorption.  
Another possible obstacle limiting the use of CDs in intraoral formulations is the effect of 
CD complexation on the formulation bulk mass and volume. When the typical molecular 
weights of drugs and pharmaceutically applicable CDs are compared, it can be seen that 
even if ideal complexation efficiency is assumed, complex formation will increase the 
dosage bulk mass by 25-fold as compared to the mass of the plain drug. It has been 
proposed that not more than 150 mg of a drug/CD complex containing 1540 mg of drug 
could be incorporated into an intraorally administered tablet, since that the maximum size 
for a buccal tablet is about 250 mg (Loftsson 2002). Currently, the highest dose of active 
drug in a commercially available intraoral tablet is 30 mg (Striant®; Columbia Laboratories; 
a mucoadhesive buccal tablet containing testosterone) (Mathias and Hussain 2010). In the 
present study, the effect of the formulation size could be evaluated in the sublingual 
absorption of perphenazine in rabbits after the administration of perphenazine as a 
micronized powder, solid dispersion or β-CD complex. As the dose of perphenazine given 
to the 4-kg rabbits was always 1 mg/kg, the amounts of solid perphenazine/β-CD complex 
(31 mg/rabbit) and perphenazine/PEG solid dispersion (21 mg/rabbit) were over fivefold 
greater than the amount of plain, micronized perphenazine (4 mg/rabbit). Although the 
differences between the AUC0-360 min values of the three formulations were not statistically 
significant, the highest absorption was observed with plain micronized perphenazine, 
indicating that its smaller bulk mass and volume may have permitted closer contact with 
the oral mucosa and faster wetting in the very small amount of saliva present in the rabbit’s 
mouth.  
Since the complexation efficiency of drugs with CDs is seldom ideal, various approaches 
have been investigated to enhance the solubilizing power of CDs. Several studies have 
demonstrated that the addition of a third component, such as a hydroxy acid (Redenti et al. 
2000, Mura et al. 2001), amino acid (Mura et al. 2003) or water-soluble polymer (Loftsson et 
al. 1994, Taupitz et al. 2013) to a drug/CD system may result in synergistic solubilization, 
where the combined effect of the CD and the excipient on the apparent solubility of the 
drug is greater than the sum of their individual effects. In the present study, the 
solubilization of midazolam by HP-β-CD could be markedly improved by the addition of 
sucrose. The exact mechanism behind this observation remains unclear, but it may be 
attributed to several factors, such as the effect of sucrose on the ordering of surrounding 
water molecules (Hüttenrauch et al. 1985), or the formation of self-associated or micelle-like 
non-inclusion complexes (Loftsson et al. 2004). Additional studies would be needed to 
clarify the nature of this phenomenon, e.g. why was the effect not seen with other 
saccharides, and whether a similar synergistic solubilizing effect could be observed with 
other drugs and CDs.  
The solid, fast-dissolving drug/CD powders used in this study were prepared by either 
spray-drying or freeze-drying, which both are common methods to produce solid CD 
complexes. These processes are also known to often produce amorphous materials, which 
may exhibit an increased dissolution rate, but on the other hand, are prone to crystallization 
and chemical degradation during processing and storage (Yu 2001, Kaushal et al. 2004). 
When intraorally fast-dissolving formulations are being developed, it is critical to ensure 
that the fast dissolution properties remain unchanged throughout the whole storage period 
of the product, and that the dissolution behaviour is not affected by external factors, e.g. 
crystallization of amorphous materials under the storage conditions. In the present study, 
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the dissolution rate of perphenazine from amorphous, spray-dried or freeze-dried 
perphenazine/β-CD complexes remained practically unchanged during the 3-month 
storage under accelerated conditions, although partial crystallization was observed for both 
materials at 40 °C, 75% RH. This was attributed to the similar dissolution behaviour of the 
amorphous and crystalline forms of β-CD. Similar findings could also be expected with 
amorphous natural α-CD and γ-CD, since in our preliminary studies, the fully amorphous 
α-CD and γ-CD powders prepared by spray-drying did not dissolve faster than the 
corresponding crystalline forms. CD technology may thus be suitable for the development 
of intraorally fast-dissolving formulations of poorly soluble drugs, since the possible 
crystallization of the amorphous complexes does not seem to affect the dissolution rate of 
the drug or the CD. However, additional studies will be needed to examine the stability of 
the complexes for a longer period, and to determine the other physical properties of these 
complexes that can affect the preparation and the performance of the final dosage forms. 
The present study shows that CDs could be useful excipients for the development of 
intraorally fast dissolving formulations. In these dosage forms, CDs could be utilized to 
increase the apparent solubility, dissolution rate and bioavailability of drugs, and to mask 
the bitter taste of compounds. The good oral and local safety of CDs is also advantageous 
for intraoral delivery. However, it is evident that CD-containing intraoral formulations will 
need to be carefully designed in order to achieve rapid release, dissolution and absorption 
of the drug from the formulation, to minimize the effect of CDs on the formulation size, and 
to ensure the chemical and physical stability of the product. Furthermore, although the 
usefulness of CDs in intraoral administration has been demonstrated in vitro and in vivo, 
clinical studies will be needed to assess the performance of CD-containing intraoral 
formulations in human subjects, and to provide information on the taste and other 
formulation characteristics affecting patient compliance.  
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9 Conclusions  
On the basis of the present results, the following conclusions can be drawn: 
 
1. A sensitive and selective gas chromatographicmass spectrometric method 
with a new sample purification procedure was developed for analysing the 
concentrations of perphenazine in plasma samples. The method was 
successfully applied for monitoring the plasma concentrations of perphenazine 
in rabbits after sublingual administration. The method is also applicable for the 
quantification of perphenazine in human plasma samples. 
 
2. Fast-dissolving perphenazine powders could be prepared by complexation 
with beta-cyclodextrin (β-CD) and by solid dispersion formation with 
polyethylene glycol (PEG). In comparison to peroral administration of an 
aqueous perphenazine solution, the systemic absorption of perphenazine could 
be increased by sublingual administration of the perphenazine/β-CD complex 
and the perphenazine/PEG solid dispersion. Good absorption was also 
achieved with micronized perphenazine administered sublingually. 
 
3. The dissolution behaviour of perphenazine from amorphous perphenazine/β-
CD powders remained practically unchanged after storage at accelerated 
conditions, although partial crystallization had occurred during the storage. 
This could be explained by the similar dissolution rates of crystalline and 
amorphous β-CD. CD technology may thus represent a suitable approach for 
preparing intraorally dissolving formulations, in which the fast dissolution rate 
of drug would be maintained during storage. 
 
4. The synergistic solubilizing effect of hydroxypropyl-beta-cyclodextrin (HP-β-
CD) and sucrose significantly improved the apparent aqueous solubility of 
midazolam. Midazolam showed rapid sublingual absorption with a high 
absolute bioavailability from both liquid and solid formulations containing 
midazolam, HP-β-CD and sucrose. The combined use of HP-β-CD and sucrose 
could be utilized in the development of concentrated, taste-masked midazolam 
formulations for pediatric patients. 
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Intraorally fast-dissolving drug 
formulations offer both good patient 
acceptability and pharmacokinetic 
advantages over conventional tablets 
and capsules. However, the poor sol-
ubility, slow dissolution rate or bitter 
taste of drugs may complicate their 
intraoral administration. In this the-
sis, cyclodextrins were demonstrated 
to be potential excipients to overcome 
these limitations in the development 
of intraorally fast-dissolving drug 
formulations.
